3 Ultra-Popular Stocks With No Buy Ratings on Wall Street_老虎社区_美港股上老虎

3 Ultra-Popular Stocks With No Buy Ratings on Wall Street

Motley Fool2021-09-28

Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio. According to data from CNBC, over 90% of all S&P 500 stock ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

202

Teerapol
·2021-09-29
I agree
回复
1
举报
Mhong
·2021-09-29
Like & comment
回复
5
举报
收起
- sunshine138:
  Like 2
  2021-09-29
  回复
  举报
Gaga71
·2021-09-29
Not touching these stocks
回复
6
举报
Karenz
·2021-09-29
Ok
回复
5
举报
生肉麵加豬油渣
·2021-09-29
No value to me
回复
4
举报
收起
- Honeybacon:
  Haiz
  2021-09-29
  回复
  举报
bearyamaze
·2021-09-29
Sound like the company is not doing well and tiger is recommending for a buy ? Or I mis read
回复
2
举报
MengYang
·2021-09-29
Nice, please like
回复
4
举报
收起
- JeremyKok:
  hi. please like and comment back. thank you.
  2021-09-29
  回复
  举报
MengYang
·2021-09-29
Nice, please like
回复
5
举报
kenong62
·2021-09-29
Please likeThanks
回复
8
举报
收起
- JeremyKok:
  hi. please like and comment back. thank you.
  2021-09-29
  回复
  举报
- XiuJ:
  Ok
  2021-09-29
  回复
  举报
- ocean_wave:
  [疑问]
  2021-09-30
  回复
  举报
lewisleeks
·2021-09-29
Great [Smile] [Smile]
回复
4
举报
replaygoh
·2021-09-29
great
回复
4
举报
Samuel123win
·2021-09-29
💪
回复
3
举报
丰人
·2021-09-29
Like
回复
2
举报
收起
- JeremyKok:
  hi. please like and comment back. thank you.
  2021-09-29
  回复
  举报
SanWangtikup
·2021-09-28
😂
回复
4
举报
anthonywhite
·2021-09-28
Don’t ever listen to mortley fool!
回复
2
举报
yngwin111
·2021-09-28
No true!
回复
6
举报
HeroSmurf
·2021-09-28
None of the above? Or should I?
回复
6
举报
Ong2021
·2021-09-28
[What]
回复
5
举报
收起
- Ong2021:
  [Miser]
  2021-09-28
  回复
  举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2170778116?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-09-28 19:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2170778116","market":"us","top_or_hot":-1,"title":"3 Ultra-Popular Stocks With No Buy Ratings on Wall Street","media":"Motley Fool","content":"<div>\n<p>Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.\nAccording to data from CNBC, over 90% of all S&P 500 stock ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/\">网页链接</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Ultra-Popular Stocks With No Buy Ratings on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Ultra-Popular Stocks With No Buy Ratings on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-28 19:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.\nAccording to data from CNBC, over 90% of all S&P 500 stock ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ACB","symbol_name":"奥罗拉大麻公司","start_time":0,"source_url":"https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/","article_id":"2170778116","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2170778116","pubTimestamp":1632829153,"columns":[],"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"These widely held stocks are getting no love from analysts.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ACB":"奥罗拉大麻公司","SNDL":"SNDL Inc.","AMC":"AMC院线"},"translate_title":"华尔街3只超受欢迎但没有买入评级的股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACB":0.9,"AMC":0.9,"SNDL":0.9},"content_text":"Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.\nAccording to data from CNBC, over 90% of all S&P 500 stock ratings from Wall Street analysts were the equivalent of \"buy\" or \"hold\" between 1997 and 2017. With the exception of short periods in 2002-2003 and 2008-2009, sell ratings have consistently accounted for only 1% to 6% of all ratings for S&P 500 companies this century.\nOne reason for this \"buy bias\" is due to the U.S. and global economy growing over time. Historically, the stock market moves higher over the long run, too. Wall Street analysts might simply be playing the favorable odds that higher-quality businesses will increase in value over time.\nAdditionally, The Wall Street Journal noted some years back that Wall Street analysts are hesitant to issue sell ratings so as not to burn bridges for their clients or themselves with the companies they cover. No matter the reasoning, sell ratings are rare on Wall Street.\nImage source: Getty Images.\nBut don't tell that to shareholders of the following three ultra-popular stocks. These are three of the 16 most-held stocks on the Robinhood (NASDAQ:HOOD) platform, and not one of them has a single buy rating from a Wall Street analyst.\nAurora Cannabis\nOne of the biggest buzzkills, according to Wall Street, is Canadian marijuana stock Aurora Cannabis (NASDAQ:ACB). Aurora, which at one time was the most-held stock on Robinhood, is being covered by 13 Wall Street institutions, seven of which rate the company the equivalent of a hold and six of which believe it's a sell.\nThough Aurora Cannabis does foot the blame for a lot of this negativity, some of its issues can be traced to Canadian federal and provincial regulators failing the pot industry. For example, Ontario's lottery system to assign retail licenses through 2019 was terrible and resulted in only a few dozen dispensaries opening. Canadian pot stocks are still trying to recover from supply chain bottlenecks in the country's most populous province.\nBut as I mentioned, Aurora Cannabis isn't without fault. The company expanded its production capacity far beyond what was needed. At one time, it held 15 production facilities that could have yielded more than 600,000 kilos of annual cannabis output if fully operational. Management has since closed five of these smaller facilities, sold a 1-million-square-foot greenhouse that wasn't retrofitted for cannabis production, and halted construction on two of the company's largest projects.\nYet, even with this aggressive cost-cutting, Aurora Cannabis is still a long way from generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). With the company continuing to burn cash and the previous management team grossly overpaying for about a dozen acquisitions, it's regularly had to sell its common stock to raise capital to pay its bills and fund buyouts.\nTaking into account a reverse split enacted last year to stave off delisting, Aurora's share count has ballooned from about 1.3 million shares in June 2014 to 198 million shares, as of mid-May. That sort of dilution is precisely why the company's shares are down nearly 95% since March 2019.\nThe salt in the wound is that Canada's legal weed sales have been hitting monthly records, all while Aurora's recreational pot revenue was more than halved in its fiscal third quarter.\nImage source: Getty Images.\nSundial Growers\nYet another Canadian pot stock in the no-buy zone for Wall Street is small-cap Sundial Growers (NASDAQ:SNDL). Even though it's the fourth most-held stock on Robinhood, four of the six analysts covering the company rate it a sell.\nDespite sitting on a boatload of cash, cash equivalents, and long-term investments (about $948 million), Sundial Growers has three factors working against it.\nTo begin with, Sundial's approach to raising capital has destroyed shareholder value. Initially, it looked as if management would sell enough common stock to simply pay off the company's outstanding debt. But in a nine-month stretch between Oct. 1, 2020 and June 30, 2021, Sundial's executives have unrelentingly issued stock to raise additional capital.\nThe end result is the issuance of roughly 1.5 billion shares of stock. With 2 billion shares now outstanding, Sundial has virtually no chance of ever generating meaningful earnings per share, and it'll likely struggle to remain listed on the Nasdaq exchange without a substantial reverse split.\nSecond, Sundial's management team hasn't laid out a concrete plan for its capital. While it did undertake a cash-and-stock deal to acquire Inner Spirit Holdings in July, and it's committed roughly $425 million to its joint venture with SAF Group, known as SunStream Bancorp, to invest in cannabis industry opportunities, the company has continued to raise cash with no stated purpose.\nThird, Sundial has shifted its operating model away from wholesale cannabis to take advantage of the higher margins associated with the retail side of the equation. Unfortunately, having to start from scratch has led to significant year-over-year sales declines at a time when legal weed sales are rapidly growing.\nIn March I more or less referred to Sundial as the worst cannabis stock money could buy. That descriptor still holds true today.\nImage source: Getty Images.\nAMC Entertainment\nBut the most popular stock of all that's getting absolutely no love from Wall Street analysts and investment banks is movie theater chain AMC Entertainment (NYSE:AMC). The third most-held stock on Robinhood has nine analysts covering the company. Five of them have it rated a sell, with four others chiming in with a hold rating.\nThis rating distribution isn't a surprise given that Wall Street's consensus price target for AMC is $5.44. Shares of the company would need to fall 86% from where they closed last week to reach this consensus target.\nThe reason AMC's share price has rocketed higher in 2021 primarily has to do with retail investors piling into the stock and betting on a short squeeze -- i.e., a very short-term event whereby pessimists (short-sellers) run for the exit and buy shares to cover their positions. The issue for these optimists is that none of the data surrounding AMC is working in their favor.\nFor one, short squeezes typically require certain conditions be met, which simply aren't there at the moment. While the company's 18.8% short interest at the end of August is higher than most stocks, its large daily trading volume means it would take less than a day for all 95.94 million short shares to be covered. The liquidity of AMC's stock means short-sellers have no fear of being trapped in their position.\nFundamentally, the movie theater industry has been in a nearly two-decade decline. Tickets sold and inflation-adjusted gross at the box office have fallen 22% between 2002 and 2019, the last full year before the pandemic. Streaming offerings and substantially reduced film exclusivity (30 to 45 days now, compared to 75 to 90 days prior to the pandemic) bode poorly for the industry's future.\nAnd then there's AMC's operating performance and liability-riddled balance sheet. Despite a record $2.023 billion in liquidity ($1.81 billion in cash), AMC burned through $576.5 million in cash in the first six months of 2021. Its lease liabilities are soaring, it owes $420 million in deferred rent, and it's lugging around nearly $5.5 billion in debt that it likely can't pay.\nMore than $1 billion in aggregate debt due in 2026 and 2027 is also valued at 70% to 74% of face value. Debt going for this much below par is a very real warning sign that bondholders believe a future default is possible.\nLong story short, Wall Street has every reason to be skeptical of AMC.","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":862748306,"gmtCreate":1632919161247,"gmtModify":1632924786529,"author":{"id":"4095574844567300","authorId":"4095574844567300","name":"Teerapol","avatar":"https://static.tigerbbs.com/2ffe268aff626e7d0b55a2f0fde51f4a","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4095574844567300","authorIdStr":"4095574844567300"},"htmlText":"I agree","listText":"I agree","text":"I agree","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862748306","repostId":2170778116,"repostType":4,"repost":{"id":"2170778116","kind":"highlight","pubTimestamp":1632829153,"share":"https://www.laohu8.com/m/news/2170778116?lang=&edition=full","pubTime":"2021-09-28 19:39","market":"us","language":"en","title":"3 Ultra-Popular Stocks With No Buy Ratings on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2170778116","media":"Motley Fool","summary":"These widely held stocks are getting no love from analysts.","content":"<p>Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.</p>\n<p>According to data from CNBC, over 90% of all <b>S&amp;P 500</b> stock ratings from Wall Street analysts were the equivalent of \"buy\" or \"hold\" between 1997 and 2017. With the exception of short periods in 2002-2003 and 2008-2009, sell ratings have consistently accounted for only 1% to 6% of all ratings for S&amp;P 500 companies this century.</p>\n<p>One reason for this \"buy bias\" is due to the U.S. and global economy growing over time. Historically, the stock market moves higher over the long run, too. Wall Street analysts might simply be playing the favorable odds that higher-quality businesses will increase in value over time.</p>\n<p>Additionally, <i>The Wall Street Journal</i> noted some years back that Wall Street analysts are hesitant to issue sell ratings so as not to burn bridges for their clients or themselves with the companies they cover. No matter the reasoning, sell ratings are rare on Wall Street.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fb1fd3c71278c123e5dd0404a4dbb43c\" tg-width=\"700\" tg-height=\"525\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<p>But don't tell that to shareholders of the following three ultra-popular stocks. These are three of the 16 most-held stocks on the <b>Robinhood</b> (NASDAQ:HOOD) platform, and not one of them has a single buy rating from a Wall Street analyst.</p>\n<h2>Aurora Cannabis</h2>\n<p>One of the biggest buzzkills, according to Wall Street, is Canadian marijuana stock <b>Aurora Cannabis</b> (NASDAQ:ACB). Aurora, which at one time was the most-held stock on Robinhood, is being covered by 13 Wall Street institutions, seven of which rate the company the equivalent of a hold and six of which believe it's a sell.</p>\n<p>Though Aurora Cannabis does foot the blame for a lot of this negativity, some of its issues can be traced to Canadian federal and provincial regulators failing the pot industry. For example, Ontario's lottery system to assign retail licenses through 2019 was terrible and resulted in only a few dozen dispensaries opening. Canadian pot stocks are still trying to recover from supply chain bottlenecks in the country's most populous province.</p>\n<p>But as I mentioned, Aurora Cannabis isn't without fault. The company expanded its production capacity far beyond what was needed. At one time, it held 15 production facilities that could have yielded more than 600,000 kilos of annual cannabis output if fully operational. Management has since closed five of these smaller facilities, sold a 1-million-square-foot greenhouse that wasn't retrofitted for cannabis production, and halted construction on two of the company's largest projects.</p>\n<p>Yet, even with this aggressive cost-cutting, Aurora Cannabis is still a long way from generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). With the company continuing to burn cash and the previous management team grossly overpaying for about a dozen acquisitions, it's regularly had to sell its common stock to raise capital to pay its bills and fund buyouts.</p>\n<p>Taking into account a reverse split enacted last year to stave off delisting, Aurora's share count has ballooned from about 1.3 million shares in June 2014 to 198 million shares, as of mid-May. That sort of dilution is precisely why the company's shares are down nearly 95% since March 2019.</p>\n<p>The salt in the wound is that Canada's legal weed sales have been hitting monthly records, all while Aurora's recreational pot revenue was more than halved in its fiscal third quarter.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/bc514068ded899a817770f684369db36\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Sundial Growers</h2>\n<p>Yet another Canadian pot stock in the no-buy zone for Wall Street is small-cap <b>Sundial Growers</b> (NASDAQ:SNDL). Even though it's the fourth most-held stock on Robinhood, four of the six analysts covering the company rate it a sell.</p>\n<p>Despite sitting on a boatload of cash, cash equivalents, and long-term investments (about $948 million), Sundial Growers has three factors working against it.</p>\n<p>To begin with, Sundial's approach to raising capital has destroyed shareholder value. Initially, it looked as if management would sell enough common stock to simply pay off the company's outstanding debt. But in a nine-month stretch between Oct. 1, 2020 and June 30, 2021, Sundial's executives have unrelentingly issued stock to raise additional capital.</p>\n<p>The end result is the issuance of roughly 1.5 billion shares of stock. With 2 billion shares now outstanding, Sundial has virtually no chance of ever generating meaningful earnings per share, and it'll likely struggle to remain listed on the <b>Nasdaq</b>&nbsp;exchange without a substantial reverse split.</p>\n<p>Second, Sundial's management team hasn't laid out a concrete plan for its capital. While it did undertake a cash-and-stock deal to acquire <a href=\"https://laohu8.com/S/INSHF\">Inner Spirit Holdings</a> in July, and it's committed roughly $425 million to its joint venture with SAF Group, known as SunStream Bancorp, to invest in cannabis industry opportunities, the company has continued to raise cash with no stated purpose.</p>\n<p>Third, Sundial has shifted its operating model away from wholesale cannabis to take advantage of the higher margins associated with the retail side of the equation. Unfortunately, having to start from scratch has led to significant year-over-year sales declines at a time when legal weed sales are rapidly growing.</p>\n<p>In March I more or less referred to Sundial as the worst cannabis stock money could buy. That descriptor still holds true today.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1c6cb4d9fcdf85f542f333fc71a2dd58\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>AMC Entertainment</h2>\n<p>But the most popular stock of all that's getting absolutely no love from Wall Street analysts and investment banks is movie theater chain <b>AMC Entertainment</b> (NYSE:AMC). The third most-held stock on Robinhood has nine analysts covering the company. Five of them have it rated a sell, with four others chiming in with a hold rating.</p>\n<p>This rating distribution isn't a surprise given that Wall Street's consensus price target for AMC is $5.44. Shares of the company would need to fall 86% from where they closed last week to reach this consensus target.</p>\n<p>The reason AMC's share price has rocketed higher in 2021 primarily has to do with retail investors piling into the stock and betting on a short squeeze -- i.e., a very short-term event whereby pessimists (short-sellers) run for the exit and buy shares to cover their positions. The issue for these optimists is that none of the data surrounding AMC is working in their favor.</p>\n<p>For one, short squeezes typically require certain conditions be met, which simply aren't there at the moment. While the company's 18.8% short interest at the end of August is higher than most stocks, its large daily trading volume means it would take less than a day for all 95.94 million short shares to be covered. The liquidity of AMC's stock means short-sellers have no fear of being trapped in their position.</p>\n<p>Fundamentally, the movie theater industry has been in a nearly two-decade decline. Tickets sold and inflation-adjusted gross at the box office have fallen 22% between 2002 and 2019, the last full year before the pandemic. Streaming offerings and substantially reduced film exclusivity (30 to 45 days now, compared to 75 to 90 days prior to the pandemic) bode poorly for the industry's future.</p>\n<p>And then there's AMC's operating performance and liability-riddled balance sheet. Despite a record $2.023 billion in liquidity ($1.81 billion in cash), AMC burned through $576.5 million in cash in the first six months of 2021. Its lease liabilities are soaring, it owes $420 million in deferred rent, and it's lugging around nearly $5.5 billion in debt that it likely can't pay.</p>\n<p>More than $1 billion in aggregate debt due in 2026 and 2027 is also valued at 70% to 74% of face value. Debt going for this much below par is a very real warning sign that bondholders believe a future default is possible.</p>\n<p>Long story short, Wall Street has every reason to be skeptical of AMC.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Ultra-Popular Stocks With No Buy Ratings on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Ultra-Popular Stocks With No Buy Ratings on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-28 19:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.\nAccording to data from CNBC, over 90% of all S&P 500 stock ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ACB":"奥罗拉大麻公司","SNDL":"SNDL Inc.","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2170778116","content_text":"Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.\nAccording to data from CNBC, over 90% of all S&P 500 stock ratings from Wall Street analysts were the equivalent of \"buy\" or \"hold\" between 1997 and 2017. With the exception of short periods in 2002-2003 and 2008-2009, sell ratings have consistently accounted for only 1% to 6% of all ratings for S&P 500 companies this century.\nOne reason for this \"buy bias\" is due to the U.S. and global economy growing over time. Historically, the stock market moves higher over the long run, too. Wall Street analysts might simply be playing the favorable odds that higher-quality businesses will increase in value over time.\nAdditionally, The Wall Street Journal noted some years back that Wall Street analysts are hesitant to issue sell ratings so as not to burn bridges for their clients or themselves with the companies they cover. No matter the reasoning, sell ratings are rare on Wall Street.\nImage source: Getty Images.\nBut don't tell that to shareholders of the following three ultra-popular stocks. These are three of the 16 most-held stocks on the Robinhood (NASDAQ:HOOD) platform, and not one of them has a single buy rating from a Wall Street analyst.\nAurora Cannabis\nOne of the biggest buzzkills, according to Wall Street, is Canadian marijuana stock Aurora Cannabis (NASDAQ:ACB). Aurora, which at one time was the most-held stock on Robinhood, is being covered by 13 Wall Street institutions, seven of which rate the company the equivalent of a hold and six of which believe it's a sell.\nThough Aurora Cannabis does foot the blame for a lot of this negativity, some of its issues can be traced to Canadian federal and provincial regulators failing the pot industry. For example, Ontario's lottery system to assign retail licenses through 2019 was terrible and resulted in only a few dozen dispensaries opening. Canadian pot stocks are still trying to recover from supply chain bottlenecks in the country's most populous province.\nBut as I mentioned, Aurora Cannabis isn't without fault. The company expanded its production capacity far beyond what was needed. At one time, it held 15 production facilities that could have yielded more than 600,000 kilos of annual cannabis output if fully operational. Management has since closed five of these smaller facilities, sold a 1-million-square-foot greenhouse that wasn't retrofitted for cannabis production, and halted construction on two of the company's largest projects.\nYet, even with this aggressive cost-cutting, Aurora Cannabis is still a long way from generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). With the company continuing to burn cash and the previous management team grossly overpaying for about a dozen acquisitions, it's regularly had to sell its common stock to raise capital to pay its bills and fund buyouts.\nTaking into account a reverse split enacted last year to stave off delisting, Aurora's share count has ballooned from about 1.3 million shares in June 2014 to 198 million shares, as of mid-May. That sort of dilution is precisely why the company's shares are down nearly 95% since March 2019.\nThe salt in the wound is that Canada's legal weed sales have been hitting monthly records, all while Aurora's recreational pot revenue was more than halved in its fiscal third quarter.\nImage source: Getty Images.\nSundial Growers\nYet another Canadian pot stock in the no-buy zone for Wall Street is small-cap Sundial Growers (NASDAQ:SNDL). Even though it's the fourth most-held stock on Robinhood, four of the six analysts covering the company rate it a sell.\nDespite sitting on a boatload of cash, cash equivalents, and long-term investments (about $948 million), Sundial Growers has three factors working against it.\nTo begin with, Sundial's approach to raising capital has destroyed shareholder value. Initially, it looked as if management would sell enough common stock to simply pay off the company's outstanding debt. But in a nine-month stretch between Oct. 1, 2020 and June 30, 2021, Sundial's executives have unrelentingly issued stock to raise additional capital.\nThe end result is the issuance of roughly 1.5 billion shares of stock. With 2 billion shares now outstanding, Sundial has virtually no chance of ever generating meaningful earnings per share, and it'll likely struggle to remain listed on the Nasdaq exchange without a substantial reverse split.\nSecond, Sundial's management team hasn't laid out a concrete plan for its capital. While it did undertake a cash-and-stock deal to acquire Inner Spirit Holdings in July, and it's committed roughly $425 million to its joint venture with SAF Group, known as SunStream Bancorp, to invest in cannabis industry opportunities, the company has continued to raise cash with no stated purpose.\nThird, Sundial has shifted its operating model away from wholesale cannabis to take advantage of the higher margins associated with the retail side of the equation. Unfortunately, having to start from scratch has led to significant year-over-year sales declines at a time when legal weed sales are rapidly growing.\nIn March I more or less referred to Sundial as the worst cannabis stock money could buy. That descriptor still holds true today.\nImage source: Getty Images.\nAMC Entertainment\nBut the most popular stock of all that's getting absolutely no love from Wall Street analysts and investment banks is movie theater chain AMC Entertainment (NYSE:AMC). The third most-held stock on Robinhood has nine analysts covering the company. Five of them have it rated a sell, with four others chiming in with a hold rating.\nThis rating distribution isn't a surprise given that Wall Street's consensus price target for AMC is $5.44. Shares of the company would need to fall 86% from where they closed last week to reach this consensus target.\nThe reason AMC's share price has rocketed higher in 2021 primarily has to do with retail investors piling into the stock and betting on a short squeeze -- i.e., a very short-term event whereby pessimists (short-sellers) run for the exit and buy shares to cover their positions. The issue for these optimists is that none of the data surrounding AMC is working in their favor.\nFor one, short squeezes typically require certain conditions be met, which simply aren't there at the moment. While the company's 18.8% short interest at the end of August is higher than most stocks, its large daily trading volume means it would take less than a day for all 95.94 million short shares to be covered. The liquidity of AMC's stock means short-sellers have no fear of being trapped in their position.\nFundamentally, the movie theater industry has been in a nearly two-decade decline. Tickets sold and inflation-adjusted gross at the box office have fallen 22% between 2002 and 2019, the last full year before the pandemic. Streaming offerings and substantially reduced film exclusivity (30 to 45 days now, compared to 75 to 90 days prior to the pandemic) bode poorly for the industry's future.\nAnd then there's AMC's operating performance and liability-riddled balance sheet. Despite a record $2.023 billion in liquidity ($1.81 billion in cash), AMC burned through $576.5 million in cash in the first six months of 2021. Its lease liabilities are soaring, it owes $420 million in deferred rent, and it's lugging around nearly $5.5 billion in debt that it likely can't pay.\nMore than $1 billion in aggregate debt due in 2026 and 2027 is also valued at 70% to 74% of face value. Debt going for this much below par is a very real warning sign that bondholders believe a future default is possible.\nLong story short, Wall Street has every reason to be skeptical of AMC.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":862237758,"gmtCreate":1632880674416,"gmtModify":1632880674818,"author":{"id":"3578449123371823","authorId":"3578449123371823","name":"Mhong","avatar":"https://static.tigerbbs.com/f1110c90505cf18cc129130892c4dc2a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3578449123371823","authorIdStr":"3578449123371823"},"htmlText":"Like &amp; comment","listText":"Like &amp; comment","text":"Like & comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/862237758","repostId":2170778116,"repostType":4,"repost":{"id":"2170778116","kind":"highlight","pubTimestamp":1632829153,"share":"https://www.laohu8.com/m/news/2170778116?lang=&edition=full","pubTime":"2021-09-28 19:39","market":"us","language":"en","title":"3 Ultra-Popular Stocks With No Buy Ratings on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2170778116","media":"Motley Fool","summary":"These widely held stocks are getting no love from analysts.","content":"<p>Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.</p>\n<p>According to data from CNBC, over 90% of all <b>S&amp;P 500</b> stock ratings from Wall Street analysts were the equivalent of \"buy\" or \"hold\" between 1997 and 2017. With the exception of short periods in 2002-2003 and 2008-2009, sell ratings have consistently accounted for only 1% to 6% of all ratings for S&amp;P 500 companies this century.</p>\n<p>One reason for this \"buy bias\" is due to the U.S. and global economy growing over time. Historically, the stock market moves higher over the long run, too. Wall Street analysts might simply be playing the favorable odds that higher-quality businesses will increase in value over time.</p>\n<p>Additionally, <i>The Wall Street Journal</i> noted some years back that Wall Street analysts are hesitant to issue sell ratings so as not to burn bridges for their clients or themselves with the companies they cover. No matter the reasoning, sell ratings are rare on Wall Street.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fb1fd3c71278c123e5dd0404a4dbb43c\" tg-width=\"700\" tg-height=\"525\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<p>But don't tell that to shareholders of the following three ultra-popular stocks. These are three of the 16 most-held stocks on the <b>Robinhood</b> (NASDAQ:HOOD) platform, and not one of them has a single buy rating from a Wall Street analyst.</p>\n<h2>Aurora Cannabis</h2>\n<p>One of the biggest buzzkills, according to Wall Street, is Canadian marijuana stock <b>Aurora Cannabis</b> (NASDAQ:ACB). Aurora, which at one time was the most-held stock on Robinhood, is being covered by 13 Wall Street institutions, seven of which rate the company the equivalent of a hold and six of which believe it's a sell.</p>\n<p>Though Aurora Cannabis does foot the blame for a lot of this negativity, some of its issues can be traced to Canadian federal and provincial regulators failing the pot industry. For example, Ontario's lottery system to assign retail licenses through 2019 was terrible and resulted in only a few dozen dispensaries opening. Canadian pot stocks are still trying to recover from supply chain bottlenecks in the country's most populous province.</p>\n<p>But as I mentioned, Aurora Cannabis isn't without fault. The company expanded its production capacity far beyond what was needed. At one time, it held 15 production facilities that could have yielded more than 600,000 kilos of annual cannabis output if fully operational. Management has since closed five of these smaller facilities, sold a 1-million-square-foot greenhouse that wasn't retrofitted for cannabis production, and halted construction on two of the company's largest projects.</p>\n<p>Yet, even with this aggressive cost-cutting, Aurora Cannabis is still a long way from generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). With the company continuing to burn cash and the previous management team grossly overpaying for about a dozen acquisitions, it's regularly had to sell its common stock to raise capital to pay its bills and fund buyouts.</p>\n<p>Taking into account a reverse split enacted last year to stave off delisting, Aurora's share count has ballooned from about 1.3 million shares in June 2014 to 198 million shares, as of mid-May. That sort of dilution is precisely why the company's shares are down nearly 95% since March 2019.</p>\n<p>The salt in the wound is that Canada's legal weed sales have been hitting monthly records, all while Aurora's recreational pot revenue was more than halved in its fiscal third quarter.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/bc514068ded899a817770f684369db36\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Sundial Growers</h2>\n<p>Yet another Canadian pot stock in the no-buy zone for Wall Street is small-cap <b>Sundial Growers</b> (NASDAQ:SNDL). Even though it's the fourth most-held stock on Robinhood, four of the six analysts covering the company rate it a sell.</p>\n<p>Despite sitting on a boatload of cash, cash equivalents, and long-term investments (about $948 million), Sundial Growers has three factors working against it.</p>\n<p>To begin with, Sundial's approach to raising capital has destroyed shareholder value. Initially, it looked as if management would sell enough common stock to simply pay off the company's outstanding debt. But in a nine-month stretch between Oct. 1, 2020 and June 30, 2021, Sundial's executives have unrelentingly issued stock to raise additional capital.</p>\n<p>The end result is the issuance of roughly 1.5 billion shares of stock. With 2 billion shares now outstanding, Sundial has virtually no chance of ever generating meaningful earnings per share, and it'll likely struggle to remain listed on the <b>Nasdaq</b>&nbsp;exchange without a substantial reverse split.</p>\n<p>Second, Sundial's management team hasn't laid out a concrete plan for its capital. While it did undertake a cash-and-stock deal to acquire <a href=\"https://laohu8.com/S/INSHF\">Inner Spirit Holdings</a> in July, and it's committed roughly $425 million to its joint venture with SAF Group, known as SunStream Bancorp, to invest in cannabis industry opportunities, the company has continued to raise cash with no stated purpose.</p>\n<p>Third, Sundial has shifted its operating model away from wholesale cannabis to take advantage of the higher margins associated with the retail side of the equation. Unfortunately, having to start from scratch has led to significant year-over-year sales declines at a time when legal weed sales are rapidly growing.</p>\n<p>In March I more or less referred to Sundial as the worst cannabis stock money could buy. That descriptor still holds true today.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1c6cb4d9fcdf85f542f333fc71a2dd58\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>AMC Entertainment</h2>\n<p>But the most popular stock of all that's getting absolutely no love from Wall Street analysts and investment banks is movie theater chain <b>AMC Entertainment</b> (NYSE:AMC). The third most-held stock on Robinhood has nine analysts covering the company. Five of them have it rated a sell, with four others chiming in with a hold rating.</p>\n<p>This rating distribution isn't a surprise given that Wall Street's consensus price target for AMC is $5.44. Shares of the company would need to fall 86% from where they closed last week to reach this consensus target.</p>\n<p>The reason AMC's share price has rocketed higher in 2021 primarily has to do with retail investors piling into the stock and betting on a short squeeze -- i.e., a very short-term event whereby pessimists (short-sellers) run for the exit and buy shares to cover their positions. The issue for these optimists is that none of the data surrounding AMC is working in their favor.</p>\n<p>For one, short squeezes typically require certain conditions be met, which simply aren't there at the moment. While the company's 18.8% short interest at the end of August is higher than most stocks, its large daily trading volume means it would take less than a day for all 95.94 million short shares to be covered. The liquidity of AMC's stock means short-sellers have no fear of being trapped in their position.</p>\n<p>Fundamentally, the movie theater industry has been in a nearly two-decade decline. Tickets sold and inflation-adjusted gross at the box office have fallen 22% between 2002 and 2019, the last full year before the pandemic. Streaming offerings and substantially reduced film exclusivity (30 to 45 days now, compared to 75 to 90 days prior to the pandemic) bode poorly for the industry's future.</p>\n<p>And then there's AMC's operating performance and liability-riddled balance sheet. Despite a record $2.023 billion in liquidity ($1.81 billion in cash), AMC burned through $576.5 million in cash in the first six months of 2021. Its lease liabilities are soaring, it owes $420 million in deferred rent, and it's lugging around nearly $5.5 billion in debt that it likely can't pay.</p>\n<p>More than $1 billion in aggregate debt due in 2026 and 2027 is also valued at 70% to 74% of face value. Debt going for this much below par is a very real warning sign that bondholders believe a future default is possible.</p>\n<p>Long story short, Wall Street has every reason to be skeptical of AMC.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Ultra-Popular Stocks With No Buy Ratings on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Ultra-Popular Stocks With No Buy Ratings on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-28 19:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.\nAccording to data from CNBC, over 90% of all S&P 500 stock ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ACB":"奥罗拉大麻公司","SNDL":"SNDL Inc.","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2170778116","content_text":"Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.\nAccording to data from CNBC, over 90% of all S&P 500 stock ratings from Wall Street analysts were the equivalent of \"buy\" or \"hold\" between 1997 and 2017. With the exception of short periods in 2002-2003 and 2008-2009, sell ratings have consistently accounted for only 1% to 6% of all ratings for S&P 500 companies this century.\nOne reason for this \"buy bias\" is due to the U.S. and global economy growing over time. Historically, the stock market moves higher over the long run, too. Wall Street analysts might simply be playing the favorable odds that higher-quality businesses will increase in value over time.\nAdditionally, The Wall Street Journal noted some years back that Wall Street analysts are hesitant to issue sell ratings so as not to burn bridges for their clients or themselves with the companies they cover. No matter the reasoning, sell ratings are rare on Wall Street.\nImage source: Getty Images.\nBut don't tell that to shareholders of the following three ultra-popular stocks. These are three of the 16 most-held stocks on the Robinhood (NASDAQ:HOOD) platform, and not one of them has a single buy rating from a Wall Street analyst.\nAurora Cannabis\nOne of the biggest buzzkills, according to Wall Street, is Canadian marijuana stock Aurora Cannabis (NASDAQ:ACB). Aurora, which at one time was the most-held stock on Robinhood, is being covered by 13 Wall Street institutions, seven of which rate the company the equivalent of a hold and six of which believe it's a sell.\nThough Aurora Cannabis does foot the blame for a lot of this negativity, some of its issues can be traced to Canadian federal and provincial regulators failing the pot industry. For example, Ontario's lottery system to assign retail licenses through 2019 was terrible and resulted in only a few dozen dispensaries opening. Canadian pot stocks are still trying to recover from supply chain bottlenecks in the country's most populous province.\nBut as I mentioned, Aurora Cannabis isn't without fault. The company expanded its production capacity far beyond what was needed. At one time, it held 15 production facilities that could have yielded more than 600,000 kilos of annual cannabis output if fully operational. Management has since closed five of these smaller facilities, sold a 1-million-square-foot greenhouse that wasn't retrofitted for cannabis production, and halted construction on two of the company's largest projects.\nYet, even with this aggressive cost-cutting, Aurora Cannabis is still a long way from generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). With the company continuing to burn cash and the previous management team grossly overpaying for about a dozen acquisitions, it's regularly had to sell its common stock to raise capital to pay its bills and fund buyouts.\nTaking into account a reverse split enacted last year to stave off delisting, Aurora's share count has ballooned from about 1.3 million shares in June 2014 to 198 million shares, as of mid-May. That sort of dilution is precisely why the company's shares are down nearly 95% since March 2019.\nThe salt in the wound is that Canada's legal weed sales have been hitting monthly records, all while Aurora's recreational pot revenue was more than halved in its fiscal third quarter.\nImage source: Getty Images.\nSundial Growers\nYet another Canadian pot stock in the no-buy zone for Wall Street is small-cap Sundial Growers (NASDAQ:SNDL). Even though it's the fourth most-held stock on Robinhood, four of the six analysts covering the company rate it a sell.\nDespite sitting on a boatload of cash, cash equivalents, and long-term investments (about $948 million), Sundial Growers has three factors working against it.\nTo begin with, Sundial's approach to raising capital has destroyed shareholder value. Initially, it looked as if management would sell enough common stock to simply pay off the company's outstanding debt. But in a nine-month stretch between Oct. 1, 2020 and June 30, 2021, Sundial's executives have unrelentingly issued stock to raise additional capital.\nThe end result is the issuance of roughly 1.5 billion shares of stock. With 2 billion shares now outstanding, Sundial has virtually no chance of ever generating meaningful earnings per share, and it'll likely struggle to remain listed on the Nasdaq exchange without a substantial reverse split.\nSecond, Sundial's management team hasn't laid out a concrete plan for its capital. While it did undertake a cash-and-stock deal to acquire Inner Spirit Holdings in July, and it's committed roughly $425 million to its joint venture with SAF Group, known as SunStream Bancorp, to invest in cannabis industry opportunities, the company has continued to raise cash with no stated purpose.\nThird, Sundial has shifted its operating model away from wholesale cannabis to take advantage of the higher margins associated with the retail side of the equation. Unfortunately, having to start from scratch has led to significant year-over-year sales declines at a time when legal weed sales are rapidly growing.\nIn March I more or less referred to Sundial as the worst cannabis stock money could buy. That descriptor still holds true today.\nImage source: Getty Images.\nAMC Entertainment\nBut the most popular stock of all that's getting absolutely no love from Wall Street analysts and investment banks is movie theater chain AMC Entertainment (NYSE:AMC). The third most-held stock on Robinhood has nine analysts covering the company. Five of them have it rated a sell, with four others chiming in with a hold rating.\nThis rating distribution isn't a surprise given that Wall Street's consensus price target for AMC is $5.44. Shares of the company would need to fall 86% from where they closed last week to reach this consensus target.\nThe reason AMC's share price has rocketed higher in 2021 primarily has to do with retail investors piling into the stock and betting on a short squeeze -- i.e., a very short-term event whereby pessimists (short-sellers) run for the exit and buy shares to cover their positions. The issue for these optimists is that none of the data surrounding AMC is working in their favor.\nFor one, short squeezes typically require certain conditions be met, which simply aren't there at the moment. While the company's 18.8% short interest at the end of August is higher than most stocks, its large daily trading volume means it would take less than a day for all 95.94 million short shares to be covered. The liquidity of AMC's stock means short-sellers have no fear of being trapped in their position.\nFundamentally, the movie theater industry has been in a nearly two-decade decline. Tickets sold and inflation-adjusted gross at the box office have fallen 22% between 2002 and 2019, the last full year before the pandemic. Streaming offerings and substantially reduced film exclusivity (30 to 45 days now, compared to 75 to 90 days prior to the pandemic) bode poorly for the industry's future.\nAnd then there's AMC's operating performance and liability-riddled balance sheet. Despite a record $2.023 billion in liquidity ($1.81 billion in cash), AMC burned through $576.5 million in cash in the first six months of 2021. Its lease liabilities are soaring, it owes $420 million in deferred rent, and it's lugging around nearly $5.5 billion in debt that it likely can't pay.\nMore than $1 billion in aggregate debt due in 2026 and 2027 is also valued at 70% to 74% of face value. Debt going for this much below par is a very real warning sign that bondholders believe a future default is possible.\nLong story short, Wall Street has every reason to be skeptical of AMC.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6033263,"gmtCreate":1632882738458,"gmtModify":1634782806087,"authorId":3586655655659820,"author":{"id":3586655655659820,"idStr":"3586655655659820","authorId":3586655655659820,"name":"sunshine138","avatar":"https://static.tigerbbs.com/23149c63a63bfeec1572cc27e1322750","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":862237758,"type":1,"supId":0,"prevId":0,"content":"Like <u>2</u>","text":"Like <u>2</u>","html":"Like <u>2</u>"}],"langContent":"CN"},{"id":862843833,"gmtCreate":1632872000061,"gmtModify":1632872000642,"author":{"id":"3579082097230100","authorId":"3579082097230100","name":"Gaga71","avatar":"https://static.tigerbbs.com/02afa88b95dc30f4a60767c18f9e2f39","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"3579082097230100","authorIdStr":"3579082097230100"},"htmlText":"Not touching these stocks","listText":"Not touching these stocks","text":"Not touching these stocks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862843833","repostId":2170778116,"repostType":4,"repost":{"id":"2170778116","kind":"highlight","pubTimestamp":1632829153,"share":"https://www.laohu8.com/m/news/2170778116?lang=&edition=full","pubTime":"2021-09-28 19:39","market":"us","language":"en","title":"3 Ultra-Popular Stocks With No Buy Ratings on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2170778116","media":"Motley Fool","summary":"These widely held stocks are getting no love from analysts.","content":"<p>Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.</p>\n<p>According to data from CNBC, over 90% of all <b>S&amp;P 500</b> stock ratings from Wall Street analysts were the equivalent of \"buy\" or \"hold\" between 1997 and 2017. With the exception of short periods in 2002-2003 and 2008-2009, sell ratings have consistently accounted for only 1% to 6% of all ratings for S&amp;P 500 companies this century.</p>\n<p>One reason for this \"buy bias\" is due to the U.S. and global economy growing over time. Historically, the stock market moves higher over the long run, too. Wall Street analysts might simply be playing the favorable odds that higher-quality businesses will increase in value over time.</p>\n<p>Additionally, <i>The Wall Street Journal</i> noted some years back that Wall Street analysts are hesitant to issue sell ratings so as not to burn bridges for their clients or themselves with the companies they cover. No matter the reasoning, sell ratings are rare on Wall Street.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fb1fd3c71278c123e5dd0404a4dbb43c\" tg-width=\"700\" tg-height=\"525\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<p>But don't tell that to shareholders of the following three ultra-popular stocks. These are three of the 16 most-held stocks on the <b>Robinhood</b> (NASDAQ:HOOD) platform, and not one of them has a single buy rating from a Wall Street analyst.</p>\n<h2>Aurora Cannabis</h2>\n<p>One of the biggest buzzkills, according to Wall Street, is Canadian marijuana stock <b>Aurora Cannabis</b> (NASDAQ:ACB). Aurora, which at one time was the most-held stock on Robinhood, is being covered by 13 Wall Street institutions, seven of which rate the company the equivalent of a hold and six of which believe it's a sell.</p>\n<p>Though Aurora Cannabis does foot the blame for a lot of this negativity, some of its issues can be traced to Canadian federal and provincial regulators failing the pot industry. For example, Ontario's lottery system to assign retail licenses through 2019 was terrible and resulted in only a few dozen dispensaries opening. Canadian pot stocks are still trying to recover from supply chain bottlenecks in the country's most populous province.</p>\n<p>But as I mentioned, Aurora Cannabis isn't without fault. The company expanded its production capacity far beyond what was needed. At one time, it held 15 production facilities that could have yielded more than 600,000 kilos of annual cannabis output if fully operational. Management has since closed five of these smaller facilities, sold a 1-million-square-foot greenhouse that wasn't retrofitted for cannabis production, and halted construction on two of the company's largest projects.</p>\n<p>Yet, even with this aggressive cost-cutting, Aurora Cannabis is still a long way from generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). With the company continuing to burn cash and the previous management team grossly overpaying for about a dozen acquisitions, it's regularly had to sell its common stock to raise capital to pay its bills and fund buyouts.</p>\n<p>Taking into account a reverse split enacted last year to stave off delisting, Aurora's share count has ballooned from about 1.3 million shares in June 2014 to 198 million shares, as of mid-May. That sort of dilution is precisely why the company's shares are down nearly 95% since March 2019.</p>\n<p>The salt in the wound is that Canada's legal weed sales have been hitting monthly records, all while Aurora's recreational pot revenue was more than halved in its fiscal third quarter.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/bc514068ded899a817770f684369db36\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Sundial Growers</h2>\n<p>Yet another Canadian pot stock in the no-buy zone for Wall Street is small-cap <b>Sundial Growers</b> (NASDAQ:SNDL). Even though it's the fourth most-held stock on Robinhood, four of the six analysts covering the company rate it a sell.</p>\n<p>Despite sitting on a boatload of cash, cash equivalents, and long-term investments (about $948 million), Sundial Growers has three factors working against it.</p>\n<p>To begin with, Sundial's approach to raising capital has destroyed shareholder value. Initially, it looked as if management would sell enough common stock to simply pay off the company's outstanding debt. But in a nine-month stretch between Oct. 1, 2020 and June 30, 2021, Sundial's executives have unrelentingly issued stock to raise additional capital.</p>\n<p>The end result is the issuance of roughly 1.5 billion shares of stock. With 2 billion shares now outstanding, Sundial has virtually no chance of ever generating meaningful earnings per share, and it'll likely struggle to remain listed on the <b>Nasdaq</b>&nbsp;exchange without a substantial reverse split.</p>\n<p>Second, Sundial's management team hasn't laid out a concrete plan for its capital. While it did undertake a cash-and-stock deal to acquire <a href=\"https://laohu8.com/S/INSHF\">Inner Spirit Holdings</a> in July, and it's committed roughly $425 million to its joint venture with SAF Group, known as SunStream Bancorp, to invest in cannabis industry opportunities, the company has continued to raise cash with no stated purpose.</p>\n<p>Third, Sundial has shifted its operating model away from wholesale cannabis to take advantage of the higher margins associated with the retail side of the equation. Unfortunately, having to start from scratch has led to significant year-over-year sales declines at a time when legal weed sales are rapidly growing.</p>\n<p>In March I more or less referred to Sundial as the worst cannabis stock money could buy. That descriptor still holds true today.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1c6cb4d9fcdf85f542f333fc71a2dd58\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>AMC Entertainment</h2>\n<p>But the most popular stock of all that's getting absolutely no love from Wall Street analysts and investment banks is movie theater chain <b>AMC Entertainment</b> (NYSE:AMC). The third most-held stock on Robinhood has nine analysts covering the company. Five of them have it rated a sell, with four others chiming in with a hold rating.</p>\n<p>This rating distribution isn't a surprise given that Wall Street's consensus price target for AMC is $5.44. Shares of the company would need to fall 86% from where they closed last week to reach this consensus target.</p>\n<p>The reason AMC's share price has rocketed higher in 2021 primarily has to do with retail investors piling into the stock and betting on a short squeeze -- i.e., a very short-term event whereby pessimists (short-sellers) run for the exit and buy shares to cover their positions. The issue for these optimists is that none of the data surrounding AMC is working in their favor.</p>\n<p>For one, short squeezes typically require certain conditions be met, which simply aren't there at the moment. While the company's 18.8% short interest at the end of August is higher than most stocks, its large daily trading volume means it would take less than a day for all 95.94 million short shares to be covered. The liquidity of AMC's stock means short-sellers have no fear of being trapped in their position.</p>\n<p>Fundamentally, the movie theater industry has been in a nearly two-decade decline. Tickets sold and inflation-adjusted gross at the box office have fallen 22% between 2002 and 2019, the last full year before the pandemic. Streaming offerings and substantially reduced film exclusivity (30 to 45 days now, compared to 75 to 90 days prior to the pandemic) bode poorly for the industry's future.</p>\n<p>And then there's AMC's operating performance and liability-riddled balance sheet. Despite a record $2.023 billion in liquidity ($1.81 billion in cash), AMC burned through $576.5 million in cash in the first six months of 2021. Its lease liabilities are soaring, it owes $420 million in deferred rent, and it's lugging around nearly $5.5 billion in debt that it likely can't pay.</p>\n<p>More than $1 billion in aggregate debt due in 2026 and 2027 is also valued at 70% to 74% of face value. Debt going for this much below par is a very real warning sign that bondholders believe a future default is possible.</p>\n<p>Long story short, Wall Street has every reason to be skeptical of AMC.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Ultra-Popular Stocks With No Buy Ratings on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Ultra-Popular Stocks With No Buy Ratings on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-28 19:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.\nAccording to data from CNBC, over 90% of all S&P 500 stock ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ACB":"奥罗拉大麻公司","SNDL":"SNDL Inc.","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2170778116","content_text":"Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.\nAccording to data from CNBC, over 90% of all S&P 500 stock ratings from Wall Street analysts were the equivalent of \"buy\" or \"hold\" between 1997 and 2017. With the exception of short periods in 2002-2003 and 2008-2009, sell ratings have consistently accounted for only 1% to 6% of all ratings for S&P 500 companies this century.\nOne reason for this \"buy bias\" is due to the U.S. and global economy growing over time. Historically, the stock market moves higher over the long run, too. Wall Street analysts might simply be playing the favorable odds that higher-quality businesses will increase in value over time.\nAdditionally, The Wall Street Journal noted some years back that Wall Street analysts are hesitant to issue sell ratings so as not to burn bridges for their clients or themselves with the companies they cover. No matter the reasoning, sell ratings are rare on Wall Street.\nImage source: Getty Images.\nBut don't tell that to shareholders of the following three ultra-popular stocks. These are three of the 16 most-held stocks on the Robinhood (NASDAQ:HOOD) platform, and not one of them has a single buy rating from a Wall Street analyst.\nAurora Cannabis\nOne of the biggest buzzkills, according to Wall Street, is Canadian marijuana stock Aurora Cannabis (NASDAQ:ACB). Aurora, which at one time was the most-held stock on Robinhood, is being covered by 13 Wall Street institutions, seven of which rate the company the equivalent of a hold and six of which believe it's a sell.\nThough Aurora Cannabis does foot the blame for a lot of this negativity, some of its issues can be traced to Canadian federal and provincial regulators failing the pot industry. For example, Ontario's lottery system to assign retail licenses through 2019 was terrible and resulted in only a few dozen dispensaries opening. Canadian pot stocks are still trying to recover from supply chain bottlenecks in the country's most populous province.\nBut as I mentioned, Aurora Cannabis isn't without fault. The company expanded its production capacity far beyond what was needed. At one time, it held 15 production facilities that could have yielded more than 600,000 kilos of annual cannabis output if fully operational. Management has since closed five of these smaller facilities, sold a 1-million-square-foot greenhouse that wasn't retrofitted for cannabis production, and halted construction on two of the company's largest projects.\nYet, even with this aggressive cost-cutting, Aurora Cannabis is still a long way from generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). With the company continuing to burn cash and the previous management team grossly overpaying for about a dozen acquisitions, it's regularly had to sell its common stock to raise capital to pay its bills and fund buyouts.\nTaking into account a reverse split enacted last year to stave off delisting, Aurora's share count has ballooned from about 1.3 million shares in June 2014 to 198 million shares, as of mid-May. That sort of dilution is precisely why the company's shares are down nearly 95% since March 2019.\nThe salt in the wound is that Canada's legal weed sales have been hitting monthly records, all while Aurora's recreational pot revenue was more than halved in its fiscal third quarter.\nImage source: Getty Images.\nSundial Growers\nYet another Canadian pot stock in the no-buy zone for Wall Street is small-cap Sundial Growers (NASDAQ:SNDL). Even though it's the fourth most-held stock on Robinhood, four of the six analysts covering the company rate it a sell.\nDespite sitting on a boatload of cash, cash equivalents, and long-term investments (about $948 million), Sundial Growers has three factors working against it.\nTo begin with, Sundial's approach to raising capital has destroyed shareholder value. Initially, it looked as if management would sell enough common stock to simply pay off the company's outstanding debt. But in a nine-month stretch between Oct. 1, 2020 and June 30, 2021, Sundial's executives have unrelentingly issued stock to raise additional capital.\nThe end result is the issuance of roughly 1.5 billion shares of stock. With 2 billion shares now outstanding, Sundial has virtually no chance of ever generating meaningful earnings per share, and it'll likely struggle to remain listed on the Nasdaq exchange without a substantial reverse split.\nSecond, Sundial's management team hasn't laid out a concrete plan for its capital. While it did undertake a cash-and-stock deal to acquire Inner Spirit Holdings in July, and it's committed roughly $425 million to its joint venture with SAF Group, known as SunStream Bancorp, to invest in cannabis industry opportunities, the company has continued to raise cash with no stated purpose.\nThird, Sundial has shifted its operating model away from wholesale cannabis to take advantage of the higher margins associated with the retail side of the equation. Unfortunately, having to start from scratch has led to significant year-over-year sales declines at a time when legal weed sales are rapidly growing.\nIn March I more or less referred to Sundial as the worst cannabis stock money could buy. That descriptor still holds true today.\nImage source: Getty Images.\nAMC Entertainment\nBut the most popular stock of all that's getting absolutely no love from Wall Street analysts and investment banks is movie theater chain AMC Entertainment (NYSE:AMC). The third most-held stock on Robinhood has nine analysts covering the company. Five of them have it rated a sell, with four others chiming in with a hold rating.\nThis rating distribution isn't a surprise given that Wall Street's consensus price target for AMC is $5.44. Shares of the company would need to fall 86% from where they closed last week to reach this consensus target.\nThe reason AMC's share price has rocketed higher in 2021 primarily has to do with retail investors piling into the stock and betting on a short squeeze -- i.e., a very short-term event whereby pessimists (short-sellers) run for the exit and buy shares to cover their positions. The issue for these optimists is that none of the data surrounding AMC is working in their favor.\nFor one, short squeezes typically require certain conditions be met, which simply aren't there at the moment. While the company's 18.8% short interest at the end of August is higher than most stocks, its large daily trading volume means it would take less than a day for all 95.94 million short shares to be covered. The liquidity of AMC's stock means short-sellers have no fear of being trapped in their position.\nFundamentally, the movie theater industry has been in a nearly two-decade decline. Tickets sold and inflation-adjusted gross at the box office have fallen 22% between 2002 and 2019, the last full year before the pandemic. Streaming offerings and substantially reduced film exclusivity (30 to 45 days now, compared to 75 to 90 days prior to the pandemic) bode poorly for the industry's future.\nAnd then there's AMC's operating performance and liability-riddled balance sheet. Despite a record $2.023 billion in liquidity ($1.81 billion in cash), AMC burned through $576.5 million in cash in the first six months of 2021. Its lease liabilities are soaring, it owes $420 million in deferred rent, and it's lugging around nearly $5.5 billion in debt that it likely can't pay.\nMore than $1 billion in aggregate debt due in 2026 and 2027 is also valued at 70% to 74% of face value. Debt going for this much below par is a very real warning sign that bondholders believe a future default is possible.\nLong story short, Wall Street has every reason to be skeptical of AMC.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":862853547,"gmtCreate":1632871461339,"gmtModify":1632871461447,"author":{"id":"3561465133588808","authorId":"3561465133588808","name":"Karenz","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3561465133588808","authorIdStr":"3561465133588808"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862853547","repostId":2170778116,"repostType":4,"repost":{"id":"2170778116","kind":"highlight","pubTimestamp":1632829153,"share":"https://www.laohu8.com/m/news/2170778116?lang=&edition=full","pubTime":"2021-09-28 19:39","market":"us","language":"en","title":"3 Ultra-Popular Stocks With No Buy Ratings on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2170778116","media":"Motley Fool","summary":"These widely held stocks are getting no love from analysts.","content":"<p>Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.</p>\n<p>According to data from CNBC, over 90% of all <b>S&amp;P 500</b> stock ratings from Wall Street analysts were the equivalent of \"buy\" or \"hold\" between 1997 and 2017. With the exception of short periods in 2002-2003 and 2008-2009, sell ratings have consistently accounted for only 1% to 6% of all ratings for S&amp;P 500 companies this century.</p>\n<p>One reason for this \"buy bias\" is due to the U.S. and global economy growing over time. Historically, the stock market moves higher over the long run, too. Wall Street analysts might simply be playing the favorable odds that higher-quality businesses will increase in value over time.</p>\n<p>Additionally, <i>The Wall Street Journal</i> noted some years back that Wall Street analysts are hesitant to issue sell ratings so as not to burn bridges for their clients or themselves with the companies they cover. No matter the reasoning, sell ratings are rare on Wall Street.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fb1fd3c71278c123e5dd0404a4dbb43c\" tg-width=\"700\" tg-height=\"525\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<p>But don't tell that to shareholders of the following three ultra-popular stocks. These are three of the 16 most-held stocks on the <b>Robinhood</b> (NASDAQ:HOOD) platform, and not one of them has a single buy rating from a Wall Street analyst.</p>\n<h2>Aurora Cannabis</h2>\n<p>One of the biggest buzzkills, according to Wall Street, is Canadian marijuana stock <b>Aurora Cannabis</b> (NASDAQ:ACB). Aurora, which at one time was the most-held stock on Robinhood, is being covered by 13 Wall Street institutions, seven of which rate the company the equivalent of a hold and six of which believe it's a sell.</p>\n<p>Though Aurora Cannabis does foot the blame for a lot of this negativity, some of its issues can be traced to Canadian federal and provincial regulators failing the pot industry. For example, Ontario's lottery system to assign retail licenses through 2019 was terrible and resulted in only a few dozen dispensaries opening. Canadian pot stocks are still trying to recover from supply chain bottlenecks in the country's most populous province.</p>\n<p>But as I mentioned, Aurora Cannabis isn't without fault. The company expanded its production capacity far beyond what was needed. At one time, it held 15 production facilities that could have yielded more than 600,000 kilos of annual cannabis output if fully operational. Management has since closed five of these smaller facilities, sold a 1-million-square-foot greenhouse that wasn't retrofitted for cannabis production, and halted construction on two of the company's largest projects.</p>\n<p>Yet, even with this aggressive cost-cutting, Aurora Cannabis is still a long way from generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). With the company continuing to burn cash and the previous management team grossly overpaying for about a dozen acquisitions, it's regularly had to sell its common stock to raise capital to pay its bills and fund buyouts.</p>\n<p>Taking into account a reverse split enacted last year to stave off delisting, Aurora's share count has ballooned from about 1.3 million shares in June 2014 to 198 million shares, as of mid-May. That sort of dilution is precisely why the company's shares are down nearly 95% since March 2019.</p>\n<p>The salt in the wound is that Canada's legal weed sales have been hitting monthly records, all while Aurora's recreational pot revenue was more than halved in its fiscal third quarter.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/bc514068ded899a817770f684369db36\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Sundial Growers</h2>\n<p>Yet another Canadian pot stock in the no-buy zone for Wall Street is small-cap <b>Sundial Growers</b> (NASDAQ:SNDL). Even though it's the fourth most-held stock on Robinhood, four of the six analysts covering the company rate it a sell.</p>\n<p>Despite sitting on a boatload of cash, cash equivalents, and long-term investments (about $948 million), Sundial Growers has three factors working against it.</p>\n<p>To begin with, Sundial's approach to raising capital has destroyed shareholder value. Initially, it looked as if management would sell enough common stock to simply pay off the company's outstanding debt. But in a nine-month stretch between Oct. 1, 2020 and June 30, 2021, Sundial's executives have unrelentingly issued stock to raise additional capital.</p>\n<p>The end result is the issuance of roughly 1.5 billion shares of stock. With 2 billion shares now outstanding, Sundial has virtually no chance of ever generating meaningful earnings per share, and it'll likely struggle to remain listed on the <b>Nasdaq</b>&nbsp;exchange without a substantial reverse split.</p>\n<p>Second, Sundial's management team hasn't laid out a concrete plan for its capital. While it did undertake a cash-and-stock deal to acquire <a href=\"https://laohu8.com/S/INSHF\">Inner Spirit Holdings</a> in July, and it's committed roughly $425 million to its joint venture with SAF Group, known as SunStream Bancorp, to invest in cannabis industry opportunities, the company has continued to raise cash with no stated purpose.</p>\n<p>Third, Sundial has shifted its operating model away from wholesale cannabis to take advantage of the higher margins associated with the retail side of the equation. Unfortunately, having to start from scratch has led to significant year-over-year sales declines at a time when legal weed sales are rapidly growing.</p>\n<p>In March I more or less referred to Sundial as the worst cannabis stock money could buy. That descriptor still holds true today.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1c6cb4d9fcdf85f542f333fc71a2dd58\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>AMC Entertainment</h2>\n<p>But the most popular stock of all that's getting absolutely no love from Wall Street analysts and investment banks is movie theater chain <b>AMC Entertainment</b> (NYSE:AMC). The third most-held stock on Robinhood has nine analysts covering the company. Five of them have it rated a sell, with four others chiming in with a hold rating.</p>\n<p>This rating distribution isn't a surprise given that Wall Street's consensus price target for AMC is $5.44. Shares of the company would need to fall 86% from where they closed last week to reach this consensus target.</p>\n<p>The reason AMC's share price has rocketed higher in 2021 primarily has to do with retail investors piling into the stock and betting on a short squeeze -- i.e., a very short-term event whereby pessimists (short-sellers) run for the exit and buy shares to cover their positions. The issue for these optimists is that none of the data surrounding AMC is working in their favor.</p>\n<p>For one, short squeezes typically require certain conditions be met, which simply aren't there at the moment. While the company's 18.8% short interest at the end of August is higher than most stocks, its large daily trading volume means it would take less than a day for all 95.94 million short shares to be covered. The liquidity of AMC's stock means short-sellers have no fear of being trapped in their position.</p>\n<p>Fundamentally, the movie theater industry has been in a nearly two-decade decline. Tickets sold and inflation-adjusted gross at the box office have fallen 22% between 2002 and 2019, the last full year before the pandemic. Streaming offerings and substantially reduced film exclusivity (30 to 45 days now, compared to 75 to 90 days prior to the pandemic) bode poorly for the industry's future.</p>\n<p>And then there's AMC's operating performance and liability-riddled balance sheet. Despite a record $2.023 billion in liquidity ($1.81 billion in cash), AMC burned through $576.5 million in cash in the first six months of 2021. Its lease liabilities are soaring, it owes $420 million in deferred rent, and it's lugging around nearly $5.5 billion in debt that it likely can't pay.</p>\n<p>More than $1 billion in aggregate debt due in 2026 and 2027 is also valued at 70% to 74% of face value. Debt going for this much below par is a very real warning sign that bondholders believe a future default is possible.</p>\n<p>Long story short, Wall Street has every reason to be skeptical of AMC.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Ultra-Popular Stocks With No Buy Ratings on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Ultra-Popular Stocks With No Buy Ratings on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-28 19:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.\nAccording to data from CNBC, over 90% of all S&P 500 stock ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ACB":"奥罗拉大麻公司","SNDL":"SNDL Inc.","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2170778116","content_text":"Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.\nAccording to data from CNBC, over 90% of all S&P 500 stock ratings from Wall Street analysts were the equivalent of \"buy\" or \"hold\" between 1997 and 2017. With the exception of short periods in 2002-2003 and 2008-2009, sell ratings have consistently accounted for only 1% to 6% of all ratings for S&P 500 companies this century.\nOne reason for this \"buy bias\" is due to the U.S. and global economy growing over time. Historically, the stock market moves higher over the long run, too. Wall Street analysts might simply be playing the favorable odds that higher-quality businesses will increase in value over time.\nAdditionally, The Wall Street Journal noted some years back that Wall Street analysts are hesitant to issue sell ratings so as not to burn bridges for their clients or themselves with the companies they cover. No matter the reasoning, sell ratings are rare on Wall Street.\nImage source: Getty Images.\nBut don't tell that to shareholders of the following three ultra-popular stocks. These are three of the 16 most-held stocks on the Robinhood (NASDAQ:HOOD) platform, and not one of them has a single buy rating from a Wall Street analyst.\nAurora Cannabis\nOne of the biggest buzzkills, according to Wall Street, is Canadian marijuana stock Aurora Cannabis (NASDAQ:ACB). Aurora, which at one time was the most-held stock on Robinhood, is being covered by 13 Wall Street institutions, seven of which rate the company the equivalent of a hold and six of which believe it's a sell.\nThough Aurora Cannabis does foot the blame for a lot of this negativity, some of its issues can be traced to Canadian federal and provincial regulators failing the pot industry. For example, Ontario's lottery system to assign retail licenses through 2019 was terrible and resulted in only a few dozen dispensaries opening. Canadian pot stocks are still trying to recover from supply chain bottlenecks in the country's most populous province.\nBut as I mentioned, Aurora Cannabis isn't without fault. The company expanded its production capacity far beyond what was needed. At one time, it held 15 production facilities that could have yielded more than 600,000 kilos of annual cannabis output if fully operational. Management has since closed five of these smaller facilities, sold a 1-million-square-foot greenhouse that wasn't retrofitted for cannabis production, and halted construction on two of the company's largest projects.\nYet, even with this aggressive cost-cutting, Aurora Cannabis is still a long way from generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). With the company continuing to burn cash and the previous management team grossly overpaying for about a dozen acquisitions, it's regularly had to sell its common stock to raise capital to pay its bills and fund buyouts.\nTaking into account a reverse split enacted last year to stave off delisting, Aurora's share count has ballooned from about 1.3 million shares in June 2014 to 198 million shares, as of mid-May. That sort of dilution is precisely why the company's shares are down nearly 95% since March 2019.\nThe salt in the wound is that Canada's legal weed sales have been hitting monthly records, all while Aurora's recreational pot revenue was more than halved in its fiscal third quarter.\nImage source: Getty Images.\nSundial Growers\nYet another Canadian pot stock in the no-buy zone for Wall Street is small-cap Sundial Growers (NASDAQ:SNDL). Even though it's the fourth most-held stock on Robinhood, four of the six analysts covering the company rate it a sell.\nDespite sitting on a boatload of cash, cash equivalents, and long-term investments (about $948 million), Sundial Growers has three factors working against it.\nTo begin with, Sundial's approach to raising capital has destroyed shareholder value. Initially, it looked as if management would sell enough common stock to simply pay off the company's outstanding debt. But in a nine-month stretch between Oct. 1, 2020 and June 30, 2021, Sundial's executives have unrelentingly issued stock to raise additional capital.\nThe end result is the issuance of roughly 1.5 billion shares of stock. With 2 billion shares now outstanding, Sundial has virtually no chance of ever generating meaningful earnings per share, and it'll likely struggle to remain listed on the Nasdaq exchange without a substantial reverse split.\nSecond, Sundial's management team hasn't laid out a concrete plan for its capital. While it did undertake a cash-and-stock deal to acquire Inner Spirit Holdings in July, and it's committed roughly $425 million to its joint venture with SAF Group, known as SunStream Bancorp, to invest in cannabis industry opportunities, the company has continued to raise cash with no stated purpose.\nThird, Sundial has shifted its operating model away from wholesale cannabis to take advantage of the higher margins associated with the retail side of the equation. Unfortunately, having to start from scratch has led to significant year-over-year sales declines at a time when legal weed sales are rapidly growing.\nIn March I more or less referred to Sundial as the worst cannabis stock money could buy. That descriptor still holds true today.\nImage source: Getty Images.\nAMC Entertainment\nBut the most popular stock of all that's getting absolutely no love from Wall Street analysts and investment banks is movie theater chain AMC Entertainment (NYSE:AMC). The third most-held stock on Robinhood has nine analysts covering the company. Five of them have it rated a sell, with four others chiming in with a hold rating.\nThis rating distribution isn't a surprise given that Wall Street's consensus price target for AMC is $5.44. Shares of the company would need to fall 86% from where they closed last week to reach this consensus target.\nThe reason AMC's share price has rocketed higher in 2021 primarily has to do with retail investors piling into the stock and betting on a short squeeze -- i.e., a very short-term event whereby pessimists (short-sellers) run for the exit and buy shares to cover their positions. The issue for these optimists is that none of the data surrounding AMC is working in their favor.\nFor one, short squeezes typically require certain conditions be met, which simply aren't there at the moment. While the company's 18.8% short interest at the end of August is higher than most stocks, its large daily trading volume means it would take less than a day for all 95.94 million short shares to be covered. The liquidity of AMC's stock means short-sellers have no fear of being trapped in their position.\nFundamentally, the movie theater industry has been in a nearly two-decade decline. Tickets sold and inflation-adjusted gross at the box office have fallen 22% between 2002 and 2019, the last full year before the pandemic. Streaming offerings and substantially reduced film exclusivity (30 to 45 days now, compared to 75 to 90 days prior to the pandemic) bode poorly for the industry's future.\nAnd then there's AMC's operating performance and liability-riddled balance sheet. Despite a record $2.023 billion in liquidity ($1.81 billion in cash), AMC burned through $576.5 million in cash in the first six months of 2021. Its lease liabilities are soaring, it owes $420 million in deferred rent, and it's lugging around nearly $5.5 billion in debt that it likely can't pay.\nMore than $1 billion in aggregate debt due in 2026 and 2027 is also valued at 70% to 74% of face value. Debt going for this much below par is a very real warning sign that bondholders believe a future default is possible.\nLong story short, Wall Street has every reason to be skeptical of AMC.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":862824506,"gmtCreate":1632871242317,"gmtModify":1632871264624,"author":{"id":"3559357742503712","authorId":"3559357742503712","name":"生肉麵加豬油渣","avatar":"https://static.tigerbbs.com/797772e5857b1091ed85d4b17fe6201b","vip":1,"crmLevel":6,"crmLevelSwitch":1,"idStr":"3559357742503712","authorIdStr":"3559357742503712"},"htmlText":"No value to me","listText":"No value to me","text":"No value to me","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/862824506","repostId":2170778116,"repostType":4,"repost":{"id":"2170778116","kind":"highlight","pubTimestamp":1632829153,"share":"https://www.laohu8.com/m/news/2170778116?lang=&edition=full","pubTime":"2021-09-28 19:39","market":"us","language":"en","title":"3 Ultra-Popular Stocks With No Buy Ratings on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2170778116","media":"Motley Fool","summary":"These widely held stocks are getting no love from analysts.","content":"<p>Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.</p>\n<p>According to data from CNBC, over 90% of all <b>S&amp;P 500</b> stock ratings from Wall Street analysts were the equivalent of \"buy\" or \"hold\" between 1997 and 2017. With the exception of short periods in 2002-2003 and 2008-2009, sell ratings have consistently accounted for only 1% to 6% of all ratings for S&amp;P 500 companies this century.</p>\n<p>One reason for this \"buy bias\" is due to the U.S. and global economy growing over time. Historically, the stock market moves higher over the long run, too. Wall Street analysts might simply be playing the favorable odds that higher-quality businesses will increase in value over time.</p>\n<p>Additionally, <i>The Wall Street Journal</i> noted some years back that Wall Street analysts are hesitant to issue sell ratings so as not to burn bridges for their clients or themselves with the companies they cover. No matter the reasoning, sell ratings are rare on Wall Street.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fb1fd3c71278c123e5dd0404a4dbb43c\" tg-width=\"700\" tg-height=\"525\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<p>But don't tell that to shareholders of the following three ultra-popular stocks. These are three of the 16 most-held stocks on the <b>Robinhood</b> (NASDAQ:HOOD) platform, and not one of them has a single buy rating from a Wall Street analyst.</p>\n<h2>Aurora Cannabis</h2>\n<p>One of the biggest buzzkills, according to Wall Street, is Canadian marijuana stock <b>Aurora Cannabis</b> (NASDAQ:ACB). Aurora, which at one time was the most-held stock on Robinhood, is being covered by 13 Wall Street institutions, seven of which rate the company the equivalent of a hold and six of which believe it's a sell.</p>\n<p>Though Aurora Cannabis does foot the blame for a lot of this negativity, some of its issues can be traced to Canadian federal and provincial regulators failing the pot industry. For example, Ontario's lottery system to assign retail licenses through 2019 was terrible and resulted in only a few dozen dispensaries opening. Canadian pot stocks are still trying to recover from supply chain bottlenecks in the country's most populous province.</p>\n<p>But as I mentioned, Aurora Cannabis isn't without fault. The company expanded its production capacity far beyond what was needed. At one time, it held 15 production facilities that could have yielded more than 600,000 kilos of annual cannabis output if fully operational. Management has since closed five of these smaller facilities, sold a 1-million-square-foot greenhouse that wasn't retrofitted for cannabis production, and halted construction on two of the company's largest projects.</p>\n<p>Yet, even with this aggressive cost-cutting, Aurora Cannabis is still a long way from generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). With the company continuing to burn cash and the previous management team grossly overpaying for about a dozen acquisitions, it's regularly had to sell its common stock to raise capital to pay its bills and fund buyouts.</p>\n<p>Taking into account a reverse split enacted last year to stave off delisting, Aurora's share count has ballooned from about 1.3 million shares in June 2014 to 198 million shares, as of mid-May. That sort of dilution is precisely why the company's shares are down nearly 95% since March 2019.</p>\n<p>The salt in the wound is that Canada's legal weed sales have been hitting monthly records, all while Aurora's recreational pot revenue was more than halved in its fiscal third quarter.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/bc514068ded899a817770f684369db36\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Sundial Growers</h2>\n<p>Yet another Canadian pot stock in the no-buy zone for Wall Street is small-cap <b>Sundial Growers</b> (NASDAQ:SNDL). Even though it's the fourth most-held stock on Robinhood, four of the six analysts covering the company rate it a sell.</p>\n<p>Despite sitting on a boatload of cash, cash equivalents, and long-term investments (about $948 million), Sundial Growers has three factors working against it.</p>\n<p>To begin with, Sundial's approach to raising capital has destroyed shareholder value. Initially, it looked as if management would sell enough common stock to simply pay off the company's outstanding debt. But in a nine-month stretch between Oct. 1, 2020 and June 30, 2021, Sundial's executives have unrelentingly issued stock to raise additional capital.</p>\n<p>The end result is the issuance of roughly 1.5 billion shares of stock. With 2 billion shares now outstanding, Sundial has virtually no chance of ever generating meaningful earnings per share, and it'll likely struggle to remain listed on the <b>Nasdaq</b>&nbsp;exchange without a substantial reverse split.</p>\n<p>Second, Sundial's management team hasn't laid out a concrete plan for its capital. While it did undertake a cash-and-stock deal to acquire <a href=\"https://laohu8.com/S/INSHF\">Inner Spirit Holdings</a> in July, and it's committed roughly $425 million to its joint venture with SAF Group, known as SunStream Bancorp, to invest in cannabis industry opportunities, the company has continued to raise cash with no stated purpose.</p>\n<p>Third, Sundial has shifted its operating model away from wholesale cannabis to take advantage of the higher margins associated with the retail side of the equation. Unfortunately, having to start from scratch has led to significant year-over-year sales declines at a time when legal weed sales are rapidly growing.</p>\n<p>In March I more or less referred to Sundial as the worst cannabis stock money could buy. That descriptor still holds true today.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1c6cb4d9fcdf85f542f333fc71a2dd58\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>AMC Entertainment</h2>\n<p>But the most popular stock of all that's getting absolutely no love from Wall Street analysts and investment banks is movie theater chain <b>AMC Entertainment</b> (NYSE:AMC). The third most-held stock on Robinhood has nine analysts covering the company. Five of them have it rated a sell, with four others chiming in with a hold rating.</p>\n<p>This rating distribution isn't a surprise given that Wall Street's consensus price target for AMC is $5.44. Shares of the company would need to fall 86% from where they closed last week to reach this consensus target.</p>\n<p>The reason AMC's share price has rocketed higher in 2021 primarily has to do with retail investors piling into the stock and betting on a short squeeze -- i.e., a very short-term event whereby pessimists (short-sellers) run for the exit and buy shares to cover their positions. The issue for these optimists is that none of the data surrounding AMC is working in their favor.</p>\n<p>For one, short squeezes typically require certain conditions be met, which simply aren't there at the moment. While the company's 18.8% short interest at the end of August is higher than most stocks, its large daily trading volume means it would take less than a day for all 95.94 million short shares to be covered. The liquidity of AMC's stock means short-sellers have no fear of being trapped in their position.</p>\n<p>Fundamentally, the movie theater industry has been in a nearly two-decade decline. Tickets sold and inflation-adjusted gross at the box office have fallen 22% between 2002 and 2019, the last full year before the pandemic. Streaming offerings and substantially reduced film exclusivity (30 to 45 days now, compared to 75 to 90 days prior to the pandemic) bode poorly for the industry's future.</p>\n<p>And then there's AMC's operating performance and liability-riddled balance sheet. Despite a record $2.023 billion in liquidity ($1.81 billion in cash), AMC burned through $576.5 million in cash in the first six months of 2021. Its lease liabilities are soaring, it owes $420 million in deferred rent, and it's lugging around nearly $5.5 billion in debt that it likely can't pay.</p>\n<p>More than $1 billion in aggregate debt due in 2026 and 2027 is also valued at 70% to 74% of face value. Debt going for this much below par is a very real warning sign that bondholders believe a future default is possible.</p>\n<p>Long story short, Wall Street has every reason to be skeptical of AMC.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Ultra-Popular Stocks With No Buy Ratings on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Ultra-Popular Stocks With No Buy Ratings on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-28 19:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.\nAccording to data from CNBC, over 90% of all S&P 500 stock ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ACB":"奥罗拉大麻公司","SNDL":"SNDL Inc.","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2170778116","content_text":"Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.\nAccording to data from CNBC, over 90% of all S&P 500 stock ratings from Wall Street analysts were the equivalent of \"buy\" or \"hold\" between 1997 and 2017. With the exception of short periods in 2002-2003 and 2008-2009, sell ratings have consistently accounted for only 1% to 6% of all ratings for S&P 500 companies this century.\nOne reason for this \"buy bias\" is due to the U.S. and global economy growing over time. Historically, the stock market moves higher over the long run, too. Wall Street analysts might simply be playing the favorable odds that higher-quality businesses will increase in value over time.\nAdditionally, The Wall Street Journal noted some years back that Wall Street analysts are hesitant to issue sell ratings so as not to burn bridges for their clients or themselves with the companies they cover. No matter the reasoning, sell ratings are rare on Wall Street.\nImage source: Getty Images.\nBut don't tell that to shareholders of the following three ultra-popular stocks. These are three of the 16 most-held stocks on the Robinhood (NASDAQ:HOOD) platform, and not one of them has a single buy rating from a Wall Street analyst.\nAurora Cannabis\nOne of the biggest buzzkills, according to Wall Street, is Canadian marijuana stock Aurora Cannabis (NASDAQ:ACB). Aurora, which at one time was the most-held stock on Robinhood, is being covered by 13 Wall Street institutions, seven of which rate the company the equivalent of a hold and six of which believe it's a sell.\nThough Aurora Cannabis does foot the blame for a lot of this negativity, some of its issues can be traced to Canadian federal and provincial regulators failing the pot industry. For example, Ontario's lottery system to assign retail licenses through 2019 was terrible and resulted in only a few dozen dispensaries opening. Canadian pot stocks are still trying to recover from supply chain bottlenecks in the country's most populous province.\nBut as I mentioned, Aurora Cannabis isn't without fault. The company expanded its production capacity far beyond what was needed. At one time, it held 15 production facilities that could have yielded more than 600,000 kilos of annual cannabis output if fully operational. Management has since closed five of these smaller facilities, sold a 1-million-square-foot greenhouse that wasn't retrofitted for cannabis production, and halted construction on two of the company's largest projects.\nYet, even with this aggressive cost-cutting, Aurora Cannabis is still a long way from generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). With the company continuing to burn cash and the previous management team grossly overpaying for about a dozen acquisitions, it's regularly had to sell its common stock to raise capital to pay its bills and fund buyouts.\nTaking into account a reverse split enacted last year to stave off delisting, Aurora's share count has ballooned from about 1.3 million shares in June 2014 to 198 million shares, as of mid-May. That sort of dilution is precisely why the company's shares are down nearly 95% since March 2019.\nThe salt in the wound is that Canada's legal weed sales have been hitting monthly records, all while Aurora's recreational pot revenue was more than halved in its fiscal third quarter.\nImage source: Getty Images.\nSundial Growers\nYet another Canadian pot stock in the no-buy zone for Wall Street is small-cap Sundial Growers (NASDAQ:SNDL). Even though it's the fourth most-held stock on Robinhood, four of the six analysts covering the company rate it a sell.\nDespite sitting on a boatload of cash, cash equivalents, and long-term investments (about $948 million), Sundial Growers has three factors working against it.\nTo begin with, Sundial's approach to raising capital has destroyed shareholder value. Initially, it looked as if management would sell enough common stock to simply pay off the company's outstanding debt. But in a nine-month stretch between Oct. 1, 2020 and June 30, 2021, Sundial's executives have unrelentingly issued stock to raise additional capital.\nThe end result is the issuance of roughly 1.5 billion shares of stock. With 2 billion shares now outstanding, Sundial has virtually no chance of ever generating meaningful earnings per share, and it'll likely struggle to remain listed on the Nasdaq exchange without a substantial reverse split.\nSecond, Sundial's management team hasn't laid out a concrete plan for its capital. While it did undertake a cash-and-stock deal to acquire Inner Spirit Holdings in July, and it's committed roughly $425 million to its joint venture with SAF Group, known as SunStream Bancorp, to invest in cannabis industry opportunities, the company has continued to raise cash with no stated purpose.\nThird, Sundial has shifted its operating model away from wholesale cannabis to take advantage of the higher margins associated with the retail side of the equation. Unfortunately, having to start from scratch has led to significant year-over-year sales declines at a time when legal weed sales are rapidly growing.\nIn March I more or less referred to Sundial as the worst cannabis stock money could buy. That descriptor still holds true today.\nImage source: Getty Images.\nAMC Entertainment\nBut the most popular stock of all that's getting absolutely no love from Wall Street analysts and investment banks is movie theater chain AMC Entertainment (NYSE:AMC). The third most-held stock on Robinhood has nine analysts covering the company. Five of them have it rated a sell, with four others chiming in with a hold rating.\nThis rating distribution isn't a surprise given that Wall Street's consensus price target for AMC is $5.44. Shares of the company would need to fall 86% from where they closed last week to reach this consensus target.\nThe reason AMC's share price has rocketed higher in 2021 primarily has to do with retail investors piling into the stock and betting on a short squeeze -- i.e., a very short-term event whereby pessimists (short-sellers) run for the exit and buy shares to cover their positions. The issue for these optimists is that none of the data surrounding AMC is working in their favor.\nFor one, short squeezes typically require certain conditions be met, which simply aren't there at the moment. While the company's 18.8% short interest at the end of August is higher than most stocks, its large daily trading volume means it would take less than a day for all 95.94 million short shares to be covered. The liquidity of AMC's stock means short-sellers have no fear of being trapped in their position.\nFundamentally, the movie theater industry has been in a nearly two-decade decline. Tickets sold and inflation-adjusted gross at the box office have fallen 22% between 2002 and 2019, the last full year before the pandemic. Streaming offerings and substantially reduced film exclusivity (30 to 45 days now, compared to 75 to 90 days prior to the pandemic) bode poorly for the industry's future.\nAnd then there's AMC's operating performance and liability-riddled balance sheet. Despite a record $2.023 billion in liquidity ($1.81 billion in cash), AMC burned through $576.5 million in cash in the first six months of 2021. Its lease liabilities are soaring, it owes $420 million in deferred rent, and it's lugging around nearly $5.5 billion in debt that it likely can't pay.\nMore than $1 billion in aggregate debt due in 2026 and 2027 is also valued at 70% to 74% of face value. Debt going for this much below par is a very real warning sign that bondholders believe a future default is possible.\nLong story short, Wall Street has every reason to be skeptical of AMC.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6037047,"gmtCreate":1632913412119,"gmtModify":1634782510063,"authorId":3572760106047837,"author":{"id":3572760106047837,"idStr":"3572760106047837","authorId":3572760106047837,"name":"Honeybacon","avatar":"https://static.tigerbbs.com/ba9dadcb282f3263c3277e3fd96c37ee","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":862824506,"type":1,"supId":0,"prevId":0,"content":"Haiz","text":"Haiz","html":"Haiz"}],"langContent":"CN"},{"id":862826589,"gmtCreate":1632871076676,"gmtModify":1632880666665,"author":{"id":"4095823151639990","authorId":"4095823151639990","name":"bearyamaze","avatar":"https://static.tigerbbs.com/d7e8e049cd56dfb2788ef23a800695d3","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4095823151639990","authorIdStr":"4095823151639990"},"htmlText":"Sound like the company is not doing well and tiger is recommending for a buy ? Or I mis read&nbsp;","listText":"Sound like the company is not doing well and tiger is recommending for a buy ? Or I mis read&nbsp;","text":"Sound like the company is not doing well and tiger is recommending for a buy ? Or I mis read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862826589","repostId":2170778116,"repostType":4,"repost":{"id":"2170778116","kind":"highlight","pubTimestamp":1632829153,"share":"https://www.laohu8.com/m/news/2170778116?lang=&edition=full","pubTime":"2021-09-28 19:39","market":"us","language":"en","title":"3 Ultra-Popular Stocks With No Buy Ratings on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2170778116","media":"Motley Fool","summary":"These widely held stocks are getting no love from analysts.","content":"<p>Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.</p>\n<p>According to data from CNBC, over 90% of all <b>S&amp;P 500</b> stock ratings from Wall Street analysts were the equivalent of \"buy\" or \"hold\" between 1997 and 2017. With the exception of short periods in 2002-2003 and 2008-2009, sell ratings have consistently accounted for only 1% to 6% of all ratings for S&amp;P 500 companies this century.</p>\n<p>One reason for this \"buy bias\" is due to the U.S. and global economy growing over time. Historically, the stock market moves higher over the long run, too. Wall Street analysts might simply be playing the favorable odds that higher-quality businesses will increase in value over time.</p>\n<p>Additionally, <i>The Wall Street Journal</i> noted some years back that Wall Street analysts are hesitant to issue sell ratings so as not to burn bridges for their clients or themselves with the companies they cover. No matter the reasoning, sell ratings are rare on Wall Street.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fb1fd3c71278c123e5dd0404a4dbb43c\" tg-width=\"700\" tg-height=\"525\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<p>But don't tell that to shareholders of the following three ultra-popular stocks. These are three of the 16 most-held stocks on the <b>Robinhood</b> (NASDAQ:HOOD) platform, and not one of them has a single buy rating from a Wall Street analyst.</p>\n<h2>Aurora Cannabis</h2>\n<p>One of the biggest buzzkills, according to Wall Street, is Canadian marijuana stock <b>Aurora Cannabis</b> (NASDAQ:ACB). Aurora, which at one time was the most-held stock on Robinhood, is being covered by 13 Wall Street institutions, seven of which rate the company the equivalent of a hold and six of which believe it's a sell.</p>\n<p>Though Aurora Cannabis does foot the blame for a lot of this negativity, some of its issues can be traced to Canadian federal and provincial regulators failing the pot industry. For example, Ontario's lottery system to assign retail licenses through 2019 was terrible and resulted in only a few dozen dispensaries opening. Canadian pot stocks are still trying to recover from supply chain bottlenecks in the country's most populous province.</p>\n<p>But as I mentioned, Aurora Cannabis isn't without fault. The company expanded its production capacity far beyond what was needed. At one time, it held 15 production facilities that could have yielded more than 600,000 kilos of annual cannabis output if fully operational. Management has since closed five of these smaller facilities, sold a 1-million-square-foot greenhouse that wasn't retrofitted for cannabis production, and halted construction on two of the company's largest projects.</p>\n<p>Yet, even with this aggressive cost-cutting, Aurora Cannabis is still a long way from generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). With the company continuing to burn cash and the previous management team grossly overpaying for about a dozen acquisitions, it's regularly had to sell its common stock to raise capital to pay its bills and fund buyouts.</p>\n<p>Taking into account a reverse split enacted last year to stave off delisting, Aurora's share count has ballooned from about 1.3 million shares in June 2014 to 198 million shares, as of mid-May. That sort of dilution is precisely why the company's shares are down nearly 95% since March 2019.</p>\n<p>The salt in the wound is that Canada's legal weed sales have been hitting monthly records, all while Aurora's recreational pot revenue was more than halved in its fiscal third quarter.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/bc514068ded899a817770f684369db36\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Sundial Growers</h2>\n<p>Yet another Canadian pot stock in the no-buy zone for Wall Street is small-cap <b>Sundial Growers</b> (NASDAQ:SNDL). Even though it's the fourth most-held stock on Robinhood, four of the six analysts covering the company rate it a sell.</p>\n<p>Despite sitting on a boatload of cash, cash equivalents, and long-term investments (about $948 million), Sundial Growers has three factors working against it.</p>\n<p>To begin with, Sundial's approach to raising capital has destroyed shareholder value. Initially, it looked as if management would sell enough common stock to simply pay off the company's outstanding debt. But in a nine-month stretch between Oct. 1, 2020 and June 30, 2021, Sundial's executives have unrelentingly issued stock to raise additional capital.</p>\n<p>The end result is the issuance of roughly 1.5 billion shares of stock. With 2 billion shares now outstanding, Sundial has virtually no chance of ever generating meaningful earnings per share, and it'll likely struggle to remain listed on the <b>Nasdaq</b>&nbsp;exchange without a substantial reverse split.</p>\n<p>Second, Sundial's management team hasn't laid out a concrete plan for its capital. While it did undertake a cash-and-stock deal to acquire <a href=\"https://laohu8.com/S/INSHF\">Inner Spirit Holdings</a> in July, and it's committed roughly $425 million to its joint venture with SAF Group, known as SunStream Bancorp, to invest in cannabis industry opportunities, the company has continued to raise cash with no stated purpose.</p>\n<p>Third, Sundial has shifted its operating model away from wholesale cannabis to take advantage of the higher margins associated with the retail side of the equation. Unfortunately, having to start from scratch has led to significant year-over-year sales declines at a time when legal weed sales are rapidly growing.</p>\n<p>In March I more or less referred to Sundial as the worst cannabis stock money could buy. That descriptor still holds true today.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1c6cb4d9fcdf85f542f333fc71a2dd58\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>AMC Entertainment</h2>\n<p>But the most popular stock of all that's getting absolutely no love from Wall Street analysts and investment banks is movie theater chain <b>AMC Entertainment</b> (NYSE:AMC). The third most-held stock on Robinhood has nine analysts covering the company. Five of them have it rated a sell, with four others chiming in with a hold rating.</p>\n<p>This rating distribution isn't a surprise given that Wall Street's consensus price target for AMC is $5.44. Shares of the company would need to fall 86% from where they closed last week to reach this consensus target.</p>\n<p>The reason AMC's share price has rocketed higher in 2021 primarily has to do with retail investors piling into the stock and betting on a short squeeze -- i.e., a very short-term event whereby pessimists (short-sellers) run for the exit and buy shares to cover their positions. The issue for these optimists is that none of the data surrounding AMC is working in their favor.</p>\n<p>For one, short squeezes typically require certain conditions be met, which simply aren't there at the moment. While the company's 18.8% short interest at the end of August is higher than most stocks, its large daily trading volume means it would take less than a day for all 95.94 million short shares to be covered. The liquidity of AMC's stock means short-sellers have no fear of being trapped in their position.</p>\n<p>Fundamentally, the movie theater industry has been in a nearly two-decade decline. Tickets sold and inflation-adjusted gross at the box office have fallen 22% between 2002 and 2019, the last full year before the pandemic. Streaming offerings and substantially reduced film exclusivity (30 to 45 days now, compared to 75 to 90 days prior to the pandemic) bode poorly for the industry's future.</p>\n<p>And then there's AMC's operating performance and liability-riddled balance sheet. Despite a record $2.023 billion in liquidity ($1.81 billion in cash), AMC burned through $576.5 million in cash in the first six months of 2021. Its lease liabilities are soaring, it owes $420 million in deferred rent, and it's lugging around nearly $5.5 billion in debt that it likely can't pay.</p>\n<p>More than $1 billion in aggregate debt due in 2026 and 2027 is also valued at 70% to 74% of face value. Debt going for this much below par is a very real warning sign that bondholders believe a future default is possible.</p>\n<p>Long story short, Wall Street has every reason to be skeptical of AMC.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Ultra-Popular Stocks With No Buy Ratings on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Ultra-Popular Stocks With No Buy Ratings on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-28 19:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.\nAccording to data from CNBC, over 90% of all S&P 500 stock ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ACB":"奥罗拉大麻公司","SNDL":"SNDL Inc.","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2170778116","content_text":"Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.\nAccording to data from CNBC, over 90% of all S&P 500 stock ratings from Wall Street analysts were the equivalent of \"buy\" or \"hold\" between 1997 and 2017. With the exception of short periods in 2002-2003 and 2008-2009, sell ratings have consistently accounted for only 1% to 6% of all ratings for S&P 500 companies this century.\nOne reason for this \"buy bias\" is due to the U.S. and global economy growing over time. Historically, the stock market moves higher over the long run, too. Wall Street analysts might simply be playing the favorable odds that higher-quality businesses will increase in value over time.\nAdditionally, The Wall Street Journal noted some years back that Wall Street analysts are hesitant to issue sell ratings so as not to burn bridges for their clients or themselves with the companies they cover. No matter the reasoning, sell ratings are rare on Wall Street.\nImage source: Getty Images.\nBut don't tell that to shareholders of the following three ultra-popular stocks. These are three of the 16 most-held stocks on the Robinhood (NASDAQ:HOOD) platform, and not one of them has a single buy rating from a Wall Street analyst.\nAurora Cannabis\nOne of the biggest buzzkills, according to Wall Street, is Canadian marijuana stock Aurora Cannabis (NASDAQ:ACB). Aurora, which at one time was the most-held stock on Robinhood, is being covered by 13 Wall Street institutions, seven of which rate the company the equivalent of a hold and six of which believe it's a sell.\nThough Aurora Cannabis does foot the blame for a lot of this negativity, some of its issues can be traced to Canadian federal and provincial regulators failing the pot industry. For example, Ontario's lottery system to assign retail licenses through 2019 was terrible and resulted in only a few dozen dispensaries opening. Canadian pot stocks are still trying to recover from supply chain bottlenecks in the country's most populous province.\nBut as I mentioned, Aurora Cannabis isn't without fault. The company expanded its production capacity far beyond what was needed. At one time, it held 15 production facilities that could have yielded more than 600,000 kilos of annual cannabis output if fully operational. Management has since closed five of these smaller facilities, sold a 1-million-square-foot greenhouse that wasn't retrofitted for cannabis production, and halted construction on two of the company's largest projects.\nYet, even with this aggressive cost-cutting, Aurora Cannabis is still a long way from generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). With the company continuing to burn cash and the previous management team grossly overpaying for about a dozen acquisitions, it's regularly had to sell its common stock to raise capital to pay its bills and fund buyouts.\nTaking into account a reverse split enacted last year to stave off delisting, Aurora's share count has ballooned from about 1.3 million shares in June 2014 to 198 million shares, as of mid-May. That sort of dilution is precisely why the company's shares are down nearly 95% since March 2019.\nThe salt in the wound is that Canada's legal weed sales have been hitting monthly records, all while Aurora's recreational pot revenue was more than halved in its fiscal third quarter.\nImage source: Getty Images.\nSundial Growers\nYet another Canadian pot stock in the no-buy zone for Wall Street is small-cap Sundial Growers (NASDAQ:SNDL). Even though it's the fourth most-held stock on Robinhood, four of the six analysts covering the company rate it a sell.\nDespite sitting on a boatload of cash, cash equivalents, and long-term investments (about $948 million), Sundial Growers has three factors working against it.\nTo begin with, Sundial's approach to raising capital has destroyed shareholder value. Initially, it looked as if management would sell enough common stock to simply pay off the company's outstanding debt. But in a nine-month stretch between Oct. 1, 2020 and June 30, 2021, Sundial's executives have unrelentingly issued stock to raise additional capital.\nThe end result is the issuance of roughly 1.5 billion shares of stock. With 2 billion shares now outstanding, Sundial has virtually no chance of ever generating meaningful earnings per share, and it'll likely struggle to remain listed on the Nasdaq exchange without a substantial reverse split.\nSecond, Sundial's management team hasn't laid out a concrete plan for its capital. While it did undertake a cash-and-stock deal to acquire Inner Spirit Holdings in July, and it's committed roughly $425 million to its joint venture with SAF Group, known as SunStream Bancorp, to invest in cannabis industry opportunities, the company has continued to raise cash with no stated purpose.\nThird, Sundial has shifted its operating model away from wholesale cannabis to take advantage of the higher margins associated with the retail side of the equation. Unfortunately, having to start from scratch has led to significant year-over-year sales declines at a time when legal weed sales are rapidly growing.\nIn March I more or less referred to Sundial as the worst cannabis stock money could buy. That descriptor still holds true today.\nImage source: Getty Images.\nAMC Entertainment\nBut the most popular stock of all that's getting absolutely no love from Wall Street analysts and investment banks is movie theater chain AMC Entertainment (NYSE:AMC). The third most-held stock on Robinhood has nine analysts covering the company. Five of them have it rated a sell, with four others chiming in with a hold rating.\nThis rating distribution isn't a surprise given that Wall Street's consensus price target for AMC is $5.44. Shares of the company would need to fall 86% from where they closed last week to reach this consensus target.\nThe reason AMC's share price has rocketed higher in 2021 primarily has to do with retail investors piling into the stock and betting on a short squeeze -- i.e., a very short-term event whereby pessimists (short-sellers) run for the exit and buy shares to cover their positions. The issue for these optimists is that none of the data surrounding AMC is working in their favor.\nFor one, short squeezes typically require certain conditions be met, which simply aren't there at the moment. While the company's 18.8% short interest at the end of August is higher than most stocks, its large daily trading volume means it would take less than a day for all 95.94 million short shares to be covered. The liquidity of AMC's stock means short-sellers have no fear of being trapped in their position.\nFundamentally, the movie theater industry has been in a nearly two-decade decline. Tickets sold and inflation-adjusted gross at the box office have fallen 22% between 2002 and 2019, the last full year before the pandemic. Streaming offerings and substantially reduced film exclusivity (30 to 45 days now, compared to 75 to 90 days prior to the pandemic) bode poorly for the industry's future.\nAnd then there's AMC's operating performance and liability-riddled balance sheet. Despite a record $2.023 billion in liquidity ($1.81 billion in cash), AMC burned through $576.5 million in cash in the first six months of 2021. Its lease liabilities are soaring, it owes $420 million in deferred rent, and it's lugging around nearly $5.5 billion in debt that it likely can't pay.\nMore than $1 billion in aggregate debt due in 2026 and 2027 is also valued at 70% to 74% of face value. Debt going for this much below par is a very real warning sign that bondholders believe a future default is possible.\nLong story short, Wall Street has every reason to be skeptical of AMC.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":862883366,"gmtCreate":1632869223967,"gmtModify":1632869224094,"author":{"id":"3575113315907312","authorId":"3575113315907312","name":"MengYang","avatar":"https://static.tigerbbs.com/2dece979ff56347c710918e7aa49d224","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3575113315907312","authorIdStr":"3575113315907312"},"htmlText":"Nice, please like","listText":"Nice, please like","text":"Nice, please like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/862883366","repostId":2170778116,"repostType":4,"repost":{"id":"2170778116","kind":"highlight","pubTimestamp":1632829153,"share":"https://www.laohu8.com/m/news/2170778116?lang=&edition=full","pubTime":"2021-09-28 19:39","market":"us","language":"en","title":"3 Ultra-Popular Stocks With No Buy Ratings on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2170778116","media":"Motley Fool","summary":"These widely held stocks are getting no love from analysts.","content":"<p>Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.</p>\n<p>According to data from CNBC, over 90% of all <b>S&amp;P 500</b> stock ratings from Wall Street analysts were the equivalent of \"buy\" or \"hold\" between 1997 and 2017. With the exception of short periods in 2002-2003 and 2008-2009, sell ratings have consistently accounted for only 1% to 6% of all ratings for S&amp;P 500 companies this century.</p>\n<p>One reason for this \"buy bias\" is due to the U.S. and global economy growing over time. Historically, the stock market moves higher over the long run, too. Wall Street analysts might simply be playing the favorable odds that higher-quality businesses will increase in value over time.</p>\n<p>Additionally, <i>The Wall Street Journal</i> noted some years back that Wall Street analysts are hesitant to issue sell ratings so as not to burn bridges for their clients or themselves with the companies they cover. No matter the reasoning, sell ratings are rare on Wall Street.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fb1fd3c71278c123e5dd0404a4dbb43c\" tg-width=\"700\" tg-height=\"525\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<p>But don't tell that to shareholders of the following three ultra-popular stocks. These are three of the 16 most-held stocks on the <b>Robinhood</b> (NASDAQ:HOOD) platform, and not one of them has a single buy rating from a Wall Street analyst.</p>\n<h2>Aurora Cannabis</h2>\n<p>One of the biggest buzzkills, according to Wall Street, is Canadian marijuana stock <b>Aurora Cannabis</b> (NASDAQ:ACB). Aurora, which at one time was the most-held stock on Robinhood, is being covered by 13 Wall Street institutions, seven of which rate the company the equivalent of a hold and six of which believe it's a sell.</p>\n<p>Though Aurora Cannabis does foot the blame for a lot of this negativity, some of its issues can be traced to Canadian federal and provincial regulators failing the pot industry. For example, Ontario's lottery system to assign retail licenses through 2019 was terrible and resulted in only a few dozen dispensaries opening. Canadian pot stocks are still trying to recover from supply chain bottlenecks in the country's most populous province.</p>\n<p>But as I mentioned, Aurora Cannabis isn't without fault. The company expanded its production capacity far beyond what was needed. At one time, it held 15 production facilities that could have yielded more than 600,000 kilos of annual cannabis output if fully operational. Management has since closed five of these smaller facilities, sold a 1-million-square-foot greenhouse that wasn't retrofitted for cannabis production, and halted construction on two of the company's largest projects.</p>\n<p>Yet, even with this aggressive cost-cutting, Aurora Cannabis is still a long way from generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). With the company continuing to burn cash and the previous management team grossly overpaying for about a dozen acquisitions, it's regularly had to sell its common stock to raise capital to pay its bills and fund buyouts.</p>\n<p>Taking into account a reverse split enacted last year to stave off delisting, Aurora's share count has ballooned from about 1.3 million shares in June 2014 to 198 million shares, as of mid-May. That sort of dilution is precisely why the company's shares are down nearly 95% since March 2019.</p>\n<p>The salt in the wound is that Canada's legal weed sales have been hitting monthly records, all while Aurora's recreational pot revenue was more than halved in its fiscal third quarter.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/bc514068ded899a817770f684369db36\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Sundial Growers</h2>\n<p>Yet another Canadian pot stock in the no-buy zone for Wall Street is small-cap <b>Sundial Growers</b> (NASDAQ:SNDL). Even though it's the fourth most-held stock on Robinhood, four of the six analysts covering the company rate it a sell.</p>\n<p>Despite sitting on a boatload of cash, cash equivalents, and long-term investments (about $948 million), Sundial Growers has three factors working against it.</p>\n<p>To begin with, Sundial's approach to raising capital has destroyed shareholder value. Initially, it looked as if management would sell enough common stock to simply pay off the company's outstanding debt. But in a nine-month stretch between Oct. 1, 2020 and June 30, 2021, Sundial's executives have unrelentingly issued stock to raise additional capital.</p>\n<p>The end result is the issuance of roughly 1.5 billion shares of stock. With 2 billion shares now outstanding, Sundial has virtually no chance of ever generating meaningful earnings per share, and it'll likely struggle to remain listed on the <b>Nasdaq</b>&nbsp;exchange without a substantial reverse split.</p>\n<p>Second, Sundial's management team hasn't laid out a concrete plan for its capital. While it did undertake a cash-and-stock deal to acquire <a href=\"https://laohu8.com/S/INSHF\">Inner Spirit Holdings</a> in July, and it's committed roughly $425 million to its joint venture with SAF Group, known as SunStream Bancorp, to invest in cannabis industry opportunities, the company has continued to raise cash with no stated purpose.</p>\n<p>Third, Sundial has shifted its operating model away from wholesale cannabis to take advantage of the higher margins associated with the retail side of the equation. Unfortunately, having to start from scratch has led to significant year-over-year sales declines at a time when legal weed sales are rapidly growing.</p>\n<p>In March I more or less referred to Sundial as the worst cannabis stock money could buy. That descriptor still holds true today.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1c6cb4d9fcdf85f542f333fc71a2dd58\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>AMC Entertainment</h2>\n<p>But the most popular stock of all that's getting absolutely no love from Wall Street analysts and investment banks is movie theater chain <b>AMC Entertainment</b> (NYSE:AMC). The third most-held stock on Robinhood has nine analysts covering the company. Five of them have it rated a sell, with four others chiming in with a hold rating.</p>\n<p>This rating distribution isn't a surprise given that Wall Street's consensus price target for AMC is $5.44. Shares of the company would need to fall 86% from where they closed last week to reach this consensus target.</p>\n<p>The reason AMC's share price has rocketed higher in 2021 primarily has to do with retail investors piling into the stock and betting on a short squeeze -- i.e., a very short-term event whereby pessimists (short-sellers) run for the exit and buy shares to cover their positions. The issue for these optimists is that none of the data surrounding AMC is working in their favor.</p>\n<p>For one, short squeezes typically require certain conditions be met, which simply aren't there at the moment. While the company's 18.8% short interest at the end of August is higher than most stocks, its large daily trading volume means it would take less than a day for all 95.94 million short shares to be covered. The liquidity of AMC's stock means short-sellers have no fear of being trapped in their position.</p>\n<p>Fundamentally, the movie theater industry has been in a nearly two-decade decline. Tickets sold and inflation-adjusted gross at the box office have fallen 22% between 2002 and 2019, the last full year before the pandemic. Streaming offerings and substantially reduced film exclusivity (30 to 45 days now, compared to 75 to 90 days prior to the pandemic) bode poorly for the industry's future.</p>\n<p>And then there's AMC's operating performance and liability-riddled balance sheet. Despite a record $2.023 billion in liquidity ($1.81 billion in cash), AMC burned through $576.5 million in cash in the first six months of 2021. Its lease liabilities are soaring, it owes $420 million in deferred rent, and it's lugging around nearly $5.5 billion in debt that it likely can't pay.</p>\n<p>More than $1 billion in aggregate debt due in 2026 and 2027 is also valued at 70% to 74% of face value. Debt going for this much below par is a very real warning sign that bondholders believe a future default is possible.</p>\n<p>Long story short, Wall Street has every reason to be skeptical of AMC.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Ultra-Popular Stocks With No Buy Ratings on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Ultra-Popular Stocks With No Buy Ratings on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-28 19:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.\nAccording to data from CNBC, over 90% of all S&P 500 stock ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ACB":"奥罗拉大麻公司","SNDL":"SNDL Inc.","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2170778116","content_text":"Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.\nAccording to data from CNBC, over 90% of all S&P 500 stock ratings from Wall Street analysts were the equivalent of \"buy\" or \"hold\" between 1997 and 2017. With the exception of short periods in 2002-2003 and 2008-2009, sell ratings have consistently accounted for only 1% to 6% of all ratings for S&P 500 companies this century.\nOne reason for this \"buy bias\" is due to the U.S. and global economy growing over time. Historically, the stock market moves higher over the long run, too. Wall Street analysts might simply be playing the favorable odds that higher-quality businesses will increase in value over time.\nAdditionally, The Wall Street Journal noted some years back that Wall Street analysts are hesitant to issue sell ratings so as not to burn bridges for their clients or themselves with the companies they cover. No matter the reasoning, sell ratings are rare on Wall Street.\nImage source: Getty Images.\nBut don't tell that to shareholders of the following three ultra-popular stocks. These are three of the 16 most-held stocks on the Robinhood (NASDAQ:HOOD) platform, and not one of them has a single buy rating from a Wall Street analyst.\nAurora Cannabis\nOne of the biggest buzzkills, according to Wall Street, is Canadian marijuana stock Aurora Cannabis (NASDAQ:ACB). Aurora, which at one time was the most-held stock on Robinhood, is being covered by 13 Wall Street institutions, seven of which rate the company the equivalent of a hold and six of which believe it's a sell.\nThough Aurora Cannabis does foot the blame for a lot of this negativity, some of its issues can be traced to Canadian federal and provincial regulators failing the pot industry. For example, Ontario's lottery system to assign retail licenses through 2019 was terrible and resulted in only a few dozen dispensaries opening. Canadian pot stocks are still trying to recover from supply chain bottlenecks in the country's most populous province.\nBut as I mentioned, Aurora Cannabis isn't without fault. The company expanded its production capacity far beyond what was needed. At one time, it held 15 production facilities that could have yielded more than 600,000 kilos of annual cannabis output if fully operational. Management has since closed five of these smaller facilities, sold a 1-million-square-foot greenhouse that wasn't retrofitted for cannabis production, and halted construction on two of the company's largest projects.\nYet, even with this aggressive cost-cutting, Aurora Cannabis is still a long way from generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). With the company continuing to burn cash and the previous management team grossly overpaying for about a dozen acquisitions, it's regularly had to sell its common stock to raise capital to pay its bills and fund buyouts.\nTaking into account a reverse split enacted last year to stave off delisting, Aurora's share count has ballooned from about 1.3 million shares in June 2014 to 198 million shares, as of mid-May. That sort of dilution is precisely why the company's shares are down nearly 95% since March 2019.\nThe salt in the wound is that Canada's legal weed sales have been hitting monthly records, all while Aurora's recreational pot revenue was more than halved in its fiscal third quarter.\nImage source: Getty Images.\nSundial Growers\nYet another Canadian pot stock in the no-buy zone for Wall Street is small-cap Sundial Growers (NASDAQ:SNDL). Even though it's the fourth most-held stock on Robinhood, four of the six analysts covering the company rate it a sell.\nDespite sitting on a boatload of cash, cash equivalents, and long-term investments (about $948 million), Sundial Growers has three factors working against it.\nTo begin with, Sundial's approach to raising capital has destroyed shareholder value. Initially, it looked as if management would sell enough common stock to simply pay off the company's outstanding debt. But in a nine-month stretch between Oct. 1, 2020 and June 30, 2021, Sundial's executives have unrelentingly issued stock to raise additional capital.\nThe end result is the issuance of roughly 1.5 billion shares of stock. With 2 billion shares now outstanding, Sundial has virtually no chance of ever generating meaningful earnings per share, and it'll likely struggle to remain listed on the Nasdaq exchange without a substantial reverse split.\nSecond, Sundial's management team hasn't laid out a concrete plan for its capital. While it did undertake a cash-and-stock deal to acquire Inner Spirit Holdings in July, and it's committed roughly $425 million to its joint venture with SAF Group, known as SunStream Bancorp, to invest in cannabis industry opportunities, the company has continued to raise cash with no stated purpose.\nThird, Sundial has shifted its operating model away from wholesale cannabis to take advantage of the higher margins associated with the retail side of the equation. Unfortunately, having to start from scratch has led to significant year-over-year sales declines at a time when legal weed sales are rapidly growing.\nIn March I more or less referred to Sundial as the worst cannabis stock money could buy. That descriptor still holds true today.\nImage source: Getty Images.\nAMC Entertainment\nBut the most popular stock of all that's getting absolutely no love from Wall Street analysts and investment banks is movie theater chain AMC Entertainment (NYSE:AMC). The third most-held stock on Robinhood has nine analysts covering the company. Five of them have it rated a sell, with four others chiming in with a hold rating.\nThis rating distribution isn't a surprise given that Wall Street's consensus price target for AMC is $5.44. Shares of the company would need to fall 86% from where they closed last week to reach this consensus target.\nThe reason AMC's share price has rocketed higher in 2021 primarily has to do with retail investors piling into the stock and betting on a short squeeze -- i.e., a very short-term event whereby pessimists (short-sellers) run for the exit and buy shares to cover their positions. The issue for these optimists is that none of the data surrounding AMC is working in their favor.\nFor one, short squeezes typically require certain conditions be met, which simply aren't there at the moment. While the company's 18.8% short interest at the end of August is higher than most stocks, its large daily trading volume means it would take less than a day for all 95.94 million short shares to be covered. The liquidity of AMC's stock means short-sellers have no fear of being trapped in their position.\nFundamentally, the movie theater industry has been in a nearly two-decade decline. Tickets sold and inflation-adjusted gross at the box office have fallen 22% between 2002 and 2019, the last full year before the pandemic. Streaming offerings and substantially reduced film exclusivity (30 to 45 days now, compared to 75 to 90 days prior to the pandemic) bode poorly for the industry's future.\nAnd then there's AMC's operating performance and liability-riddled balance sheet. Despite a record $2.023 billion in liquidity ($1.81 billion in cash), AMC burned through $576.5 million in cash in the first six months of 2021. Its lease liabilities are soaring, it owes $420 million in deferred rent, and it's lugging around nearly $5.5 billion in debt that it likely can't pay.\nMore than $1 billion in aggregate debt due in 2026 and 2027 is also valued at 70% to 74% of face value. Debt going for this much below par is a very real warning sign that bondholders believe a future default is possible.\nLong story short, Wall Street has every reason to be skeptical of AMC.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6030133,"gmtCreate":1632871110677,"gmtModify":1634783103040,"authorId":3567307840510045,"author":{"id":3567307840510045,"idStr":"3567307840510045","authorId":3567307840510045,"name":"JeremyKok","avatar":"https://static.tigerbbs.com/01b03a485f83b6b2615fad8ac9b87bf4","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":862883366,"type":1,"supId":0,"prevId":0,"content":"hi. please like and comment back. thank you.","text":"hi. please like and comment back. thank you.","html":"hi. please like and comment back. thank you."}],"langContent":"CN"},{"id":862889225,"gmtCreate":1632869209098,"gmtModify":1632869209229,"author":{"id":"3575113315907312","authorId":"3575113315907312","name":"MengYang","avatar":"https://static.tigerbbs.com/2dece979ff56347c710918e7aa49d224","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3575113315907312","authorIdStr":"3575113315907312"},"htmlText":"Nice, please like","listText":"Nice, please like","text":"Nice, please like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862889225","repostId":2170778116,"repostType":4,"repost":{"id":"2170778116","kind":"highlight","pubTimestamp":1632829153,"share":"https://www.laohu8.com/m/news/2170778116?lang=&edition=full","pubTime":"2021-09-28 19:39","market":"us","language":"en","title":"3 Ultra-Popular Stocks With No Buy Ratings on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2170778116","media":"Motley Fool","summary":"These widely held stocks are getting no love from analysts.","content":"<p>Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.</p>\n<p>According to data from CNBC, over 90% of all <b>S&amp;P 500</b> stock ratings from Wall Street analysts were the equivalent of \"buy\" or \"hold\" between 1997 and 2017. With the exception of short periods in 2002-2003 and 2008-2009, sell ratings have consistently accounted for only 1% to 6% of all ratings for S&amp;P 500 companies this century.</p>\n<p>One reason for this \"buy bias\" is due to the U.S. and global economy growing over time. Historically, the stock market moves higher over the long run, too. Wall Street analysts might simply be playing the favorable odds that higher-quality businesses will increase in value over time.</p>\n<p>Additionally, <i>The Wall Street Journal</i> noted some years back that Wall Street analysts are hesitant to issue sell ratings so as not to burn bridges for their clients or themselves with the companies they cover. No matter the reasoning, sell ratings are rare on Wall Street.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fb1fd3c71278c123e5dd0404a4dbb43c\" tg-width=\"700\" tg-height=\"525\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<p>But don't tell that to shareholders of the following three ultra-popular stocks. These are three of the 16 most-held stocks on the <b>Robinhood</b> (NASDAQ:HOOD) platform, and not one of them has a single buy rating from a Wall Street analyst.</p>\n<h2>Aurora Cannabis</h2>\n<p>One of the biggest buzzkills, according to Wall Street, is Canadian marijuana stock <b>Aurora Cannabis</b> (NASDAQ:ACB). Aurora, which at one time was the most-held stock on Robinhood, is being covered by 13 Wall Street institutions, seven of which rate the company the equivalent of a hold and six of which believe it's a sell.</p>\n<p>Though Aurora Cannabis does foot the blame for a lot of this negativity, some of its issues can be traced to Canadian federal and provincial regulators failing the pot industry. For example, Ontario's lottery system to assign retail licenses through 2019 was terrible and resulted in only a few dozen dispensaries opening. Canadian pot stocks are still trying to recover from supply chain bottlenecks in the country's most populous province.</p>\n<p>But as I mentioned, Aurora Cannabis isn't without fault. The company expanded its production capacity far beyond what was needed. At one time, it held 15 production facilities that could have yielded more than 600,000 kilos of annual cannabis output if fully operational. Management has since closed five of these smaller facilities, sold a 1-million-square-foot greenhouse that wasn't retrofitted for cannabis production, and halted construction on two of the company's largest projects.</p>\n<p>Yet, even with this aggressive cost-cutting, Aurora Cannabis is still a long way from generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). With the company continuing to burn cash and the previous management team grossly overpaying for about a dozen acquisitions, it's regularly had to sell its common stock to raise capital to pay its bills and fund buyouts.</p>\n<p>Taking into account a reverse split enacted last year to stave off delisting, Aurora's share count has ballooned from about 1.3 million shares in June 2014 to 198 million shares, as of mid-May. That sort of dilution is precisely why the company's shares are down nearly 95% since March 2019.</p>\n<p>The salt in the wound is that Canada's legal weed sales have been hitting monthly records, all while Aurora's recreational pot revenue was more than halved in its fiscal third quarter.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/bc514068ded899a817770f684369db36\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Sundial Growers</h2>\n<p>Yet another Canadian pot stock in the no-buy zone for Wall Street is small-cap <b>Sundial Growers</b> (NASDAQ:SNDL). Even though it's the fourth most-held stock on Robinhood, four of the six analysts covering the company rate it a sell.</p>\n<p>Despite sitting on a boatload of cash, cash equivalents, and long-term investments (about $948 million), Sundial Growers has three factors working against it.</p>\n<p>To begin with, Sundial's approach to raising capital has destroyed shareholder value. Initially, it looked as if management would sell enough common stock to simply pay off the company's outstanding debt. But in a nine-month stretch between Oct. 1, 2020 and June 30, 2021, Sundial's executives have unrelentingly issued stock to raise additional capital.</p>\n<p>The end result is the issuance of roughly 1.5 billion shares of stock. With 2 billion shares now outstanding, Sundial has virtually no chance of ever generating meaningful earnings per share, and it'll likely struggle to remain listed on the <b>Nasdaq</b>&nbsp;exchange without a substantial reverse split.</p>\n<p>Second, Sundial's management team hasn't laid out a concrete plan for its capital. While it did undertake a cash-and-stock deal to acquire <a href=\"https://laohu8.com/S/INSHF\">Inner Spirit Holdings</a> in July, and it's committed roughly $425 million to its joint venture with SAF Group, known as SunStream Bancorp, to invest in cannabis industry opportunities, the company has continued to raise cash with no stated purpose.</p>\n<p>Third, Sundial has shifted its operating model away from wholesale cannabis to take advantage of the higher margins associated with the retail side of the equation. Unfortunately, having to start from scratch has led to significant year-over-year sales declines at a time when legal weed sales are rapidly growing.</p>\n<p>In March I more or less referred to Sundial as the worst cannabis stock money could buy. That descriptor still holds true today.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1c6cb4d9fcdf85f542f333fc71a2dd58\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>AMC Entertainment</h2>\n<p>But the most popular stock of all that's getting absolutely no love from Wall Street analysts and investment banks is movie theater chain <b>AMC Entertainment</b> (NYSE:AMC). The third most-held stock on Robinhood has nine analysts covering the company. Five of them have it rated a sell, with four others chiming in with a hold rating.</p>\n<p>This rating distribution isn't a surprise given that Wall Street's consensus price target for AMC is $5.44. Shares of the company would need to fall 86% from where they closed last week to reach this consensus target.</p>\n<p>The reason AMC's share price has rocketed higher in 2021 primarily has to do with retail investors piling into the stock and betting on a short squeeze -- i.e., a very short-term event whereby pessimists (short-sellers) run for the exit and buy shares to cover their positions. The issue for these optimists is that none of the data surrounding AMC is working in their favor.</p>\n<p>For one, short squeezes typically require certain conditions be met, which simply aren't there at the moment. While the company's 18.8% short interest at the end of August is higher than most stocks, its large daily trading volume means it would take less than a day for all 95.94 million short shares to be covered. The liquidity of AMC's stock means short-sellers have no fear of being trapped in their position.</p>\n<p>Fundamentally, the movie theater industry has been in a nearly two-decade decline. Tickets sold and inflation-adjusted gross at the box office have fallen 22% between 2002 and 2019, the last full year before the pandemic. Streaming offerings and substantially reduced film exclusivity (30 to 45 days now, compared to 75 to 90 days prior to the pandemic) bode poorly for the industry's future.</p>\n<p>And then there's AMC's operating performance and liability-riddled balance sheet. Despite a record $2.023 billion in liquidity ($1.81 billion in cash), AMC burned through $576.5 million in cash in the first six months of 2021. Its lease liabilities are soaring, it owes $420 million in deferred rent, and it's lugging around nearly $5.5 billion in debt that it likely can't pay.</p>\n<p>More than $1 billion in aggregate debt due in 2026 and 2027 is also valued at 70% to 74% of face value. Debt going for this much below par is a very real warning sign that bondholders believe a future default is possible.</p>\n<p>Long story short, Wall Street has every reason to be skeptical of AMC.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Ultra-Popular Stocks With No Buy Ratings on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Ultra-Popular Stocks With No Buy Ratings on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-28 19:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.\nAccording to data from CNBC, over 90% of all S&P 500 stock ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ACB":"奥罗拉大麻公司","SNDL":"SNDL Inc.","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2170778116","content_text":"Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.\nAccording to data from CNBC, over 90% of all S&P 500 stock ratings from Wall Street analysts were the equivalent of \"buy\" or \"hold\" between 1997 and 2017. With the exception of short periods in 2002-2003 and 2008-2009, sell ratings have consistently accounted for only 1% to 6% of all ratings for S&P 500 companies this century.\nOne reason for this \"buy bias\" is due to the U.S. and global economy growing over time. Historically, the stock market moves higher over the long run, too. Wall Street analysts might simply be playing the favorable odds that higher-quality businesses will increase in value over time.\nAdditionally, The Wall Street Journal noted some years back that Wall Street analysts are hesitant to issue sell ratings so as not to burn bridges for their clients or themselves with the companies they cover. No matter the reasoning, sell ratings are rare on Wall Street.\nImage source: Getty Images.\nBut don't tell that to shareholders of the following three ultra-popular stocks. These are three of the 16 most-held stocks on the Robinhood (NASDAQ:HOOD) platform, and not one of them has a single buy rating from a Wall Street analyst.\nAurora Cannabis\nOne of the biggest buzzkills, according to Wall Street, is Canadian marijuana stock Aurora Cannabis (NASDAQ:ACB). Aurora, which at one time was the most-held stock on Robinhood, is being covered by 13 Wall Street institutions, seven of which rate the company the equivalent of a hold and six of which believe it's a sell.\nThough Aurora Cannabis does foot the blame for a lot of this negativity, some of its issues can be traced to Canadian federal and provincial regulators failing the pot industry. For example, Ontario's lottery system to assign retail licenses through 2019 was terrible and resulted in only a few dozen dispensaries opening. Canadian pot stocks are still trying to recover from supply chain bottlenecks in the country's most populous province.\nBut as I mentioned, Aurora Cannabis isn't without fault. The company expanded its production capacity far beyond what was needed. At one time, it held 15 production facilities that could have yielded more than 600,000 kilos of annual cannabis output if fully operational. Management has since closed five of these smaller facilities, sold a 1-million-square-foot greenhouse that wasn't retrofitted for cannabis production, and halted construction on two of the company's largest projects.\nYet, even with this aggressive cost-cutting, Aurora Cannabis is still a long way from generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). With the company continuing to burn cash and the previous management team grossly overpaying for about a dozen acquisitions, it's regularly had to sell its common stock to raise capital to pay its bills and fund buyouts.\nTaking into account a reverse split enacted last year to stave off delisting, Aurora's share count has ballooned from about 1.3 million shares in June 2014 to 198 million shares, as of mid-May. That sort of dilution is precisely why the company's shares are down nearly 95% since March 2019.\nThe salt in the wound is that Canada's legal weed sales have been hitting monthly records, all while Aurora's recreational pot revenue was more than halved in its fiscal third quarter.\nImage source: Getty Images.\nSundial Growers\nYet another Canadian pot stock in the no-buy zone for Wall Street is small-cap Sundial Growers (NASDAQ:SNDL). Even though it's the fourth most-held stock on Robinhood, four of the six analysts covering the company rate it a sell.\nDespite sitting on a boatload of cash, cash equivalents, and long-term investments (about $948 million), Sundial Growers has three factors working against it.\nTo begin with, Sundial's approach to raising capital has destroyed shareholder value. Initially, it looked as if management would sell enough common stock to simply pay off the company's outstanding debt. But in a nine-month stretch between Oct. 1, 2020 and June 30, 2021, Sundial's executives have unrelentingly issued stock to raise additional capital.\nThe end result is the issuance of roughly 1.5 billion shares of stock. With 2 billion shares now outstanding, Sundial has virtually no chance of ever generating meaningful earnings per share, and it'll likely struggle to remain listed on the Nasdaq exchange without a substantial reverse split.\nSecond, Sundial's management team hasn't laid out a concrete plan for its capital. While it did undertake a cash-and-stock deal to acquire Inner Spirit Holdings in July, and it's committed roughly $425 million to its joint venture with SAF Group, known as SunStream Bancorp, to invest in cannabis industry opportunities, the company has continued to raise cash with no stated purpose.\nThird, Sundial has shifted its operating model away from wholesale cannabis to take advantage of the higher margins associated with the retail side of the equation. Unfortunately, having to start from scratch has led to significant year-over-year sales declines at a time when legal weed sales are rapidly growing.\nIn March I more or less referred to Sundial as the worst cannabis stock money could buy. That descriptor still holds true today.\nImage source: Getty Images.\nAMC Entertainment\nBut the most popular stock of all that's getting absolutely no love from Wall Street analysts and investment banks is movie theater chain AMC Entertainment (NYSE:AMC). The third most-held stock on Robinhood has nine analysts covering the company. Five of them have it rated a sell, with four others chiming in with a hold rating.\nThis rating distribution isn't a surprise given that Wall Street's consensus price target for AMC is $5.44. Shares of the company would need to fall 86% from where they closed last week to reach this consensus target.\nThe reason AMC's share price has rocketed higher in 2021 primarily has to do with retail investors piling into the stock and betting on a short squeeze -- i.e., a very short-term event whereby pessimists (short-sellers) run for the exit and buy shares to cover their positions. The issue for these optimists is that none of the data surrounding AMC is working in their favor.\nFor one, short squeezes typically require certain conditions be met, which simply aren't there at the moment. While the company's 18.8% short interest at the end of August is higher than most stocks, its large daily trading volume means it would take less than a day for all 95.94 million short shares to be covered. The liquidity of AMC's stock means short-sellers have no fear of being trapped in their position.\nFundamentally, the movie theater industry has been in a nearly two-decade decline. Tickets sold and inflation-adjusted gross at the box office have fallen 22% between 2002 and 2019, the last full year before the pandemic. Streaming offerings and substantially reduced film exclusivity (30 to 45 days now, compared to 75 to 90 days prior to the pandemic) bode poorly for the industry's future.\nAnd then there's AMC's operating performance and liability-riddled balance sheet. Despite a record $2.023 billion in liquidity ($1.81 billion in cash), AMC burned through $576.5 million in cash in the first six months of 2021. Its lease liabilities are soaring, it owes $420 million in deferred rent, and it's lugging around nearly $5.5 billion in debt that it likely can't pay.\nMore than $1 billion in aggregate debt due in 2026 and 2027 is also valued at 70% to 74% of face value. Debt going for this much below par is a very real warning sign that bondholders believe a future default is possible.\nLong story short, Wall Street has every reason to be skeptical of AMC.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":862897387,"gmtCreate":1632866631401,"gmtModify":1632866632057,"author":{"id":"3574928367638029","authorId":"3574928367638029","name":"kenong62","avatar":"https://static.tigerbbs.com/37fd00bd8cea11b8aa1aed6d9ddd9413","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3574928367638029","authorIdStr":"3574928367638029"},"htmlText":"Please likeThanks","listText":"Please likeThanks","text":"Please likeThanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/862897387","repostId":2170778116,"repostType":4,"repost":{"id":"2170778116","kind":"highlight","pubTimestamp":1632829153,"share":"https://www.laohu8.com/m/news/2170778116?lang=&edition=full","pubTime":"2021-09-28 19:39","market":"us","language":"en","title":"3 Ultra-Popular Stocks With No Buy Ratings on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2170778116","media":"Motley Fool","summary":"These widely held stocks are getting no love from analysts.","content":"<p>Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.</p>\n<p>According to data from CNBC, over 90% of all <b>S&amp;P 500</b> stock ratings from Wall Street analysts were the equivalent of \"buy\" or \"hold\" between 1997 and 2017. With the exception of short periods in 2002-2003 and 2008-2009, sell ratings have consistently accounted for only 1% to 6% of all ratings for S&amp;P 500 companies this century.</p>\n<p>One reason for this \"buy bias\" is due to the U.S. and global economy growing over time. Historically, the stock market moves higher over the long run, too. Wall Street analysts might simply be playing the favorable odds that higher-quality businesses will increase in value over time.</p>\n<p>Additionally, <i>The Wall Street Journal</i> noted some years back that Wall Street analysts are hesitant to issue sell ratings so as not to burn bridges for their clients or themselves with the companies they cover. No matter the reasoning, sell ratings are rare on Wall Street.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fb1fd3c71278c123e5dd0404a4dbb43c\" tg-width=\"700\" tg-height=\"525\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<p>But don't tell that to shareholders of the following three ultra-popular stocks. These are three of the 16 most-held stocks on the <b>Robinhood</b> (NASDAQ:HOOD) platform, and not one of them has a single buy rating from a Wall Street analyst.</p>\n<h2>Aurora Cannabis</h2>\n<p>One of the biggest buzzkills, according to Wall Street, is Canadian marijuana stock <b>Aurora Cannabis</b> (NASDAQ:ACB). Aurora, which at one time was the most-held stock on Robinhood, is being covered by 13 Wall Street institutions, seven of which rate the company the equivalent of a hold and six of which believe it's a sell.</p>\n<p>Though Aurora Cannabis does foot the blame for a lot of this negativity, some of its issues can be traced to Canadian federal and provincial regulators failing the pot industry. For example, Ontario's lottery system to assign retail licenses through 2019 was terrible and resulted in only a few dozen dispensaries opening. Canadian pot stocks are still trying to recover from supply chain bottlenecks in the country's most populous province.</p>\n<p>But as I mentioned, Aurora Cannabis isn't without fault. The company expanded its production capacity far beyond what was needed. At one time, it held 15 production facilities that could have yielded more than 600,000 kilos of annual cannabis output if fully operational. Management has since closed five of these smaller facilities, sold a 1-million-square-foot greenhouse that wasn't retrofitted for cannabis production, and halted construction on two of the company's largest projects.</p>\n<p>Yet, even with this aggressive cost-cutting, Aurora Cannabis is still a long way from generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). With the company continuing to burn cash and the previous management team grossly overpaying for about a dozen acquisitions, it's regularly had to sell its common stock to raise capital to pay its bills and fund buyouts.</p>\n<p>Taking into account a reverse split enacted last year to stave off delisting, Aurora's share count has ballooned from about 1.3 million shares in June 2014 to 198 million shares, as of mid-May. That sort of dilution is precisely why the company's shares are down nearly 95% since March 2019.</p>\n<p>The salt in the wound is that Canada's legal weed sales have been hitting monthly records, all while Aurora's recreational pot revenue was more than halved in its fiscal third quarter.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/bc514068ded899a817770f684369db36\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Sundial Growers</h2>\n<p>Yet another Canadian pot stock in the no-buy zone for Wall Street is small-cap <b>Sundial Growers</b> (NASDAQ:SNDL). Even though it's the fourth most-held stock on Robinhood, four of the six analysts covering the company rate it a sell.</p>\n<p>Despite sitting on a boatload of cash, cash equivalents, and long-term investments (about $948 million), Sundial Growers has three factors working against it.</p>\n<p>To begin with, Sundial's approach to raising capital has destroyed shareholder value. Initially, it looked as if management would sell enough common stock to simply pay off the company's outstanding debt. But in a nine-month stretch between Oct. 1, 2020 and June 30, 2021, Sundial's executives have unrelentingly issued stock to raise additional capital.</p>\n<p>The end result is the issuance of roughly 1.5 billion shares of stock. With 2 billion shares now outstanding, Sundial has virtually no chance of ever generating meaningful earnings per share, and it'll likely struggle to remain listed on the <b>Nasdaq</b>&nbsp;exchange without a substantial reverse split.</p>\n<p>Second, Sundial's management team hasn't laid out a concrete plan for its capital. While it did undertake a cash-and-stock deal to acquire <a href=\"https://laohu8.com/S/INSHF\">Inner Spirit Holdings</a> in July, and it's committed roughly $425 million to its joint venture with SAF Group, known as SunStream Bancorp, to invest in cannabis industry opportunities, the company has continued to raise cash with no stated purpose.</p>\n<p>Third, Sundial has shifted its operating model away from wholesale cannabis to take advantage of the higher margins associated with the retail side of the equation. Unfortunately, having to start from scratch has led to significant year-over-year sales declines at a time when legal weed sales are rapidly growing.</p>\n<p>In March I more or less referred to Sundial as the worst cannabis stock money could buy. That descriptor still holds true today.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1c6cb4d9fcdf85f542f333fc71a2dd58\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>AMC Entertainment</h2>\n<p>But the most popular stock of all that's getting absolutely no love from Wall Street analysts and investment banks is movie theater chain <b>AMC Entertainment</b> (NYSE:AMC). The third most-held stock on Robinhood has nine analysts covering the company. Five of them have it rated a sell, with four others chiming in with a hold rating.</p>\n<p>This rating distribution isn't a surprise given that Wall Street's consensus price target for AMC is $5.44. Shares of the company would need to fall 86% from where they closed last week to reach this consensus target.</p>\n<p>The reason AMC's share price has rocketed higher in 2021 primarily has to do with retail investors piling into the stock and betting on a short squeeze -- i.e., a very short-term event whereby pessimists (short-sellers) run for the exit and buy shares to cover their positions. The issue for these optimists is that none of the data surrounding AMC is working in their favor.</p>\n<p>For one, short squeezes typically require certain conditions be met, which simply aren't there at the moment. While the company's 18.8% short interest at the end of August is higher than most stocks, its large daily trading volume means it would take less than a day for all 95.94 million short shares to be covered. The liquidity of AMC's stock means short-sellers have no fear of being trapped in their position.</p>\n<p>Fundamentally, the movie theater industry has been in a nearly two-decade decline. Tickets sold and inflation-adjusted gross at the box office have fallen 22% between 2002 and 2019, the last full year before the pandemic. Streaming offerings and substantially reduced film exclusivity (30 to 45 days now, compared to 75 to 90 days prior to the pandemic) bode poorly for the industry's future.</p>\n<p>And then there's AMC's operating performance and liability-riddled balance sheet. Despite a record $2.023 billion in liquidity ($1.81 billion in cash), AMC burned through $576.5 million in cash in the first six months of 2021. Its lease liabilities are soaring, it owes $420 million in deferred rent, and it's lugging around nearly $5.5 billion in debt that it likely can't pay.</p>\n<p>More than $1 billion in aggregate debt due in 2026 and 2027 is also valued at 70% to 74% of face value. Debt going for this much below par is a very real warning sign that bondholders believe a future default is possible.</p>\n<p>Long story short, Wall Street has every reason to be skeptical of AMC.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Ultra-Popular Stocks With No Buy Ratings on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Ultra-Popular Stocks With No Buy Ratings on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-28 19:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.\nAccording to data from CNBC, over 90% of all S&P 500 stock ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ACB":"奥罗拉大麻公司","SNDL":"SNDL Inc.","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2170778116","content_text":"Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.\nAccording to data from CNBC, over 90% of all S&P 500 stock ratings from Wall Street analysts were the equivalent of \"buy\" or \"hold\" between 1997 and 2017. With the exception of short periods in 2002-2003 and 2008-2009, sell ratings have consistently accounted for only 1% to 6% of all ratings for S&P 500 companies this century.\nOne reason for this \"buy bias\" is due to the U.S. and global economy growing over time. Historically, the stock market moves higher over the long run, too. Wall Street analysts might simply be playing the favorable odds that higher-quality businesses will increase in value over time.\nAdditionally, The Wall Street Journal noted some years back that Wall Street analysts are hesitant to issue sell ratings so as not to burn bridges for their clients or themselves with the companies they cover. No matter the reasoning, sell ratings are rare on Wall Street.\nImage source: Getty Images.\nBut don't tell that to shareholders of the following three ultra-popular stocks. These are three of the 16 most-held stocks on the Robinhood (NASDAQ:HOOD) platform, and not one of them has a single buy rating from a Wall Street analyst.\nAurora Cannabis\nOne of the biggest buzzkills, according to Wall Street, is Canadian marijuana stock Aurora Cannabis (NASDAQ:ACB). Aurora, which at one time was the most-held stock on Robinhood, is being covered by 13 Wall Street institutions, seven of which rate the company the equivalent of a hold and six of which believe it's a sell.\nThough Aurora Cannabis does foot the blame for a lot of this negativity, some of its issues can be traced to Canadian federal and provincial regulators failing the pot industry. For example, Ontario's lottery system to assign retail licenses through 2019 was terrible and resulted in only a few dozen dispensaries opening. Canadian pot stocks are still trying to recover from supply chain bottlenecks in the country's most populous province.\nBut as I mentioned, Aurora Cannabis isn't without fault. The company expanded its production capacity far beyond what was needed. At one time, it held 15 production facilities that could have yielded more than 600,000 kilos of annual cannabis output if fully operational. Management has since closed five of these smaller facilities, sold a 1-million-square-foot greenhouse that wasn't retrofitted for cannabis production, and halted construction on two of the company's largest projects.\nYet, even with this aggressive cost-cutting, Aurora Cannabis is still a long way from generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). With the company continuing to burn cash and the previous management team grossly overpaying for about a dozen acquisitions, it's regularly had to sell its common stock to raise capital to pay its bills and fund buyouts.\nTaking into account a reverse split enacted last year to stave off delisting, Aurora's share count has ballooned from about 1.3 million shares in June 2014 to 198 million shares, as of mid-May. That sort of dilution is precisely why the company's shares are down nearly 95% since March 2019.\nThe salt in the wound is that Canada's legal weed sales have been hitting monthly records, all while Aurora's recreational pot revenue was more than halved in its fiscal third quarter.\nImage source: Getty Images.\nSundial Growers\nYet another Canadian pot stock in the no-buy zone for Wall Street is small-cap Sundial Growers (NASDAQ:SNDL). Even though it's the fourth most-held stock on Robinhood, four of the six analysts covering the company rate it a sell.\nDespite sitting on a boatload of cash, cash equivalents, and long-term investments (about $948 million), Sundial Growers has three factors working against it.\nTo begin with, Sundial's approach to raising capital has destroyed shareholder value. Initially, it looked as if management would sell enough common stock to simply pay off the company's outstanding debt. But in a nine-month stretch between Oct. 1, 2020 and June 30, 2021, Sundial's executives have unrelentingly issued stock to raise additional capital.\nThe end result is the issuance of roughly 1.5 billion shares of stock. With 2 billion shares now outstanding, Sundial has virtually no chance of ever generating meaningful earnings per share, and it'll likely struggle to remain listed on the Nasdaq exchange without a substantial reverse split.\nSecond, Sundial's management team hasn't laid out a concrete plan for its capital. While it did undertake a cash-and-stock deal to acquire Inner Spirit Holdings in July, and it's committed roughly $425 million to its joint venture with SAF Group, known as SunStream Bancorp, to invest in cannabis industry opportunities, the company has continued to raise cash with no stated purpose.\nThird, Sundial has shifted its operating model away from wholesale cannabis to take advantage of the higher margins associated with the retail side of the equation. Unfortunately, having to start from scratch has led to significant year-over-year sales declines at a time when legal weed sales are rapidly growing.\nIn March I more or less referred to Sundial as the worst cannabis stock money could buy. That descriptor still holds true today.\nImage source: Getty Images.\nAMC Entertainment\nBut the most popular stock of all that's getting absolutely no love from Wall Street analysts and investment banks is movie theater chain AMC Entertainment (NYSE:AMC). The third most-held stock on Robinhood has nine analysts covering the company. Five of them have it rated a sell, with four others chiming in with a hold rating.\nThis rating distribution isn't a surprise given that Wall Street's consensus price target for AMC is $5.44. Shares of the company would need to fall 86% from where they closed last week to reach this consensus target.\nThe reason AMC's share price has rocketed higher in 2021 primarily has to do with retail investors piling into the stock and betting on a short squeeze -- i.e., a very short-term event whereby pessimists (short-sellers) run for the exit and buy shares to cover their positions. The issue for these optimists is that none of the data surrounding AMC is working in their favor.\nFor one, short squeezes typically require certain conditions be met, which simply aren't there at the moment. While the company's 18.8% short interest at the end of August is higher than most stocks, its large daily trading volume means it would take less than a day for all 95.94 million short shares to be covered. The liquidity of AMC's stock means short-sellers have no fear of being trapped in their position.\nFundamentally, the movie theater industry has been in a nearly two-decade decline. Tickets sold and inflation-adjusted gross at the box office have fallen 22% between 2002 and 2019, the last full year before the pandemic. Streaming offerings and substantially reduced film exclusivity (30 to 45 days now, compared to 75 to 90 days prior to the pandemic) bode poorly for the industry's future.\nAnd then there's AMC's operating performance and liability-riddled balance sheet. Despite a record $2.023 billion in liquidity ($1.81 billion in cash), AMC burned through $576.5 million in cash in the first six months of 2021. Its lease liabilities are soaring, it owes $420 million in deferred rent, and it's lugging around nearly $5.5 billion in debt that it likely can't pay.\nMore than $1 billion in aggregate debt due in 2026 and 2027 is also valued at 70% to 74% of face value. Debt going for this much below par is a very real warning sign that bondholders believe a future default is possible.\nLong story short, Wall Street has every reason to be skeptical of AMC.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6030135,"gmtCreate":1632871119135,"gmtModify":1634783102823,"authorId":3567307840510045,"author":{"id":3567307840510045,"idStr":"3567307840510045","authorId":3567307840510045,"name":"JeremyKok","avatar":"https://static.tigerbbs.com/01b03a485f83b6b2615fad8ac9b87bf4","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":862897387,"type":1,"supId":0,"prevId":0,"content":"hi. please like and comment back. thank you.","text":"hi. please like and comment back. thank you.","html":"hi. please like and comment back. thank you."},{"id":6030787,"gmtCreate":1632873216028,"gmtModify":1634783039708,"authorId":3582013193139368,"author":{"id":3582013193139368,"idStr":"3582013193139368","authorId":3582013193139368,"name":"XiuJ","avatar":"https://static.tigerbbs.com/2679b64d21b553ca13b45b2f03e15f76","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":862897387,"type":1,"supId":6030135,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":6044393,"gmtCreate":1632965563805,"gmtModify":1634726069740,"authorId":3578971018458145,"author":{"id":3578971018458145,"idStr":"3578971018458145","authorId":3578971018458145,"name":"ocean_wave","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":862897387,"type":1,"supId":0,"prevId":0,"content":"[疑问]","text":"[疑问]","html":"[疑问]"}],"langContent":"CN"},{"id":862894905,"gmtCreate":1632866438110,"gmtModify":1632866438267,"author":{"id":"4089010444435920","authorId":"4089010444435920","name":"lewisleeks","avatar":"https://static.tigerbbs.com/d39cf835a09bdd21dce8a780b993940c","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4089010444435920","authorIdStr":"4089010444435920"},"htmlText":"Great [Smile]&nbsp;[Smile]&nbsp;","listText":"Great [Smile]&nbsp;[Smile]&nbsp;","text":"Great [Smile] [Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862894905","repostId":2170778116,"repostType":4,"repost":{"id":"2170778116","kind":"highlight","pubTimestamp":1632829153,"share":"https://www.laohu8.com/m/news/2170778116?lang=&edition=full","pubTime":"2021-09-28 19:39","market":"us","language":"en","title":"3 Ultra-Popular Stocks With No Buy Ratings on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2170778116","media":"Motley Fool","summary":"These widely held stocks are getting no love from analysts.","content":"<p>Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.</p>\n<p>According to data from CNBC, over 90% of all <b>S&amp;P 500</b> stock ratings from Wall Street analysts were the equivalent of \"buy\" or \"hold\" between 1997 and 2017. With the exception of short periods in 2002-2003 and 2008-2009, sell ratings have consistently accounted for only 1% to 6% of all ratings for S&amp;P 500 companies this century.</p>\n<p>One reason for this \"buy bias\" is due to the U.S. and global economy growing over time. Historically, the stock market moves higher over the long run, too. Wall Street analysts might simply be playing the favorable odds that higher-quality businesses will increase in value over time.</p>\n<p>Additionally, <i>The Wall Street Journal</i> noted some years back that Wall Street analysts are hesitant to issue sell ratings so as not to burn bridges for their clients or themselves with the companies they cover. No matter the reasoning, sell ratings are rare on Wall Street.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fb1fd3c71278c123e5dd0404a4dbb43c\" tg-width=\"700\" tg-height=\"525\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<p>But don't tell that to shareholders of the following three ultra-popular stocks. These are three of the 16 most-held stocks on the <b>Robinhood</b> (NASDAQ:HOOD) platform, and not one of them has a single buy rating from a Wall Street analyst.</p>\n<h2>Aurora Cannabis</h2>\n<p>One of the biggest buzzkills, according to Wall Street, is Canadian marijuana stock <b>Aurora Cannabis</b> (NASDAQ:ACB). Aurora, which at one time was the most-held stock on Robinhood, is being covered by 13 Wall Street institutions, seven of which rate the company the equivalent of a hold and six of which believe it's a sell.</p>\n<p>Though Aurora Cannabis does foot the blame for a lot of this negativity, some of its issues can be traced to Canadian federal and provincial regulators failing the pot industry. For example, Ontario's lottery system to assign retail licenses through 2019 was terrible and resulted in only a few dozen dispensaries opening. Canadian pot stocks are still trying to recover from supply chain bottlenecks in the country's most populous province.</p>\n<p>But as I mentioned, Aurora Cannabis isn't without fault. The company expanded its production capacity far beyond what was needed. At one time, it held 15 production facilities that could have yielded more than 600,000 kilos of annual cannabis output if fully operational. Management has since closed five of these smaller facilities, sold a 1-million-square-foot greenhouse that wasn't retrofitted for cannabis production, and halted construction on two of the company's largest projects.</p>\n<p>Yet, even with this aggressive cost-cutting, Aurora Cannabis is still a long way from generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). With the company continuing to burn cash and the previous management team grossly overpaying for about a dozen acquisitions, it's regularly had to sell its common stock to raise capital to pay its bills and fund buyouts.</p>\n<p>Taking into account a reverse split enacted last year to stave off delisting, Aurora's share count has ballooned from about 1.3 million shares in June 2014 to 198 million shares, as of mid-May. That sort of dilution is precisely why the company's shares are down nearly 95% since March 2019.</p>\n<p>The salt in the wound is that Canada's legal weed sales have been hitting monthly records, all while Aurora's recreational pot revenue was more than halved in its fiscal third quarter.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/bc514068ded899a817770f684369db36\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Sundial Growers</h2>\n<p>Yet another Canadian pot stock in the no-buy zone for Wall Street is small-cap <b>Sundial Growers</b> (NASDAQ:SNDL). Even though it's the fourth most-held stock on Robinhood, four of the six analysts covering the company rate it a sell.</p>\n<p>Despite sitting on a boatload of cash, cash equivalents, and long-term investments (about $948 million), Sundial Growers has three factors working against it.</p>\n<p>To begin with, Sundial's approach to raising capital has destroyed shareholder value. Initially, it looked as if management would sell enough common stock to simply pay off the company's outstanding debt. But in a nine-month stretch between Oct. 1, 2020 and June 30, 2021, Sundial's executives have unrelentingly issued stock to raise additional capital.</p>\n<p>The end result is the issuance of roughly 1.5 billion shares of stock. With 2 billion shares now outstanding, Sundial has virtually no chance of ever generating meaningful earnings per share, and it'll likely struggle to remain listed on the <b>Nasdaq</b>&nbsp;exchange without a substantial reverse split.</p>\n<p>Second, Sundial's management team hasn't laid out a concrete plan for its capital. While it did undertake a cash-and-stock deal to acquire <a href=\"https://laohu8.com/S/INSHF\">Inner Spirit Holdings</a> in July, and it's committed roughly $425 million to its joint venture with SAF Group, known as SunStream Bancorp, to invest in cannabis industry opportunities, the company has continued to raise cash with no stated purpose.</p>\n<p>Third, Sundial has shifted its operating model away from wholesale cannabis to take advantage of the higher margins associated with the retail side of the equation. Unfortunately, having to start from scratch has led to significant year-over-year sales declines at a time when legal weed sales are rapidly growing.</p>\n<p>In March I more or less referred to Sundial as the worst cannabis stock money could buy. That descriptor still holds true today.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1c6cb4d9fcdf85f542f333fc71a2dd58\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>AMC Entertainment</h2>\n<p>But the most popular stock of all that's getting absolutely no love from Wall Street analysts and investment banks is movie theater chain <b>AMC Entertainment</b> (NYSE:AMC). The third most-held stock on Robinhood has nine analysts covering the company. Five of them have it rated a sell, with four others chiming in with a hold rating.</p>\n<p>This rating distribution isn't a surprise given that Wall Street's consensus price target for AMC is $5.44. Shares of the company would need to fall 86% from where they closed last week to reach this consensus target.</p>\n<p>The reason AMC's share price has rocketed higher in 2021 primarily has to do with retail investors piling into the stock and betting on a short squeeze -- i.e., a very short-term event whereby pessimists (short-sellers) run for the exit and buy shares to cover their positions. The issue for these optimists is that none of the data surrounding AMC is working in their favor.</p>\n<p>For one, short squeezes typically require certain conditions be met, which simply aren't there at the moment. While the company's 18.8% short interest at the end of August is higher than most stocks, its large daily trading volume means it would take less than a day for all 95.94 million short shares to be covered. The liquidity of AMC's stock means short-sellers have no fear of being trapped in their position.</p>\n<p>Fundamentally, the movie theater industry has been in a nearly two-decade decline. Tickets sold and inflation-adjusted gross at the box office have fallen 22% between 2002 and 2019, the last full year before the pandemic. Streaming offerings and substantially reduced film exclusivity (30 to 45 days now, compared to 75 to 90 days prior to the pandemic) bode poorly for the industry's future.</p>\n<p>And then there's AMC's operating performance and liability-riddled balance sheet. Despite a record $2.023 billion in liquidity ($1.81 billion in cash), AMC burned through $576.5 million in cash in the first six months of 2021. Its lease liabilities are soaring, it owes $420 million in deferred rent, and it's lugging around nearly $5.5 billion in debt that it likely can't pay.</p>\n<p>More than $1 billion in aggregate debt due in 2026 and 2027 is also valued at 70% to 74% of face value. Debt going for this much below par is a very real warning sign that bondholders believe a future default is possible.</p>\n<p>Long story short, Wall Street has every reason to be skeptical of AMC.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Ultra-Popular Stocks With No Buy Ratings on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Ultra-Popular Stocks With No Buy Ratings on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-28 19:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.\nAccording to data from CNBC, over 90% of all S&P 500 stock ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ACB":"奥罗拉大麻公司","SNDL":"SNDL Inc.","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2170778116","content_text":"Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.\nAccording to data from CNBC, over 90% of all S&P 500 stock ratings from Wall Street analysts were the equivalent of \"buy\" or \"hold\" between 1997 and 2017. With the exception of short periods in 2002-2003 and 2008-2009, sell ratings have consistently accounted for only 1% to 6% of all ratings for S&P 500 companies this century.\nOne reason for this \"buy bias\" is due to the U.S. and global economy growing over time. Historically, the stock market moves higher over the long run, too. Wall Street analysts might simply be playing the favorable odds that higher-quality businesses will increase in value over time.\nAdditionally, The Wall Street Journal noted some years back that Wall Street analysts are hesitant to issue sell ratings so as not to burn bridges for their clients or themselves with the companies they cover. No matter the reasoning, sell ratings are rare on Wall Street.\nImage source: Getty Images.\nBut don't tell that to shareholders of the following three ultra-popular stocks. These are three of the 16 most-held stocks on the Robinhood (NASDAQ:HOOD) platform, and not one of them has a single buy rating from a Wall Street analyst.\nAurora Cannabis\nOne of the biggest buzzkills, according to Wall Street, is Canadian marijuana stock Aurora Cannabis (NASDAQ:ACB). Aurora, which at one time was the most-held stock on Robinhood, is being covered by 13 Wall Street institutions, seven of which rate the company the equivalent of a hold and six of which believe it's a sell.\nThough Aurora Cannabis does foot the blame for a lot of this negativity, some of its issues can be traced to Canadian federal and provincial regulators failing the pot industry. For example, Ontario's lottery system to assign retail licenses through 2019 was terrible and resulted in only a few dozen dispensaries opening. Canadian pot stocks are still trying to recover from supply chain bottlenecks in the country's most populous province.\nBut as I mentioned, Aurora Cannabis isn't without fault. The company expanded its production capacity far beyond what was needed. At one time, it held 15 production facilities that could have yielded more than 600,000 kilos of annual cannabis output if fully operational. Management has since closed five of these smaller facilities, sold a 1-million-square-foot greenhouse that wasn't retrofitted for cannabis production, and halted construction on two of the company's largest projects.\nYet, even with this aggressive cost-cutting, Aurora Cannabis is still a long way from generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). With the company continuing to burn cash and the previous management team grossly overpaying for about a dozen acquisitions, it's regularly had to sell its common stock to raise capital to pay its bills and fund buyouts.\nTaking into account a reverse split enacted last year to stave off delisting, Aurora's share count has ballooned from about 1.3 million shares in June 2014 to 198 million shares, as of mid-May. That sort of dilution is precisely why the company's shares are down nearly 95% since March 2019.\nThe salt in the wound is that Canada's legal weed sales have been hitting monthly records, all while Aurora's recreational pot revenue was more than halved in its fiscal third quarter.\nImage source: Getty Images.\nSundial Growers\nYet another Canadian pot stock in the no-buy zone for Wall Street is small-cap Sundial Growers (NASDAQ:SNDL). Even though it's the fourth most-held stock on Robinhood, four of the six analysts covering the company rate it a sell.\nDespite sitting on a boatload of cash, cash equivalents, and long-term investments (about $948 million), Sundial Growers has three factors working against it.\nTo begin with, Sundial's approach to raising capital has destroyed shareholder value. Initially, it looked as if management would sell enough common stock to simply pay off the company's outstanding debt. But in a nine-month stretch between Oct. 1, 2020 and June 30, 2021, Sundial's executives have unrelentingly issued stock to raise additional capital.\nThe end result is the issuance of roughly 1.5 billion shares of stock. With 2 billion shares now outstanding, Sundial has virtually no chance of ever generating meaningful earnings per share, and it'll likely struggle to remain listed on the Nasdaq exchange without a substantial reverse split.\nSecond, Sundial's management team hasn't laid out a concrete plan for its capital. While it did undertake a cash-and-stock deal to acquire Inner Spirit Holdings in July, and it's committed roughly $425 million to its joint venture with SAF Group, known as SunStream Bancorp, to invest in cannabis industry opportunities, the company has continued to raise cash with no stated purpose.\nThird, Sundial has shifted its operating model away from wholesale cannabis to take advantage of the higher margins associated with the retail side of the equation. Unfortunately, having to start from scratch has led to significant year-over-year sales declines at a time when legal weed sales are rapidly growing.\nIn March I more or less referred to Sundial as the worst cannabis stock money could buy. That descriptor still holds true today.\nImage source: Getty Images.\nAMC Entertainment\nBut the most popular stock of all that's getting absolutely no love from Wall Street analysts and investment banks is movie theater chain AMC Entertainment (NYSE:AMC). The third most-held stock on Robinhood has nine analysts covering the company. Five of them have it rated a sell, with four others chiming in with a hold rating.\nThis rating distribution isn't a surprise given that Wall Street's consensus price target for AMC is $5.44. Shares of the company would need to fall 86% from where they closed last week to reach this consensus target.\nThe reason AMC's share price has rocketed higher in 2021 primarily has to do with retail investors piling into the stock and betting on a short squeeze -- i.e., a very short-term event whereby pessimists (short-sellers) run for the exit and buy shares to cover their positions. The issue for these optimists is that none of the data surrounding AMC is working in their favor.\nFor one, short squeezes typically require certain conditions be met, which simply aren't there at the moment. While the company's 18.8% short interest at the end of August is higher than most stocks, its large daily trading volume means it would take less than a day for all 95.94 million short shares to be covered. The liquidity of AMC's stock means short-sellers have no fear of being trapped in their position.\nFundamentally, the movie theater industry has been in a nearly two-decade decline. Tickets sold and inflation-adjusted gross at the box office have fallen 22% between 2002 and 2019, the last full year before the pandemic. Streaming offerings and substantially reduced film exclusivity (30 to 45 days now, compared to 75 to 90 days prior to the pandemic) bode poorly for the industry's future.\nAnd then there's AMC's operating performance and liability-riddled balance sheet. Despite a record $2.023 billion in liquidity ($1.81 billion in cash), AMC burned through $576.5 million in cash in the first six months of 2021. Its lease liabilities are soaring, it owes $420 million in deferred rent, and it's lugging around nearly $5.5 billion in debt that it likely can't pay.\nMore than $1 billion in aggregate debt due in 2026 and 2027 is also valued at 70% to 74% of face value. Debt going for this much below par is a very real warning sign that bondholders believe a future default is possible.\nLong story short, Wall Street has every reason to be skeptical of AMC.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":862893805,"gmtCreate":1632865531120,"gmtModify":1632865531427,"author":{"id":"3582963095283492","authorId":"3582963095283492","name":"replaygoh","avatar":"https://static.tigerbbs.com/d47b21291424a3d55039334a8de5cdb9","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3582963095283492","authorIdStr":"3582963095283492"},"htmlText":"great","listText":"great","text":"great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862893805","repostId":2170778116,"repostType":4,"repost":{"id":"2170778116","kind":"highlight","pubTimestamp":1632829153,"share":"https://www.laohu8.com/m/news/2170778116?lang=&edition=full","pubTime":"2021-09-28 19:39","market":"us","language":"en","title":"3 Ultra-Popular Stocks With No Buy Ratings on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2170778116","media":"Motley Fool","summary":"These widely held stocks are getting no love from analysts.","content":"<p>Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.</p>\n<p>According to data from CNBC, over 90% of all <b>S&amp;P 500</b> stock ratings from Wall Street analysts were the equivalent of \"buy\" or \"hold\" between 1997 and 2017. With the exception of short periods in 2002-2003 and 2008-2009, sell ratings have consistently accounted for only 1% to 6% of all ratings for S&amp;P 500 companies this century.</p>\n<p>One reason for this \"buy bias\" is due to the U.S. and global economy growing over time. Historically, the stock market moves higher over the long run, too. Wall Street analysts might simply be playing the favorable odds that higher-quality businesses will increase in value over time.</p>\n<p>Additionally, <i>The Wall Street Journal</i> noted some years back that Wall Street analysts are hesitant to issue sell ratings so as not to burn bridges for their clients or themselves with the companies they cover. No matter the reasoning, sell ratings are rare on Wall Street.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fb1fd3c71278c123e5dd0404a4dbb43c\" tg-width=\"700\" tg-height=\"525\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<p>But don't tell that to shareholders of the following three ultra-popular stocks. These are three of the 16 most-held stocks on the <b>Robinhood</b> (NASDAQ:HOOD) platform, and not one of them has a single buy rating from a Wall Street analyst.</p>\n<h2>Aurora Cannabis</h2>\n<p>One of the biggest buzzkills, according to Wall Street, is Canadian marijuana stock <b>Aurora Cannabis</b> (NASDAQ:ACB). Aurora, which at one time was the most-held stock on Robinhood, is being covered by 13 Wall Street institutions, seven of which rate the company the equivalent of a hold and six of which believe it's a sell.</p>\n<p>Though Aurora Cannabis does foot the blame for a lot of this negativity, some of its issues can be traced to Canadian federal and provincial regulators failing the pot industry. For example, Ontario's lottery system to assign retail licenses through 2019 was terrible and resulted in only a few dozen dispensaries opening. Canadian pot stocks are still trying to recover from supply chain bottlenecks in the country's most populous province.</p>\n<p>But as I mentioned, Aurora Cannabis isn't without fault. The company expanded its production capacity far beyond what was needed. At one time, it held 15 production facilities that could have yielded more than 600,000 kilos of annual cannabis output if fully operational. Management has since closed five of these smaller facilities, sold a 1-million-square-foot greenhouse that wasn't retrofitted for cannabis production, and halted construction on two of the company's largest projects.</p>\n<p>Yet, even with this aggressive cost-cutting, Aurora Cannabis is still a long way from generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). With the company continuing to burn cash and the previous management team grossly overpaying for about a dozen acquisitions, it's regularly had to sell its common stock to raise capital to pay its bills and fund buyouts.</p>\n<p>Taking into account a reverse split enacted last year to stave off delisting, Aurora's share count has ballooned from about 1.3 million shares in June 2014 to 198 million shares, as of mid-May. That sort of dilution is precisely why the company's shares are down nearly 95% since March 2019.</p>\n<p>The salt in the wound is that Canada's legal weed sales have been hitting monthly records, all while Aurora's recreational pot revenue was more than halved in its fiscal third quarter.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/bc514068ded899a817770f684369db36\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Sundial Growers</h2>\n<p>Yet another Canadian pot stock in the no-buy zone for Wall Street is small-cap <b>Sundial Growers</b> (NASDAQ:SNDL). Even though it's the fourth most-held stock on Robinhood, four of the six analysts covering the company rate it a sell.</p>\n<p>Despite sitting on a boatload of cash, cash equivalents, and long-term investments (about $948 million), Sundial Growers has three factors working against it.</p>\n<p>To begin with, Sundial's approach to raising capital has destroyed shareholder value. Initially, it looked as if management would sell enough common stock to simply pay off the company's outstanding debt. But in a nine-month stretch between Oct. 1, 2020 and June 30, 2021, Sundial's executives have unrelentingly issued stock to raise additional capital.</p>\n<p>The end result is the issuance of roughly 1.5 billion shares of stock. With 2 billion shares now outstanding, Sundial has virtually no chance of ever generating meaningful earnings per share, and it'll likely struggle to remain listed on the <b>Nasdaq</b>&nbsp;exchange without a substantial reverse split.</p>\n<p>Second, Sundial's management team hasn't laid out a concrete plan for its capital. While it did undertake a cash-and-stock deal to acquire <a href=\"https://laohu8.com/S/INSHF\">Inner Spirit Holdings</a> in July, and it's committed roughly $425 million to its joint venture with SAF Group, known as SunStream Bancorp, to invest in cannabis industry opportunities, the company has continued to raise cash with no stated purpose.</p>\n<p>Third, Sundial has shifted its operating model away from wholesale cannabis to take advantage of the higher margins associated with the retail side of the equation. Unfortunately, having to start from scratch has led to significant year-over-year sales declines at a time when legal weed sales are rapidly growing.</p>\n<p>In March I more or less referred to Sundial as the worst cannabis stock money could buy. That descriptor still holds true today.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1c6cb4d9fcdf85f542f333fc71a2dd58\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>AMC Entertainment</h2>\n<p>But the most popular stock of all that's getting absolutely no love from Wall Street analysts and investment banks is movie theater chain <b>AMC Entertainment</b> (NYSE:AMC). The third most-held stock on Robinhood has nine analysts covering the company. Five of them have it rated a sell, with four others chiming in with a hold rating.</p>\n<p>This rating distribution isn't a surprise given that Wall Street's consensus price target for AMC is $5.44. Shares of the company would need to fall 86% from where they closed last week to reach this consensus target.</p>\n<p>The reason AMC's share price has rocketed higher in 2021 primarily has to do with retail investors piling into the stock and betting on a short squeeze -- i.e., a very short-term event whereby pessimists (short-sellers) run for the exit and buy shares to cover their positions. The issue for these optimists is that none of the data surrounding AMC is working in their favor.</p>\n<p>For one, short squeezes typically require certain conditions be met, which simply aren't there at the moment. While the company's 18.8% short interest at the end of August is higher than most stocks, its large daily trading volume means it would take less than a day for all 95.94 million short shares to be covered. The liquidity of AMC's stock means short-sellers have no fear of being trapped in their position.</p>\n<p>Fundamentally, the movie theater industry has been in a nearly two-decade decline. Tickets sold and inflation-adjusted gross at the box office have fallen 22% between 2002 and 2019, the last full year before the pandemic. Streaming offerings and substantially reduced film exclusivity (30 to 45 days now, compared to 75 to 90 days prior to the pandemic) bode poorly for the industry's future.</p>\n<p>And then there's AMC's operating performance and liability-riddled balance sheet. Despite a record $2.023 billion in liquidity ($1.81 billion in cash), AMC burned through $576.5 million in cash in the first six months of 2021. Its lease liabilities are soaring, it owes $420 million in deferred rent, and it's lugging around nearly $5.5 billion in debt that it likely can't pay.</p>\n<p>More than $1 billion in aggregate debt due in 2026 and 2027 is also valued at 70% to 74% of face value. Debt going for this much below par is a very real warning sign that bondholders believe a future default is possible.</p>\n<p>Long story short, Wall Street has every reason to be skeptical of AMC.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Ultra-Popular Stocks With No Buy Ratings on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Ultra-Popular Stocks With No Buy Ratings on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-28 19:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.\nAccording to data from CNBC, over 90% of all S&P 500 stock ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ACB":"奥罗拉大麻公司","SNDL":"SNDL Inc.","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2170778116","content_text":"Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.\nAccording to data from CNBC, over 90% of all S&P 500 stock ratings from Wall Street analysts were the equivalent of \"buy\" or \"hold\" between 1997 and 2017. With the exception of short periods in 2002-2003 and 2008-2009, sell ratings have consistently accounted for only 1% to 6% of all ratings for S&P 500 companies this century.\nOne reason for this \"buy bias\" is due to the U.S. and global economy growing over time. Historically, the stock market moves higher over the long run, too. Wall Street analysts might simply be playing the favorable odds that higher-quality businesses will increase in value over time.\nAdditionally, The Wall Street Journal noted some years back that Wall Street analysts are hesitant to issue sell ratings so as not to burn bridges for their clients or themselves with the companies they cover. No matter the reasoning, sell ratings are rare on Wall Street.\nImage source: Getty Images.\nBut don't tell that to shareholders of the following three ultra-popular stocks. These are three of the 16 most-held stocks on the Robinhood (NASDAQ:HOOD) platform, and not one of them has a single buy rating from a Wall Street analyst.\nAurora Cannabis\nOne of the biggest buzzkills, according to Wall Street, is Canadian marijuana stock Aurora Cannabis (NASDAQ:ACB). Aurora, which at one time was the most-held stock on Robinhood, is being covered by 13 Wall Street institutions, seven of which rate the company the equivalent of a hold and six of which believe it's a sell.\nThough Aurora Cannabis does foot the blame for a lot of this negativity, some of its issues can be traced to Canadian federal and provincial regulators failing the pot industry. For example, Ontario's lottery system to assign retail licenses through 2019 was terrible and resulted in only a few dozen dispensaries opening. Canadian pot stocks are still trying to recover from supply chain bottlenecks in the country's most populous province.\nBut as I mentioned, Aurora Cannabis isn't without fault. The company expanded its production capacity far beyond what was needed. At one time, it held 15 production facilities that could have yielded more than 600,000 kilos of annual cannabis output if fully operational. Management has since closed five of these smaller facilities, sold a 1-million-square-foot greenhouse that wasn't retrofitted for cannabis production, and halted construction on two of the company's largest projects.\nYet, even with this aggressive cost-cutting, Aurora Cannabis is still a long way from generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). With the company continuing to burn cash and the previous management team grossly overpaying for about a dozen acquisitions, it's regularly had to sell its common stock to raise capital to pay its bills and fund buyouts.\nTaking into account a reverse split enacted last year to stave off delisting, Aurora's share count has ballooned from about 1.3 million shares in June 2014 to 198 million shares, as of mid-May. That sort of dilution is precisely why the company's shares are down nearly 95% since March 2019.\nThe salt in the wound is that Canada's legal weed sales have been hitting monthly records, all while Aurora's recreational pot revenue was more than halved in its fiscal third quarter.\nImage source: Getty Images.\nSundial Growers\nYet another Canadian pot stock in the no-buy zone for Wall Street is small-cap Sundial Growers (NASDAQ:SNDL). Even though it's the fourth most-held stock on Robinhood, four of the six analysts covering the company rate it a sell.\nDespite sitting on a boatload of cash, cash equivalents, and long-term investments (about $948 million), Sundial Growers has three factors working against it.\nTo begin with, Sundial's approach to raising capital has destroyed shareholder value. Initially, it looked as if management would sell enough common stock to simply pay off the company's outstanding debt. But in a nine-month stretch between Oct. 1, 2020 and June 30, 2021, Sundial's executives have unrelentingly issued stock to raise additional capital.\nThe end result is the issuance of roughly 1.5 billion shares of stock. With 2 billion shares now outstanding, Sundial has virtually no chance of ever generating meaningful earnings per share, and it'll likely struggle to remain listed on the Nasdaq exchange without a substantial reverse split.\nSecond, Sundial's management team hasn't laid out a concrete plan for its capital. While it did undertake a cash-and-stock deal to acquire Inner Spirit Holdings in July, and it's committed roughly $425 million to its joint venture with SAF Group, known as SunStream Bancorp, to invest in cannabis industry opportunities, the company has continued to raise cash with no stated purpose.\nThird, Sundial has shifted its operating model away from wholesale cannabis to take advantage of the higher margins associated with the retail side of the equation. Unfortunately, having to start from scratch has led to significant year-over-year sales declines at a time when legal weed sales are rapidly growing.\nIn March I more or less referred to Sundial as the worst cannabis stock money could buy. That descriptor still holds true today.\nImage source: Getty Images.\nAMC Entertainment\nBut the most popular stock of all that's getting absolutely no love from Wall Street analysts and investment banks is movie theater chain AMC Entertainment (NYSE:AMC). The third most-held stock on Robinhood has nine analysts covering the company. Five of them have it rated a sell, with four others chiming in with a hold rating.\nThis rating distribution isn't a surprise given that Wall Street's consensus price target for AMC is $5.44. Shares of the company would need to fall 86% from where they closed last week to reach this consensus target.\nThe reason AMC's share price has rocketed higher in 2021 primarily has to do with retail investors piling into the stock and betting on a short squeeze -- i.e., a very short-term event whereby pessimists (short-sellers) run for the exit and buy shares to cover their positions. The issue for these optimists is that none of the data surrounding AMC is working in their favor.\nFor one, short squeezes typically require certain conditions be met, which simply aren't there at the moment. While the company's 18.8% short interest at the end of August is higher than most stocks, its large daily trading volume means it would take less than a day for all 95.94 million short shares to be covered. The liquidity of AMC's stock means short-sellers have no fear of being trapped in their position.\nFundamentally, the movie theater industry has been in a nearly two-decade decline. Tickets sold and inflation-adjusted gross at the box office have fallen 22% between 2002 and 2019, the last full year before the pandemic. Streaming offerings and substantially reduced film exclusivity (30 to 45 days now, compared to 75 to 90 days prior to the pandemic) bode poorly for the industry's future.\nAnd then there's AMC's operating performance and liability-riddled balance sheet. Despite a record $2.023 billion in liquidity ($1.81 billion in cash), AMC burned through $576.5 million in cash in the first six months of 2021. Its lease liabilities are soaring, it owes $420 million in deferred rent, and it's lugging around nearly $5.5 billion in debt that it likely can't pay.\nMore than $1 billion in aggregate debt due in 2026 and 2027 is also valued at 70% to 74% of face value. Debt going for this much below par is a very real warning sign that bondholders believe a future default is possible.\nLong story short, Wall Street has every reason to be skeptical of AMC.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":862899146,"gmtCreate":1632865388417,"gmtModify":1632865388417,"author":{"id":"4092554906611330","authorId":"4092554906611330","name":"Samuel123win","avatar":"https://static.tigerbbs.com/fb615bd9d23d3ee707625d59ccb06f5e","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4092554906611330","authorIdStr":"4092554906611330"},"htmlText":"💪","listText":"💪","text":"💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862899146","repostId":2170778116,"repostType":4,"repost":{"id":"2170778116","kind":"highlight","pubTimestamp":1632829153,"share":"https://www.laohu8.com/m/news/2170778116?lang=&edition=full","pubTime":"2021-09-28 19:39","market":"us","language":"en","title":"3 Ultra-Popular Stocks With No Buy Ratings on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2170778116","media":"Motley Fool","summary":"These widely held stocks are getting no love from analysts.","content":"<p>Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.</p>\n<p>According to data from CNBC, over 90% of all <b>S&amp;P 500</b> stock ratings from Wall Street analysts were the equivalent of \"buy\" or \"hold\" between 1997 and 2017. With the exception of short periods in 2002-2003 and 2008-2009, sell ratings have consistently accounted for only 1% to 6% of all ratings for S&amp;P 500 companies this century.</p>\n<p>One reason for this \"buy bias\" is due to the U.S. and global economy growing over time. Historically, the stock market moves higher over the long run, too. Wall Street analysts might simply be playing the favorable odds that higher-quality businesses will increase in value over time.</p>\n<p>Additionally, <i>The Wall Street Journal</i> noted some years back that Wall Street analysts are hesitant to issue sell ratings so as not to burn bridges for their clients or themselves with the companies they cover. No matter the reasoning, sell ratings are rare on Wall Street.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fb1fd3c71278c123e5dd0404a4dbb43c\" tg-width=\"700\" tg-height=\"525\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<p>But don't tell that to shareholders of the following three ultra-popular stocks. These are three of the 16 most-held stocks on the <b>Robinhood</b> (NASDAQ:HOOD) platform, and not one of them has a single buy rating from a Wall Street analyst.</p>\n<h2>Aurora Cannabis</h2>\n<p>One of the biggest buzzkills, according to Wall Street, is Canadian marijuana stock <b>Aurora Cannabis</b> (NASDAQ:ACB). Aurora, which at one time was the most-held stock on Robinhood, is being covered by 13 Wall Street institutions, seven of which rate the company the equivalent of a hold and six of which believe it's a sell.</p>\n<p>Though Aurora Cannabis does foot the blame for a lot of this negativity, some of its issues can be traced to Canadian federal and provincial regulators failing the pot industry. For example, Ontario's lottery system to assign retail licenses through 2019 was terrible and resulted in only a few dozen dispensaries opening. Canadian pot stocks are still trying to recover from supply chain bottlenecks in the country's most populous province.</p>\n<p>But as I mentioned, Aurora Cannabis isn't without fault. The company expanded its production capacity far beyond what was needed. At one time, it held 15 production facilities that could have yielded more than 600,000 kilos of annual cannabis output if fully operational. Management has since closed five of these smaller facilities, sold a 1-million-square-foot greenhouse that wasn't retrofitted for cannabis production, and halted construction on two of the company's largest projects.</p>\n<p>Yet, even with this aggressive cost-cutting, Aurora Cannabis is still a long way from generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). With the company continuing to burn cash and the previous management team grossly overpaying for about a dozen acquisitions, it's regularly had to sell its common stock to raise capital to pay its bills and fund buyouts.</p>\n<p>Taking into account a reverse split enacted last year to stave off delisting, Aurora's share count has ballooned from about 1.3 million shares in June 2014 to 198 million shares, as of mid-May. That sort of dilution is precisely why the company's shares are down nearly 95% since March 2019.</p>\n<p>The salt in the wound is that Canada's legal weed sales have been hitting monthly records, all while Aurora's recreational pot revenue was more than halved in its fiscal third quarter.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/bc514068ded899a817770f684369db36\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Sundial Growers</h2>\n<p>Yet another Canadian pot stock in the no-buy zone for Wall Street is small-cap <b>Sundial Growers</b> (NASDAQ:SNDL). Even though it's the fourth most-held stock on Robinhood, four of the six analysts covering the company rate it a sell.</p>\n<p>Despite sitting on a boatload of cash, cash equivalents, and long-term investments (about $948 million), Sundial Growers has three factors working against it.</p>\n<p>To begin with, Sundial's approach to raising capital has destroyed shareholder value. Initially, it looked as if management would sell enough common stock to simply pay off the company's outstanding debt. But in a nine-month stretch between Oct. 1, 2020 and June 30, 2021, Sundial's executives have unrelentingly issued stock to raise additional capital.</p>\n<p>The end result is the issuance of roughly 1.5 billion shares of stock. With 2 billion shares now outstanding, Sundial has virtually no chance of ever generating meaningful earnings per share, and it'll likely struggle to remain listed on the <b>Nasdaq</b>&nbsp;exchange without a substantial reverse split.</p>\n<p>Second, Sundial's management team hasn't laid out a concrete plan for its capital. While it did undertake a cash-and-stock deal to acquire <a href=\"https://laohu8.com/S/INSHF\">Inner Spirit Holdings</a> in July, and it's committed roughly $425 million to its joint venture with SAF Group, known as SunStream Bancorp, to invest in cannabis industry opportunities, the company has continued to raise cash with no stated purpose.</p>\n<p>Third, Sundial has shifted its operating model away from wholesale cannabis to take advantage of the higher margins associated with the retail side of the equation. Unfortunately, having to start from scratch has led to significant year-over-year sales declines at a time when legal weed sales are rapidly growing.</p>\n<p>In March I more or less referred to Sundial as the worst cannabis stock money could buy. That descriptor still holds true today.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1c6cb4d9fcdf85f542f333fc71a2dd58\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>AMC Entertainment</h2>\n<p>But the most popular stock of all that's getting absolutely no love from Wall Street analysts and investment banks is movie theater chain <b>AMC Entertainment</b> (NYSE:AMC). The third most-held stock on Robinhood has nine analysts covering the company. Five of them have it rated a sell, with four others chiming in with a hold rating.</p>\n<p>This rating distribution isn't a surprise given that Wall Street's consensus price target for AMC is $5.44. Shares of the company would need to fall 86% from where they closed last week to reach this consensus target.</p>\n<p>The reason AMC's share price has rocketed higher in 2021 primarily has to do with retail investors piling into the stock and betting on a short squeeze -- i.e., a very short-term event whereby pessimists (short-sellers) run for the exit and buy shares to cover their positions. The issue for these optimists is that none of the data surrounding AMC is working in their favor.</p>\n<p>For one, short squeezes typically require certain conditions be met, which simply aren't there at the moment. While the company's 18.8% short interest at the end of August is higher than most stocks, its large daily trading volume means it would take less than a day for all 95.94 million short shares to be covered. The liquidity of AMC's stock means short-sellers have no fear of being trapped in their position.</p>\n<p>Fundamentally, the movie theater industry has been in a nearly two-decade decline. Tickets sold and inflation-adjusted gross at the box office have fallen 22% between 2002 and 2019, the last full year before the pandemic. Streaming offerings and substantially reduced film exclusivity (30 to 45 days now, compared to 75 to 90 days prior to the pandemic) bode poorly for the industry's future.</p>\n<p>And then there's AMC's operating performance and liability-riddled balance sheet. Despite a record $2.023 billion in liquidity ($1.81 billion in cash), AMC burned through $576.5 million in cash in the first six months of 2021. Its lease liabilities are soaring, it owes $420 million in deferred rent, and it's lugging around nearly $5.5 billion in debt that it likely can't pay.</p>\n<p>More than $1 billion in aggregate debt due in 2026 and 2027 is also valued at 70% to 74% of face value. Debt going for this much below par is a very real warning sign that bondholders believe a future default is possible.</p>\n<p>Long story short, Wall Street has every reason to be skeptical of AMC.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Ultra-Popular Stocks With No Buy Ratings on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Ultra-Popular Stocks With No Buy Ratings on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-28 19:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.\nAccording to data from CNBC, over 90% of all S&P 500 stock ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ACB":"奥罗拉大麻公司","SNDL":"SNDL Inc.","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2170778116","content_text":"Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.\nAccording to data from CNBC, over 90% of all S&P 500 stock ratings from Wall Street analysts were the equivalent of \"buy\" or \"hold\" between 1997 and 2017. With the exception of short periods in 2002-2003 and 2008-2009, sell ratings have consistently accounted for only 1% to 6% of all ratings for S&P 500 companies this century.\nOne reason for this \"buy bias\" is due to the U.S. and global economy growing over time. Historically, the stock market moves higher over the long run, too. Wall Street analysts might simply be playing the favorable odds that higher-quality businesses will increase in value over time.\nAdditionally, The Wall Street Journal noted some years back that Wall Street analysts are hesitant to issue sell ratings so as not to burn bridges for their clients or themselves with the companies they cover. No matter the reasoning, sell ratings are rare on Wall Street.\nImage source: Getty Images.\nBut don't tell that to shareholders of the following three ultra-popular stocks. These are three of the 16 most-held stocks on the Robinhood (NASDAQ:HOOD) platform, and not one of them has a single buy rating from a Wall Street analyst.\nAurora Cannabis\nOne of the biggest buzzkills, according to Wall Street, is Canadian marijuana stock Aurora Cannabis (NASDAQ:ACB). Aurora, which at one time was the most-held stock on Robinhood, is being covered by 13 Wall Street institutions, seven of which rate the company the equivalent of a hold and six of which believe it's a sell.\nThough Aurora Cannabis does foot the blame for a lot of this negativity, some of its issues can be traced to Canadian federal and provincial regulators failing the pot industry. For example, Ontario's lottery system to assign retail licenses through 2019 was terrible and resulted in only a few dozen dispensaries opening. Canadian pot stocks are still trying to recover from supply chain bottlenecks in the country's most populous province.\nBut as I mentioned, Aurora Cannabis isn't without fault. The company expanded its production capacity far beyond what was needed. At one time, it held 15 production facilities that could have yielded more than 600,000 kilos of annual cannabis output if fully operational. Management has since closed five of these smaller facilities, sold a 1-million-square-foot greenhouse that wasn't retrofitted for cannabis production, and halted construction on two of the company's largest projects.\nYet, even with this aggressive cost-cutting, Aurora Cannabis is still a long way from generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). With the company continuing to burn cash and the previous management team grossly overpaying for about a dozen acquisitions, it's regularly had to sell its common stock to raise capital to pay its bills and fund buyouts.\nTaking into account a reverse split enacted last year to stave off delisting, Aurora's share count has ballooned from about 1.3 million shares in June 2014 to 198 million shares, as of mid-May. That sort of dilution is precisely why the company's shares are down nearly 95% since March 2019.\nThe salt in the wound is that Canada's legal weed sales have been hitting monthly records, all while Aurora's recreational pot revenue was more than halved in its fiscal third quarter.\nImage source: Getty Images.\nSundial Growers\nYet another Canadian pot stock in the no-buy zone for Wall Street is small-cap Sundial Growers (NASDAQ:SNDL). Even though it's the fourth most-held stock on Robinhood, four of the six analysts covering the company rate it a sell.\nDespite sitting on a boatload of cash, cash equivalents, and long-term investments (about $948 million), Sundial Growers has three factors working against it.\nTo begin with, Sundial's approach to raising capital has destroyed shareholder value. Initially, it looked as if management would sell enough common stock to simply pay off the company's outstanding debt. But in a nine-month stretch between Oct. 1, 2020 and June 30, 2021, Sundial's executives have unrelentingly issued stock to raise additional capital.\nThe end result is the issuance of roughly 1.5 billion shares of stock. With 2 billion shares now outstanding, Sundial has virtually no chance of ever generating meaningful earnings per share, and it'll likely struggle to remain listed on the Nasdaq exchange without a substantial reverse split.\nSecond, Sundial's management team hasn't laid out a concrete plan for its capital. While it did undertake a cash-and-stock deal to acquire Inner Spirit Holdings in July, and it's committed roughly $425 million to its joint venture with SAF Group, known as SunStream Bancorp, to invest in cannabis industry opportunities, the company has continued to raise cash with no stated purpose.\nThird, Sundial has shifted its operating model away from wholesale cannabis to take advantage of the higher margins associated with the retail side of the equation. Unfortunately, having to start from scratch has led to significant year-over-year sales declines at a time when legal weed sales are rapidly growing.\nIn March I more or less referred to Sundial as the worst cannabis stock money could buy. That descriptor still holds true today.\nImage source: Getty Images.\nAMC Entertainment\nBut the most popular stock of all that's getting absolutely no love from Wall Street analysts and investment banks is movie theater chain AMC Entertainment (NYSE:AMC). The third most-held stock on Robinhood has nine analysts covering the company. Five of them have it rated a sell, with four others chiming in with a hold rating.\nThis rating distribution isn't a surprise given that Wall Street's consensus price target for AMC is $5.44. Shares of the company would need to fall 86% from where they closed last week to reach this consensus target.\nThe reason AMC's share price has rocketed higher in 2021 primarily has to do with retail investors piling into the stock and betting on a short squeeze -- i.e., a very short-term event whereby pessimists (short-sellers) run for the exit and buy shares to cover their positions. The issue for these optimists is that none of the data surrounding AMC is working in their favor.\nFor one, short squeezes typically require certain conditions be met, which simply aren't there at the moment. While the company's 18.8% short interest at the end of August is higher than most stocks, its large daily trading volume means it would take less than a day for all 95.94 million short shares to be covered. The liquidity of AMC's stock means short-sellers have no fear of being trapped in their position.\nFundamentally, the movie theater industry has been in a nearly two-decade decline. Tickets sold and inflation-adjusted gross at the box office have fallen 22% between 2002 and 2019, the last full year before the pandemic. Streaming offerings and substantially reduced film exclusivity (30 to 45 days now, compared to 75 to 90 days prior to the pandemic) bode poorly for the industry's future.\nAnd then there's AMC's operating performance and liability-riddled balance sheet. Despite a record $2.023 billion in liquidity ($1.81 billion in cash), AMC burned through $576.5 million in cash in the first six months of 2021. Its lease liabilities are soaring, it owes $420 million in deferred rent, and it's lugging around nearly $5.5 billion in debt that it likely can't pay.\nMore than $1 billion in aggregate debt due in 2026 and 2027 is also valued at 70% to 74% of face value. Debt going for this much below par is a very real warning sign that bondholders believe a future default is possible.\nLong story short, Wall Street has every reason to be skeptical of AMC.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":862807399,"gmtCreate":1632864959490,"gmtModify":1632864959645,"author":{"id":"4088035849823630","authorId":"4088035849823630","name":"丰人","avatar":"https://static.tigerbbs.com/35bfaa2970044533bc9763d63a71e1dd","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4088035849823630","authorIdStr":"4088035849823630"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/862807399","repostId":2170778116,"repostType":4,"repost":{"id":"2170778116","kind":"highlight","pubTimestamp":1632829153,"share":"https://www.laohu8.com/m/news/2170778116?lang=&edition=full","pubTime":"2021-09-28 19:39","market":"us","language":"en","title":"3 Ultra-Popular Stocks With No Buy Ratings on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2170778116","media":"Motley Fool","summary":"These widely held stocks are getting no love from analysts.","content":"<p>Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.</p>\n<p>According to data from CNBC, over 90% of all <b>S&amp;P 500</b> stock ratings from Wall Street analysts were the equivalent of \"buy\" or \"hold\" between 1997 and 2017. With the exception of short periods in 2002-2003 and 2008-2009, sell ratings have consistently accounted for only 1% to 6% of all ratings for S&amp;P 500 companies this century.</p>\n<p>One reason for this \"buy bias\" is due to the U.S. and global economy growing over time. Historically, the stock market moves higher over the long run, too. Wall Street analysts might simply be playing the favorable odds that higher-quality businesses will increase in value over time.</p>\n<p>Additionally, <i>The Wall Street Journal</i> noted some years back that Wall Street analysts are hesitant to issue sell ratings so as not to burn bridges for their clients or themselves with the companies they cover. No matter the reasoning, sell ratings are rare on Wall Street.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fb1fd3c71278c123e5dd0404a4dbb43c\" tg-width=\"700\" tg-height=\"525\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<p>But don't tell that to shareholders of the following three ultra-popular stocks. These are three of the 16 most-held stocks on the <b>Robinhood</b> (NASDAQ:HOOD) platform, and not one of them has a single buy rating from a Wall Street analyst.</p>\n<h2>Aurora Cannabis</h2>\n<p>One of the biggest buzzkills, according to Wall Street, is Canadian marijuana stock <b>Aurora Cannabis</b> (NASDAQ:ACB). Aurora, which at one time was the most-held stock on Robinhood, is being covered by 13 Wall Street institutions, seven of which rate the company the equivalent of a hold and six of which believe it's a sell.</p>\n<p>Though Aurora Cannabis does foot the blame for a lot of this negativity, some of its issues can be traced to Canadian federal and provincial regulators failing the pot industry. For example, Ontario's lottery system to assign retail licenses through 2019 was terrible and resulted in only a few dozen dispensaries opening. Canadian pot stocks are still trying to recover from supply chain bottlenecks in the country's most populous province.</p>\n<p>But as I mentioned, Aurora Cannabis isn't without fault. The company expanded its production capacity far beyond what was needed. At one time, it held 15 production facilities that could have yielded more than 600,000 kilos of annual cannabis output if fully operational. Management has since closed five of these smaller facilities, sold a 1-million-square-foot greenhouse that wasn't retrofitted for cannabis production, and halted construction on two of the company's largest projects.</p>\n<p>Yet, even with this aggressive cost-cutting, Aurora Cannabis is still a long way from generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). With the company continuing to burn cash and the previous management team grossly overpaying for about a dozen acquisitions, it's regularly had to sell its common stock to raise capital to pay its bills and fund buyouts.</p>\n<p>Taking into account a reverse split enacted last year to stave off delisting, Aurora's share count has ballooned from about 1.3 million shares in June 2014 to 198 million shares, as of mid-May. That sort of dilution is precisely why the company's shares are down nearly 95% since March 2019.</p>\n<p>The salt in the wound is that Canada's legal weed sales have been hitting monthly records, all while Aurora's recreational pot revenue was more than halved in its fiscal third quarter.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/bc514068ded899a817770f684369db36\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Sundial Growers</h2>\n<p>Yet another Canadian pot stock in the no-buy zone for Wall Street is small-cap <b>Sundial Growers</b> (NASDAQ:SNDL). Even though it's the fourth most-held stock on Robinhood, four of the six analysts covering the company rate it a sell.</p>\n<p>Despite sitting on a boatload of cash, cash equivalents, and long-term investments (about $948 million), Sundial Growers has three factors working against it.</p>\n<p>To begin with, Sundial's approach to raising capital has destroyed shareholder value. Initially, it looked as if management would sell enough common stock to simply pay off the company's outstanding debt. But in a nine-month stretch between Oct. 1, 2020 and June 30, 2021, Sundial's executives have unrelentingly issued stock to raise additional capital.</p>\n<p>The end result is the issuance of roughly 1.5 billion shares of stock. With 2 billion shares now outstanding, Sundial has virtually no chance of ever generating meaningful earnings per share, and it'll likely struggle to remain listed on the <b>Nasdaq</b>&nbsp;exchange without a substantial reverse split.</p>\n<p>Second, Sundial's management team hasn't laid out a concrete plan for its capital. While it did undertake a cash-and-stock deal to acquire <a href=\"https://laohu8.com/S/INSHF\">Inner Spirit Holdings</a> in July, and it's committed roughly $425 million to its joint venture with SAF Group, known as SunStream Bancorp, to invest in cannabis industry opportunities, the company has continued to raise cash with no stated purpose.</p>\n<p>Third, Sundial has shifted its operating model away from wholesale cannabis to take advantage of the higher margins associated with the retail side of the equation. Unfortunately, having to start from scratch has led to significant year-over-year sales declines at a time when legal weed sales are rapidly growing.</p>\n<p>In March I more or less referred to Sundial as the worst cannabis stock money could buy. That descriptor still holds true today.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1c6cb4d9fcdf85f542f333fc71a2dd58\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>AMC Entertainment</h2>\n<p>But the most popular stock of all that's getting absolutely no love from Wall Street analysts and investment banks is movie theater chain <b>AMC Entertainment</b> (NYSE:AMC). The third most-held stock on Robinhood has nine analysts covering the company. Five of them have it rated a sell, with four others chiming in with a hold rating.</p>\n<p>This rating distribution isn't a surprise given that Wall Street's consensus price target for AMC is $5.44. Shares of the company would need to fall 86% from where they closed last week to reach this consensus target.</p>\n<p>The reason AMC's share price has rocketed higher in 2021 primarily has to do with retail investors piling into the stock and betting on a short squeeze -- i.e., a very short-term event whereby pessimists (short-sellers) run for the exit and buy shares to cover their positions. The issue for these optimists is that none of the data surrounding AMC is working in their favor.</p>\n<p>For one, short squeezes typically require certain conditions be met, which simply aren't there at the moment. While the company's 18.8% short interest at the end of August is higher than most stocks, its large daily trading volume means it would take less than a day for all 95.94 million short shares to be covered. The liquidity of AMC's stock means short-sellers have no fear of being trapped in their position.</p>\n<p>Fundamentally, the movie theater industry has been in a nearly two-decade decline. Tickets sold and inflation-adjusted gross at the box office have fallen 22% between 2002 and 2019, the last full year before the pandemic. Streaming offerings and substantially reduced film exclusivity (30 to 45 days now, compared to 75 to 90 days prior to the pandemic) bode poorly for the industry's future.</p>\n<p>And then there's AMC's operating performance and liability-riddled balance sheet. Despite a record $2.023 billion in liquidity ($1.81 billion in cash), AMC burned through $576.5 million in cash in the first six months of 2021. Its lease liabilities are soaring, it owes $420 million in deferred rent, and it's lugging around nearly $5.5 billion in debt that it likely can't pay.</p>\n<p>More than $1 billion in aggregate debt due in 2026 and 2027 is also valued at 70% to 74% of face value. Debt going for this much below par is a very real warning sign that bondholders believe a future default is possible.</p>\n<p>Long story short, Wall Street has every reason to be skeptical of AMC.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Ultra-Popular Stocks With No Buy Ratings on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Ultra-Popular Stocks With No Buy Ratings on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-28 19:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.\nAccording to data from CNBC, over 90% of all S&P 500 stock ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ACB":"奥罗拉大麻公司","SNDL":"SNDL Inc.","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2170778116","content_text":"Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.\nAccording to data from CNBC, over 90% of all S&P 500 stock ratings from Wall Street analysts were the equivalent of \"buy\" or \"hold\" between 1997 and 2017. With the exception of short periods in 2002-2003 and 2008-2009, sell ratings have consistently accounted for only 1% to 6% of all ratings for S&P 500 companies this century.\nOne reason for this \"buy bias\" is due to the U.S. and global economy growing over time. Historically, the stock market moves higher over the long run, too. Wall Street analysts might simply be playing the favorable odds that higher-quality businesses will increase in value over time.\nAdditionally, The Wall Street Journal noted some years back that Wall Street analysts are hesitant to issue sell ratings so as not to burn bridges for their clients or themselves with the companies they cover. No matter the reasoning, sell ratings are rare on Wall Street.\nImage source: Getty Images.\nBut don't tell that to shareholders of the following three ultra-popular stocks. These are three of the 16 most-held stocks on the Robinhood (NASDAQ:HOOD) platform, and not one of them has a single buy rating from a Wall Street analyst.\nAurora Cannabis\nOne of the biggest buzzkills, according to Wall Street, is Canadian marijuana stock Aurora Cannabis (NASDAQ:ACB). Aurora, which at one time was the most-held stock on Robinhood, is being covered by 13 Wall Street institutions, seven of which rate the company the equivalent of a hold and six of which believe it's a sell.\nThough Aurora Cannabis does foot the blame for a lot of this negativity, some of its issues can be traced to Canadian federal and provincial regulators failing the pot industry. For example, Ontario's lottery system to assign retail licenses through 2019 was terrible and resulted in only a few dozen dispensaries opening. Canadian pot stocks are still trying to recover from supply chain bottlenecks in the country's most populous province.\nBut as I mentioned, Aurora Cannabis isn't without fault. The company expanded its production capacity far beyond what was needed. At one time, it held 15 production facilities that could have yielded more than 600,000 kilos of annual cannabis output if fully operational. Management has since closed five of these smaller facilities, sold a 1-million-square-foot greenhouse that wasn't retrofitted for cannabis production, and halted construction on two of the company's largest projects.\nYet, even with this aggressive cost-cutting, Aurora Cannabis is still a long way from generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). With the company continuing to burn cash and the previous management team grossly overpaying for about a dozen acquisitions, it's regularly had to sell its common stock to raise capital to pay its bills and fund buyouts.\nTaking into account a reverse split enacted last year to stave off delisting, Aurora's share count has ballooned from about 1.3 million shares in June 2014 to 198 million shares, as of mid-May. That sort of dilution is precisely why the company's shares are down nearly 95% since March 2019.\nThe salt in the wound is that Canada's legal weed sales have been hitting monthly records, all while Aurora's recreational pot revenue was more than halved in its fiscal third quarter.\nImage source: Getty Images.\nSundial Growers\nYet another Canadian pot stock in the no-buy zone for Wall Street is small-cap Sundial Growers (NASDAQ:SNDL). Even though it's the fourth most-held stock on Robinhood, four of the six analysts covering the company rate it a sell.\nDespite sitting on a boatload of cash, cash equivalents, and long-term investments (about $948 million), Sundial Growers has three factors working against it.\nTo begin with, Sundial's approach to raising capital has destroyed shareholder value. Initially, it looked as if management would sell enough common stock to simply pay off the company's outstanding debt. But in a nine-month stretch between Oct. 1, 2020 and June 30, 2021, Sundial's executives have unrelentingly issued stock to raise additional capital.\nThe end result is the issuance of roughly 1.5 billion shares of stock. With 2 billion shares now outstanding, Sundial has virtually no chance of ever generating meaningful earnings per share, and it'll likely struggle to remain listed on the Nasdaq exchange without a substantial reverse split.\nSecond, Sundial's management team hasn't laid out a concrete plan for its capital. While it did undertake a cash-and-stock deal to acquire Inner Spirit Holdings in July, and it's committed roughly $425 million to its joint venture with SAF Group, known as SunStream Bancorp, to invest in cannabis industry opportunities, the company has continued to raise cash with no stated purpose.\nThird, Sundial has shifted its operating model away from wholesale cannabis to take advantage of the higher margins associated with the retail side of the equation. Unfortunately, having to start from scratch has led to significant year-over-year sales declines at a time when legal weed sales are rapidly growing.\nIn March I more or less referred to Sundial as the worst cannabis stock money could buy. That descriptor still holds true today.\nImage source: Getty Images.\nAMC Entertainment\nBut the most popular stock of all that's getting absolutely no love from Wall Street analysts and investment banks is movie theater chain AMC Entertainment (NYSE:AMC). The third most-held stock on Robinhood has nine analysts covering the company. Five of them have it rated a sell, with four others chiming in with a hold rating.\nThis rating distribution isn't a surprise given that Wall Street's consensus price target for AMC is $5.44. Shares of the company would need to fall 86% from where they closed last week to reach this consensus target.\nThe reason AMC's share price has rocketed higher in 2021 primarily has to do with retail investors piling into the stock and betting on a short squeeze -- i.e., a very short-term event whereby pessimists (short-sellers) run for the exit and buy shares to cover their positions. The issue for these optimists is that none of the data surrounding AMC is working in their favor.\nFor one, short squeezes typically require certain conditions be met, which simply aren't there at the moment. While the company's 18.8% short interest at the end of August is higher than most stocks, its large daily trading volume means it would take less than a day for all 95.94 million short shares to be covered. The liquidity of AMC's stock means short-sellers have no fear of being trapped in their position.\nFundamentally, the movie theater industry has been in a nearly two-decade decline. Tickets sold and inflation-adjusted gross at the box office have fallen 22% between 2002 and 2019, the last full year before the pandemic. Streaming offerings and substantially reduced film exclusivity (30 to 45 days now, compared to 75 to 90 days prior to the pandemic) bode poorly for the industry's future.\nAnd then there's AMC's operating performance and liability-riddled balance sheet. Despite a record $2.023 billion in liquidity ($1.81 billion in cash), AMC burned through $576.5 million in cash in the first six months of 2021. Its lease liabilities are soaring, it owes $420 million in deferred rent, and it's lugging around nearly $5.5 billion in debt that it likely can't pay.\nMore than $1 billion in aggregate debt due in 2026 and 2027 is also valued at 70% to 74% of face value. Debt going for this much below par is a very real warning sign that bondholders believe a future default is possible.\nLong story short, Wall Street has every reason to be skeptical of AMC.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6030138,"gmtCreate":1632871128948,"gmtModify":1634783102494,"authorId":3567307840510045,"author":{"id":3567307840510045,"idStr":"3567307840510045","authorId":3567307840510045,"name":"JeremyKok","avatar":"https://static.tigerbbs.com/01b03a485f83b6b2615fad8ac9b87bf4","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":862807399,"type":1,"supId":0,"prevId":0,"content":"hi. please like and comment back. thank you.","text":"hi. please like and comment back. thank you.","html":"hi. please like and comment back. thank you."}],"langContent":"CN"},{"id":862137794,"gmtCreate":1632842439950,"gmtModify":1632842440117,"author":{"id":"4087452914358580","authorId":"4087452914358580","name":"SanWangtikup","avatar":"https://static.tigerbbs.com/c7f061d50a9f915d0ce8e8c879871960","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4087452914358580","authorIdStr":"4087452914358580"},"htmlText":"😂","listText":"😂","text":"😂","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862137794","repostId":2170778116,"repostType":4,"repost":{"id":"2170778116","kind":"highlight","pubTimestamp":1632829153,"share":"https://www.laohu8.com/m/news/2170778116?lang=&edition=full","pubTime":"2021-09-28 19:39","market":"us","language":"en","title":"3 Ultra-Popular Stocks With No Buy Ratings on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2170778116","media":"Motley Fool","summary":"These widely held stocks are getting no love from analysts.","content":"<p>Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.</p>\n<p>According to data from CNBC, over 90% of all <b>S&amp;P 500</b> stock ratings from Wall Street analysts were the equivalent of \"buy\" or \"hold\" between 1997 and 2017. With the exception of short periods in 2002-2003 and 2008-2009, sell ratings have consistently accounted for only 1% to 6% of all ratings for S&amp;P 500 companies this century.</p>\n<p>One reason for this \"buy bias\" is due to the U.S. and global economy growing over time. Historically, the stock market moves higher over the long run, too. Wall Street analysts might simply be playing the favorable odds that higher-quality businesses will increase in value over time.</p>\n<p>Additionally, <i>The Wall Street Journal</i> noted some years back that Wall Street analysts are hesitant to issue sell ratings so as not to burn bridges for their clients or themselves with the companies they cover. No matter the reasoning, sell ratings are rare on Wall Street.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fb1fd3c71278c123e5dd0404a4dbb43c\" tg-width=\"700\" tg-height=\"525\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<p>But don't tell that to shareholders of the following three ultra-popular stocks. These are three of the 16 most-held stocks on the <b>Robinhood</b> (NASDAQ:HOOD) platform, and not one of them has a single buy rating from a Wall Street analyst.</p>\n<h2>Aurora Cannabis</h2>\n<p>One of the biggest buzzkills, according to Wall Street, is Canadian marijuana stock <b>Aurora Cannabis</b> (NASDAQ:ACB). Aurora, which at one time was the most-held stock on Robinhood, is being covered by 13 Wall Street institutions, seven of which rate the company the equivalent of a hold and six of which believe it's a sell.</p>\n<p>Though Aurora Cannabis does foot the blame for a lot of this negativity, some of its issues can be traced to Canadian federal and provincial regulators failing the pot industry. For example, Ontario's lottery system to assign retail licenses through 2019 was terrible and resulted in only a few dozen dispensaries opening. Canadian pot stocks are still trying to recover from supply chain bottlenecks in the country's most populous province.</p>\n<p>But as I mentioned, Aurora Cannabis isn't without fault. The company expanded its production capacity far beyond what was needed. At one time, it held 15 production facilities that could have yielded more than 600,000 kilos of annual cannabis output if fully operational. Management has since closed five of these smaller facilities, sold a 1-million-square-foot greenhouse that wasn't retrofitted for cannabis production, and halted construction on two of the company's largest projects.</p>\n<p>Yet, even with this aggressive cost-cutting, Aurora Cannabis is still a long way from generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). With the company continuing to burn cash and the previous management team grossly overpaying for about a dozen acquisitions, it's regularly had to sell its common stock to raise capital to pay its bills and fund buyouts.</p>\n<p>Taking into account a reverse split enacted last year to stave off delisting, Aurora's share count has ballooned from about 1.3 million shares in June 2014 to 198 million shares, as of mid-May. That sort of dilution is precisely why the company's shares are down nearly 95% since March 2019.</p>\n<p>The salt in the wound is that Canada's legal weed sales have been hitting monthly records, all while Aurora's recreational pot revenue was more than halved in its fiscal third quarter.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/bc514068ded899a817770f684369db36\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Sundial Growers</h2>\n<p>Yet another Canadian pot stock in the no-buy zone for Wall Street is small-cap <b>Sundial Growers</b> (NASDAQ:SNDL). Even though it's the fourth most-held stock on Robinhood, four of the six analysts covering the company rate it a sell.</p>\n<p>Despite sitting on a boatload of cash, cash equivalents, and long-term investments (about $948 million), Sundial Growers has three factors working against it.</p>\n<p>To begin with, Sundial's approach to raising capital has destroyed shareholder value. Initially, it looked as if management would sell enough common stock to simply pay off the company's outstanding debt. But in a nine-month stretch between Oct. 1, 2020 and June 30, 2021, Sundial's executives have unrelentingly issued stock to raise additional capital.</p>\n<p>The end result is the issuance of roughly 1.5 billion shares of stock. With 2 billion shares now outstanding, Sundial has virtually no chance of ever generating meaningful earnings per share, and it'll likely struggle to remain listed on the <b>Nasdaq</b>&nbsp;exchange without a substantial reverse split.</p>\n<p>Second, Sundial's management team hasn't laid out a concrete plan for its capital. While it did undertake a cash-and-stock deal to acquire <a href=\"https://laohu8.com/S/INSHF\">Inner Spirit Holdings</a> in July, and it's committed roughly $425 million to its joint venture with SAF Group, known as SunStream Bancorp, to invest in cannabis industry opportunities, the company has continued to raise cash with no stated purpose.</p>\n<p>Third, Sundial has shifted its operating model away from wholesale cannabis to take advantage of the higher margins associated with the retail side of the equation. Unfortunately, having to start from scratch has led to significant year-over-year sales declines at a time when legal weed sales are rapidly growing.</p>\n<p>In March I more or less referred to Sundial as the worst cannabis stock money could buy. That descriptor still holds true today.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1c6cb4d9fcdf85f542f333fc71a2dd58\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>AMC Entertainment</h2>\n<p>But the most popular stock of all that's getting absolutely no love from Wall Street analysts and investment banks is movie theater chain <b>AMC Entertainment</b> (NYSE:AMC). The third most-held stock on Robinhood has nine analysts covering the company. Five of them have it rated a sell, with four others chiming in with a hold rating.</p>\n<p>This rating distribution isn't a surprise given that Wall Street's consensus price target for AMC is $5.44. Shares of the company would need to fall 86% from where they closed last week to reach this consensus target.</p>\n<p>The reason AMC's share price has rocketed higher in 2021 primarily has to do with retail investors piling into the stock and betting on a short squeeze -- i.e., a very short-term event whereby pessimists (short-sellers) run for the exit and buy shares to cover their positions. The issue for these optimists is that none of the data surrounding AMC is working in their favor.</p>\n<p>For one, short squeezes typically require certain conditions be met, which simply aren't there at the moment. While the company's 18.8% short interest at the end of August is higher than most stocks, its large daily trading volume means it would take less than a day for all 95.94 million short shares to be covered. The liquidity of AMC's stock means short-sellers have no fear of being trapped in their position.</p>\n<p>Fundamentally, the movie theater industry has been in a nearly two-decade decline. Tickets sold and inflation-adjusted gross at the box office have fallen 22% between 2002 and 2019, the last full year before the pandemic. Streaming offerings and substantially reduced film exclusivity (30 to 45 days now, compared to 75 to 90 days prior to the pandemic) bode poorly for the industry's future.</p>\n<p>And then there's AMC's operating performance and liability-riddled balance sheet. Despite a record $2.023 billion in liquidity ($1.81 billion in cash), AMC burned through $576.5 million in cash in the first six months of 2021. Its lease liabilities are soaring, it owes $420 million in deferred rent, and it's lugging around nearly $5.5 billion in debt that it likely can't pay.</p>\n<p>More than $1 billion in aggregate debt due in 2026 and 2027 is also valued at 70% to 74% of face value. Debt going for this much below par is a very real warning sign that bondholders believe a future default is possible.</p>\n<p>Long story short, Wall Street has every reason to be skeptical of AMC.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Ultra-Popular Stocks With No Buy Ratings on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Ultra-Popular Stocks With No Buy Ratings on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-28 19:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.\nAccording to data from CNBC, over 90% of all S&P 500 stock ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ACB":"奥罗拉大麻公司","SNDL":"SNDL Inc.","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2170778116","content_text":"Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.\nAccording to data from CNBC, over 90% of all S&P 500 stock ratings from Wall Street analysts were the equivalent of \"buy\" or \"hold\" between 1997 and 2017. With the exception of short periods in 2002-2003 and 2008-2009, sell ratings have consistently accounted for only 1% to 6% of all ratings for S&P 500 companies this century.\nOne reason for this \"buy bias\" is due to the U.S. and global economy growing over time. Historically, the stock market moves higher over the long run, too. Wall Street analysts might simply be playing the favorable odds that higher-quality businesses will increase in value over time.\nAdditionally, The Wall Street Journal noted some years back that Wall Street analysts are hesitant to issue sell ratings so as not to burn bridges for their clients or themselves with the companies they cover. No matter the reasoning, sell ratings are rare on Wall Street.\nImage source: Getty Images.\nBut don't tell that to shareholders of the following three ultra-popular stocks. These are three of the 16 most-held stocks on the Robinhood (NASDAQ:HOOD) platform, and not one of them has a single buy rating from a Wall Street analyst.\nAurora Cannabis\nOne of the biggest buzzkills, according to Wall Street, is Canadian marijuana stock Aurora Cannabis (NASDAQ:ACB). Aurora, which at one time was the most-held stock on Robinhood, is being covered by 13 Wall Street institutions, seven of which rate the company the equivalent of a hold and six of which believe it's a sell.\nThough Aurora Cannabis does foot the blame for a lot of this negativity, some of its issues can be traced to Canadian federal and provincial regulators failing the pot industry. For example, Ontario's lottery system to assign retail licenses through 2019 was terrible and resulted in only a few dozen dispensaries opening. Canadian pot stocks are still trying to recover from supply chain bottlenecks in the country's most populous province.\nBut as I mentioned, Aurora Cannabis isn't without fault. The company expanded its production capacity far beyond what was needed. At one time, it held 15 production facilities that could have yielded more than 600,000 kilos of annual cannabis output if fully operational. Management has since closed five of these smaller facilities, sold a 1-million-square-foot greenhouse that wasn't retrofitted for cannabis production, and halted construction on two of the company's largest projects.\nYet, even with this aggressive cost-cutting, Aurora Cannabis is still a long way from generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). With the company continuing to burn cash and the previous management team grossly overpaying for about a dozen acquisitions, it's regularly had to sell its common stock to raise capital to pay its bills and fund buyouts.\nTaking into account a reverse split enacted last year to stave off delisting, Aurora's share count has ballooned from about 1.3 million shares in June 2014 to 198 million shares, as of mid-May. That sort of dilution is precisely why the company's shares are down nearly 95% since March 2019.\nThe salt in the wound is that Canada's legal weed sales have been hitting monthly records, all while Aurora's recreational pot revenue was more than halved in its fiscal third quarter.\nImage source: Getty Images.\nSundial Growers\nYet another Canadian pot stock in the no-buy zone for Wall Street is small-cap Sundial Growers (NASDAQ:SNDL). Even though it's the fourth most-held stock on Robinhood, four of the six analysts covering the company rate it a sell.\nDespite sitting on a boatload of cash, cash equivalents, and long-term investments (about $948 million), Sundial Growers has three factors working against it.\nTo begin with, Sundial's approach to raising capital has destroyed shareholder value. Initially, it looked as if management would sell enough common stock to simply pay off the company's outstanding debt. But in a nine-month stretch between Oct. 1, 2020 and June 30, 2021, Sundial's executives have unrelentingly issued stock to raise additional capital.\nThe end result is the issuance of roughly 1.5 billion shares of stock. With 2 billion shares now outstanding, Sundial has virtually no chance of ever generating meaningful earnings per share, and it'll likely struggle to remain listed on the Nasdaq exchange without a substantial reverse split.\nSecond, Sundial's management team hasn't laid out a concrete plan for its capital. While it did undertake a cash-and-stock deal to acquire Inner Spirit Holdings in July, and it's committed roughly $425 million to its joint venture with SAF Group, known as SunStream Bancorp, to invest in cannabis industry opportunities, the company has continued to raise cash with no stated purpose.\nThird, Sundial has shifted its operating model away from wholesale cannabis to take advantage of the higher margins associated with the retail side of the equation. Unfortunately, having to start from scratch has led to significant year-over-year sales declines at a time when legal weed sales are rapidly growing.\nIn March I more or less referred to Sundial as the worst cannabis stock money could buy. That descriptor still holds true today.\nImage source: Getty Images.\nAMC Entertainment\nBut the most popular stock of all that's getting absolutely no love from Wall Street analysts and investment banks is movie theater chain AMC Entertainment (NYSE:AMC). The third most-held stock on Robinhood has nine analysts covering the company. Five of them have it rated a sell, with four others chiming in with a hold rating.\nThis rating distribution isn't a surprise given that Wall Street's consensus price target for AMC is $5.44. Shares of the company would need to fall 86% from where they closed last week to reach this consensus target.\nThe reason AMC's share price has rocketed higher in 2021 primarily has to do with retail investors piling into the stock and betting on a short squeeze -- i.e., a very short-term event whereby pessimists (short-sellers) run for the exit and buy shares to cover their positions. The issue for these optimists is that none of the data surrounding AMC is working in their favor.\nFor one, short squeezes typically require certain conditions be met, which simply aren't there at the moment. While the company's 18.8% short interest at the end of August is higher than most stocks, its large daily trading volume means it would take less than a day for all 95.94 million short shares to be covered. The liquidity of AMC's stock means short-sellers have no fear of being trapped in their position.\nFundamentally, the movie theater industry has been in a nearly two-decade decline. Tickets sold and inflation-adjusted gross at the box office have fallen 22% between 2002 and 2019, the last full year before the pandemic. Streaming offerings and substantially reduced film exclusivity (30 to 45 days now, compared to 75 to 90 days prior to the pandemic) bode poorly for the industry's future.\nAnd then there's AMC's operating performance and liability-riddled balance sheet. Despite a record $2.023 billion in liquidity ($1.81 billion in cash), AMC burned through $576.5 million in cash in the first six months of 2021. Its lease liabilities are soaring, it owes $420 million in deferred rent, and it's lugging around nearly $5.5 billion in debt that it likely can't pay.\nMore than $1 billion in aggregate debt due in 2026 and 2027 is also valued at 70% to 74% of face value. Debt going for this much below par is a very real warning sign that bondholders believe a future default is possible.\nLong story short, Wall Street has every reason to be skeptical of AMC.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":862192825,"gmtCreate":1632841736615,"gmtModify":1632878808222,"author":{"id":"3582056888971510","authorId":"3582056888971510","name":"anthonywhite","avatar":"https://static.tigerbbs.com/0526b170aa6ae84256c1c1104ce0f4f8","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582056888971510","authorIdStr":"3582056888971510"},"htmlText":"Don’t ever&nbsp;listen to mortley fool!","listText":"Don’t ever&nbsp;listen to mortley fool!","text":"Don’t ever listen to mortley fool!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862192825","repostId":2170778116,"repostType":4,"repost":{"id":"2170778116","kind":"highlight","pubTimestamp":1632829153,"share":"https://www.laohu8.com/m/news/2170778116?lang=&edition=full","pubTime":"2021-09-28 19:39","market":"us","language":"en","title":"3 Ultra-Popular Stocks With No Buy Ratings on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2170778116","media":"Motley Fool","summary":"These widely held stocks are getting no love from analysts.","content":"<p>Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.</p>\n<p>According to data from CNBC, over 90% of all <b>S&amp;P 500</b> stock ratings from Wall Street analysts were the equivalent of \"buy\" or \"hold\" between 1997 and 2017. With the exception of short periods in 2002-2003 and 2008-2009, sell ratings have consistently accounted for only 1% to 6% of all ratings for S&amp;P 500 companies this century.</p>\n<p>One reason for this \"buy bias\" is due to the U.S. and global economy growing over time. Historically, the stock market moves higher over the long run, too. Wall Street analysts might simply be playing the favorable odds that higher-quality businesses will increase in value over time.</p>\n<p>Additionally, <i>The Wall Street Journal</i> noted some years back that Wall Street analysts are hesitant to issue sell ratings so as not to burn bridges for their clients or themselves with the companies they cover. No matter the reasoning, sell ratings are rare on Wall Street.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fb1fd3c71278c123e5dd0404a4dbb43c\" tg-width=\"700\" tg-height=\"525\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<p>But don't tell that to shareholders of the following three ultra-popular stocks. These are three of the 16 most-held stocks on the <b>Robinhood</b> (NASDAQ:HOOD) platform, and not one of them has a single buy rating from a Wall Street analyst.</p>\n<h2>Aurora Cannabis</h2>\n<p>One of the biggest buzzkills, according to Wall Street, is Canadian marijuana stock <b>Aurora Cannabis</b> (NASDAQ:ACB). Aurora, which at one time was the most-held stock on Robinhood, is being covered by 13 Wall Street institutions, seven of which rate the company the equivalent of a hold and six of which believe it's a sell.</p>\n<p>Though Aurora Cannabis does foot the blame for a lot of this negativity, some of its issues can be traced to Canadian federal and provincial regulators failing the pot industry. For example, Ontario's lottery system to assign retail licenses through 2019 was terrible and resulted in only a few dozen dispensaries opening. Canadian pot stocks are still trying to recover from supply chain bottlenecks in the country's most populous province.</p>\n<p>But as I mentioned, Aurora Cannabis isn't without fault. The company expanded its production capacity far beyond what was needed. At one time, it held 15 production facilities that could have yielded more than 600,000 kilos of annual cannabis output if fully operational. Management has since closed five of these smaller facilities, sold a 1-million-square-foot greenhouse that wasn't retrofitted for cannabis production, and halted construction on two of the company's largest projects.</p>\n<p>Yet, even with this aggressive cost-cutting, Aurora Cannabis is still a long way from generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). With the company continuing to burn cash and the previous management team grossly overpaying for about a dozen acquisitions, it's regularly had to sell its common stock to raise capital to pay its bills and fund buyouts.</p>\n<p>Taking into account a reverse split enacted last year to stave off delisting, Aurora's share count has ballooned from about 1.3 million shares in June 2014 to 198 million shares, as of mid-May. That sort of dilution is precisely why the company's shares are down nearly 95% since March 2019.</p>\n<p>The salt in the wound is that Canada's legal weed sales have been hitting monthly records, all while Aurora's recreational pot revenue was more than halved in its fiscal third quarter.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/bc514068ded899a817770f684369db36\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Sundial Growers</h2>\n<p>Yet another Canadian pot stock in the no-buy zone for Wall Street is small-cap <b>Sundial Growers</b> (NASDAQ:SNDL). Even though it's the fourth most-held stock on Robinhood, four of the six analysts covering the company rate it a sell.</p>\n<p>Despite sitting on a boatload of cash, cash equivalents, and long-term investments (about $948 million), Sundial Growers has three factors working against it.</p>\n<p>To begin with, Sundial's approach to raising capital has destroyed shareholder value. Initially, it looked as if management would sell enough common stock to simply pay off the company's outstanding debt. But in a nine-month stretch between Oct. 1, 2020 and June 30, 2021, Sundial's executives have unrelentingly issued stock to raise additional capital.</p>\n<p>The end result is the issuance of roughly 1.5 billion shares of stock. With 2 billion shares now outstanding, Sundial has virtually no chance of ever generating meaningful earnings per share, and it'll likely struggle to remain listed on the <b>Nasdaq</b>&nbsp;exchange without a substantial reverse split.</p>\n<p>Second, Sundial's management team hasn't laid out a concrete plan for its capital. While it did undertake a cash-and-stock deal to acquire <a href=\"https://laohu8.com/S/INSHF\">Inner Spirit Holdings</a> in July, and it's committed roughly $425 million to its joint venture with SAF Group, known as SunStream Bancorp, to invest in cannabis industry opportunities, the company has continued to raise cash with no stated purpose.</p>\n<p>Third, Sundial has shifted its operating model away from wholesale cannabis to take advantage of the higher margins associated with the retail side of the equation. Unfortunately, having to start from scratch has led to significant year-over-year sales declines at a time when legal weed sales are rapidly growing.</p>\n<p>In March I more or less referred to Sundial as the worst cannabis stock money could buy. That descriptor still holds true today.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1c6cb4d9fcdf85f542f333fc71a2dd58\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>AMC Entertainment</h2>\n<p>But the most popular stock of all that's getting absolutely no love from Wall Street analysts and investment banks is movie theater chain <b>AMC Entertainment</b> (NYSE:AMC). The third most-held stock on Robinhood has nine analysts covering the company. Five of them have it rated a sell, with four others chiming in with a hold rating.</p>\n<p>This rating distribution isn't a surprise given that Wall Street's consensus price target for AMC is $5.44. Shares of the company would need to fall 86% from where they closed last week to reach this consensus target.</p>\n<p>The reason AMC's share price has rocketed higher in 2021 primarily has to do with retail investors piling into the stock and betting on a short squeeze -- i.e., a very short-term event whereby pessimists (short-sellers) run for the exit and buy shares to cover their positions. The issue for these optimists is that none of the data surrounding AMC is working in their favor.</p>\n<p>For one, short squeezes typically require certain conditions be met, which simply aren't there at the moment. While the company's 18.8% short interest at the end of August is higher than most stocks, its large daily trading volume means it would take less than a day for all 95.94 million short shares to be covered. The liquidity of AMC's stock means short-sellers have no fear of being trapped in their position.</p>\n<p>Fundamentally, the movie theater industry has been in a nearly two-decade decline. Tickets sold and inflation-adjusted gross at the box office have fallen 22% between 2002 and 2019, the last full year before the pandemic. Streaming offerings and substantially reduced film exclusivity (30 to 45 days now, compared to 75 to 90 days prior to the pandemic) bode poorly for the industry's future.</p>\n<p>And then there's AMC's operating performance and liability-riddled balance sheet. Despite a record $2.023 billion in liquidity ($1.81 billion in cash), AMC burned through $576.5 million in cash in the first six months of 2021. Its lease liabilities are soaring, it owes $420 million in deferred rent, and it's lugging around nearly $5.5 billion in debt that it likely can't pay.</p>\n<p>More than $1 billion in aggregate debt due in 2026 and 2027 is also valued at 70% to 74% of face value. Debt going for this much below par is a very real warning sign that bondholders believe a future default is possible.</p>\n<p>Long story short, Wall Street has every reason to be skeptical of AMC.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Ultra-Popular Stocks With No Buy Ratings on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Ultra-Popular Stocks With No Buy Ratings on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-28 19:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.\nAccording to data from CNBC, over 90% of all S&P 500 stock ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ACB":"奥罗拉大麻公司","SNDL":"SNDL Inc.","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2170778116","content_text":"Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.\nAccording to data from CNBC, over 90% of all S&P 500 stock ratings from Wall Street analysts were the equivalent of \"buy\" or \"hold\" between 1997 and 2017. With the exception of short periods in 2002-2003 and 2008-2009, sell ratings have consistently accounted for only 1% to 6% of all ratings for S&P 500 companies this century.\nOne reason for this \"buy bias\" is due to the U.S. and global economy growing over time. Historically, the stock market moves higher over the long run, too. Wall Street analysts might simply be playing the favorable odds that higher-quality businesses will increase in value over time.\nAdditionally, The Wall Street Journal noted some years back that Wall Street analysts are hesitant to issue sell ratings so as not to burn bridges for their clients or themselves with the companies they cover. No matter the reasoning, sell ratings are rare on Wall Street.\nImage source: Getty Images.\nBut don't tell that to shareholders of the following three ultra-popular stocks. These are three of the 16 most-held stocks on the Robinhood (NASDAQ:HOOD) platform, and not one of them has a single buy rating from a Wall Street analyst.\nAurora Cannabis\nOne of the biggest buzzkills, according to Wall Street, is Canadian marijuana stock Aurora Cannabis (NASDAQ:ACB). Aurora, which at one time was the most-held stock on Robinhood, is being covered by 13 Wall Street institutions, seven of which rate the company the equivalent of a hold and six of which believe it's a sell.\nThough Aurora Cannabis does foot the blame for a lot of this negativity, some of its issues can be traced to Canadian federal and provincial regulators failing the pot industry. For example, Ontario's lottery system to assign retail licenses through 2019 was terrible and resulted in only a few dozen dispensaries opening. Canadian pot stocks are still trying to recover from supply chain bottlenecks in the country's most populous province.\nBut as I mentioned, Aurora Cannabis isn't without fault. The company expanded its production capacity far beyond what was needed. At one time, it held 15 production facilities that could have yielded more than 600,000 kilos of annual cannabis output if fully operational. Management has since closed five of these smaller facilities, sold a 1-million-square-foot greenhouse that wasn't retrofitted for cannabis production, and halted construction on two of the company's largest projects.\nYet, even with this aggressive cost-cutting, Aurora Cannabis is still a long way from generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). With the company continuing to burn cash and the previous management team grossly overpaying for about a dozen acquisitions, it's regularly had to sell its common stock to raise capital to pay its bills and fund buyouts.\nTaking into account a reverse split enacted last year to stave off delisting, Aurora's share count has ballooned from about 1.3 million shares in June 2014 to 198 million shares, as of mid-May. That sort of dilution is precisely why the company's shares are down nearly 95% since March 2019.\nThe salt in the wound is that Canada's legal weed sales have been hitting monthly records, all while Aurora's recreational pot revenue was more than halved in its fiscal third quarter.\nImage source: Getty Images.\nSundial Growers\nYet another Canadian pot stock in the no-buy zone for Wall Street is small-cap Sundial Growers (NASDAQ:SNDL). Even though it's the fourth most-held stock on Robinhood, four of the six analysts covering the company rate it a sell.\nDespite sitting on a boatload of cash, cash equivalents, and long-term investments (about $948 million), Sundial Growers has three factors working against it.\nTo begin with, Sundial's approach to raising capital has destroyed shareholder value. Initially, it looked as if management would sell enough common stock to simply pay off the company's outstanding debt. But in a nine-month stretch between Oct. 1, 2020 and June 30, 2021, Sundial's executives have unrelentingly issued stock to raise additional capital.\nThe end result is the issuance of roughly 1.5 billion shares of stock. With 2 billion shares now outstanding, Sundial has virtually no chance of ever generating meaningful earnings per share, and it'll likely struggle to remain listed on the Nasdaq exchange without a substantial reverse split.\nSecond, Sundial's management team hasn't laid out a concrete plan for its capital. While it did undertake a cash-and-stock deal to acquire Inner Spirit Holdings in July, and it's committed roughly $425 million to its joint venture with SAF Group, known as SunStream Bancorp, to invest in cannabis industry opportunities, the company has continued to raise cash with no stated purpose.\nThird, Sundial has shifted its operating model away from wholesale cannabis to take advantage of the higher margins associated with the retail side of the equation. Unfortunately, having to start from scratch has led to significant year-over-year sales declines at a time when legal weed sales are rapidly growing.\nIn March I more or less referred to Sundial as the worst cannabis stock money could buy. That descriptor still holds true today.\nImage source: Getty Images.\nAMC Entertainment\nBut the most popular stock of all that's getting absolutely no love from Wall Street analysts and investment banks is movie theater chain AMC Entertainment (NYSE:AMC). The third most-held stock on Robinhood has nine analysts covering the company. Five of them have it rated a sell, with four others chiming in with a hold rating.\nThis rating distribution isn't a surprise given that Wall Street's consensus price target for AMC is $5.44. Shares of the company would need to fall 86% from where they closed last week to reach this consensus target.\nThe reason AMC's share price has rocketed higher in 2021 primarily has to do with retail investors piling into the stock and betting on a short squeeze -- i.e., a very short-term event whereby pessimists (short-sellers) run for the exit and buy shares to cover their positions. The issue for these optimists is that none of the data surrounding AMC is working in their favor.\nFor one, short squeezes typically require certain conditions be met, which simply aren't there at the moment. While the company's 18.8% short interest at the end of August is higher than most stocks, its large daily trading volume means it would take less than a day for all 95.94 million short shares to be covered. The liquidity of AMC's stock means short-sellers have no fear of being trapped in their position.\nFundamentally, the movie theater industry has been in a nearly two-decade decline. Tickets sold and inflation-adjusted gross at the box office have fallen 22% between 2002 and 2019, the last full year before the pandemic. Streaming offerings and substantially reduced film exclusivity (30 to 45 days now, compared to 75 to 90 days prior to the pandemic) bode poorly for the industry's future.\nAnd then there's AMC's operating performance and liability-riddled balance sheet. Despite a record $2.023 billion in liquidity ($1.81 billion in cash), AMC burned through $576.5 million in cash in the first six months of 2021. Its lease liabilities are soaring, it owes $420 million in deferred rent, and it's lugging around nearly $5.5 billion in debt that it likely can't pay.\nMore than $1 billion in aggregate debt due in 2026 and 2027 is also valued at 70% to 74% of face value. Debt going for this much below par is a very real warning sign that bondholders believe a future default is possible.\nLong story short, Wall Street has every reason to be skeptical of AMC.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":862341117,"gmtCreate":1632839614544,"gmtModify":1632839614692,"author":{"id":"3565225896317833","authorId":"3565225896317833","name":"yngwin111","avatar":"https://static.tigerbbs.com/7b6da8ffb6e7348c5800f5edb3ff9e62","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3565225896317833","authorIdStr":"3565225896317833"},"htmlText":"No true!&nbsp;","listText":"No true!&nbsp;","text":"No true!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862341117","repostId":2170778116,"repostType":4,"repost":{"id":"2170778116","kind":"highlight","pubTimestamp":1632829153,"share":"https://www.laohu8.com/m/news/2170778116?lang=&edition=full","pubTime":"2021-09-28 19:39","market":"us","language":"en","title":"3 Ultra-Popular Stocks With No Buy Ratings on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2170778116","media":"Motley Fool","summary":"These widely held stocks are getting no love from analysts.","content":"<p>Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.</p>\n<p>According to data from CNBC, over 90% of all <b>S&amp;P 500</b> stock ratings from Wall Street analysts were the equivalent of \"buy\" or \"hold\" between 1997 and 2017. With the exception of short periods in 2002-2003 and 2008-2009, sell ratings have consistently accounted for only 1% to 6% of all ratings for S&amp;P 500 companies this century.</p>\n<p>One reason for this \"buy bias\" is due to the U.S. and global economy growing over time. Historically, the stock market moves higher over the long run, too. Wall Street analysts might simply be playing the favorable odds that higher-quality businesses will increase in value over time.</p>\n<p>Additionally, <i>The Wall Street Journal</i> noted some years back that Wall Street analysts are hesitant to issue sell ratings so as not to burn bridges for their clients or themselves with the companies they cover. No matter the reasoning, sell ratings are rare on Wall Street.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fb1fd3c71278c123e5dd0404a4dbb43c\" tg-width=\"700\" tg-height=\"525\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<p>But don't tell that to shareholders of the following three ultra-popular stocks. These are three of the 16 most-held stocks on the <b>Robinhood</b> (NASDAQ:HOOD) platform, and not one of them has a single buy rating from a Wall Street analyst.</p>\n<h2>Aurora Cannabis</h2>\n<p>One of the biggest buzzkills, according to Wall Street, is Canadian marijuana stock <b>Aurora Cannabis</b> (NASDAQ:ACB). Aurora, which at one time was the most-held stock on Robinhood, is being covered by 13 Wall Street institutions, seven of which rate the company the equivalent of a hold and six of which believe it's a sell.</p>\n<p>Though Aurora Cannabis does foot the blame for a lot of this negativity, some of its issues can be traced to Canadian federal and provincial regulators failing the pot industry. For example, Ontario's lottery system to assign retail licenses through 2019 was terrible and resulted in only a few dozen dispensaries opening. Canadian pot stocks are still trying to recover from supply chain bottlenecks in the country's most populous province.</p>\n<p>But as I mentioned, Aurora Cannabis isn't without fault. The company expanded its production capacity far beyond what was needed. At one time, it held 15 production facilities that could have yielded more than 600,000 kilos of annual cannabis output if fully operational. Management has since closed five of these smaller facilities, sold a 1-million-square-foot greenhouse that wasn't retrofitted for cannabis production, and halted construction on two of the company's largest projects.</p>\n<p>Yet, even with this aggressive cost-cutting, Aurora Cannabis is still a long way from generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). With the company continuing to burn cash and the previous management team grossly overpaying for about a dozen acquisitions, it's regularly had to sell its common stock to raise capital to pay its bills and fund buyouts.</p>\n<p>Taking into account a reverse split enacted last year to stave off delisting, Aurora's share count has ballooned from about 1.3 million shares in June 2014 to 198 million shares, as of mid-May. That sort of dilution is precisely why the company's shares are down nearly 95% since March 2019.</p>\n<p>The salt in the wound is that Canada's legal weed sales have been hitting monthly records, all while Aurora's recreational pot revenue was more than halved in its fiscal third quarter.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/bc514068ded899a817770f684369db36\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Sundial Growers</h2>\n<p>Yet another Canadian pot stock in the no-buy zone for Wall Street is small-cap <b>Sundial Growers</b> (NASDAQ:SNDL). Even though it's the fourth most-held stock on Robinhood, four of the six analysts covering the company rate it a sell.</p>\n<p>Despite sitting on a boatload of cash, cash equivalents, and long-term investments (about $948 million), Sundial Growers has three factors working against it.</p>\n<p>To begin with, Sundial's approach to raising capital has destroyed shareholder value. Initially, it looked as if management would sell enough common stock to simply pay off the company's outstanding debt. But in a nine-month stretch between Oct. 1, 2020 and June 30, 2021, Sundial's executives have unrelentingly issued stock to raise additional capital.</p>\n<p>The end result is the issuance of roughly 1.5 billion shares of stock. With 2 billion shares now outstanding, Sundial has virtually no chance of ever generating meaningful earnings per share, and it'll likely struggle to remain listed on the <b>Nasdaq</b>&nbsp;exchange without a substantial reverse split.</p>\n<p>Second, Sundial's management team hasn't laid out a concrete plan for its capital. While it did undertake a cash-and-stock deal to acquire <a href=\"https://laohu8.com/S/INSHF\">Inner Spirit Holdings</a> in July, and it's committed roughly $425 million to its joint venture with SAF Group, known as SunStream Bancorp, to invest in cannabis industry opportunities, the company has continued to raise cash with no stated purpose.</p>\n<p>Third, Sundial has shifted its operating model away from wholesale cannabis to take advantage of the higher margins associated with the retail side of the equation. Unfortunately, having to start from scratch has led to significant year-over-year sales declines at a time when legal weed sales are rapidly growing.</p>\n<p>In March I more or less referred to Sundial as the worst cannabis stock money could buy. That descriptor still holds true today.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1c6cb4d9fcdf85f542f333fc71a2dd58\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>AMC Entertainment</h2>\n<p>But the most popular stock of all that's getting absolutely no love from Wall Street analysts and investment banks is movie theater chain <b>AMC Entertainment</b> (NYSE:AMC). The third most-held stock on Robinhood has nine analysts covering the company. Five of them have it rated a sell, with four others chiming in with a hold rating.</p>\n<p>This rating distribution isn't a surprise given that Wall Street's consensus price target for AMC is $5.44. Shares of the company would need to fall 86% from where they closed last week to reach this consensus target.</p>\n<p>The reason AMC's share price has rocketed higher in 2021 primarily has to do with retail investors piling into the stock and betting on a short squeeze -- i.e., a very short-term event whereby pessimists (short-sellers) run for the exit and buy shares to cover their positions. The issue for these optimists is that none of the data surrounding AMC is working in their favor.</p>\n<p>For one, short squeezes typically require certain conditions be met, which simply aren't there at the moment. While the company's 18.8% short interest at the end of August is higher than most stocks, its large daily trading volume means it would take less than a day for all 95.94 million short shares to be covered. The liquidity of AMC's stock means short-sellers have no fear of being trapped in their position.</p>\n<p>Fundamentally, the movie theater industry has been in a nearly two-decade decline. Tickets sold and inflation-adjusted gross at the box office have fallen 22% between 2002 and 2019, the last full year before the pandemic. Streaming offerings and substantially reduced film exclusivity (30 to 45 days now, compared to 75 to 90 days prior to the pandemic) bode poorly for the industry's future.</p>\n<p>And then there's AMC's operating performance and liability-riddled balance sheet. Despite a record $2.023 billion in liquidity ($1.81 billion in cash), AMC burned through $576.5 million in cash in the first six months of 2021. Its lease liabilities are soaring, it owes $420 million in deferred rent, and it's lugging around nearly $5.5 billion in debt that it likely can't pay.</p>\n<p>More than $1 billion in aggregate debt due in 2026 and 2027 is also valued at 70% to 74% of face value. Debt going for this much below par is a very real warning sign that bondholders believe a future default is possible.</p>\n<p>Long story short, Wall Street has every reason to be skeptical of AMC.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Ultra-Popular Stocks With No Buy Ratings on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Ultra-Popular Stocks With No Buy Ratings on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-28 19:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.\nAccording to data from CNBC, over 90% of all S&P 500 stock ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ACB":"奥罗拉大麻公司","SNDL":"SNDL Inc.","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2170778116","content_text":"Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.\nAccording to data from CNBC, over 90% of all S&P 500 stock ratings from Wall Street analysts were the equivalent of \"buy\" or \"hold\" between 1997 and 2017. With the exception of short periods in 2002-2003 and 2008-2009, sell ratings have consistently accounted for only 1% to 6% of all ratings for S&P 500 companies this century.\nOne reason for this \"buy bias\" is due to the U.S. and global economy growing over time. Historically, the stock market moves higher over the long run, too. Wall Street analysts might simply be playing the favorable odds that higher-quality businesses will increase in value over time.\nAdditionally, The Wall Street Journal noted some years back that Wall Street analysts are hesitant to issue sell ratings so as not to burn bridges for their clients or themselves with the companies they cover. No matter the reasoning, sell ratings are rare on Wall Street.\nImage source: Getty Images.\nBut don't tell that to shareholders of the following three ultra-popular stocks. These are three of the 16 most-held stocks on the Robinhood (NASDAQ:HOOD) platform, and not one of them has a single buy rating from a Wall Street analyst.\nAurora Cannabis\nOne of the biggest buzzkills, according to Wall Street, is Canadian marijuana stock Aurora Cannabis (NASDAQ:ACB). Aurora, which at one time was the most-held stock on Robinhood, is being covered by 13 Wall Street institutions, seven of which rate the company the equivalent of a hold and six of which believe it's a sell.\nThough Aurora Cannabis does foot the blame for a lot of this negativity, some of its issues can be traced to Canadian federal and provincial regulators failing the pot industry. For example, Ontario's lottery system to assign retail licenses through 2019 was terrible and resulted in only a few dozen dispensaries opening. Canadian pot stocks are still trying to recover from supply chain bottlenecks in the country's most populous province.\nBut as I mentioned, Aurora Cannabis isn't without fault. The company expanded its production capacity far beyond what was needed. At one time, it held 15 production facilities that could have yielded more than 600,000 kilos of annual cannabis output if fully operational. Management has since closed five of these smaller facilities, sold a 1-million-square-foot greenhouse that wasn't retrofitted for cannabis production, and halted construction on two of the company's largest projects.\nYet, even with this aggressive cost-cutting, Aurora Cannabis is still a long way from generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). With the company continuing to burn cash and the previous management team grossly overpaying for about a dozen acquisitions, it's regularly had to sell its common stock to raise capital to pay its bills and fund buyouts.\nTaking into account a reverse split enacted last year to stave off delisting, Aurora's share count has ballooned from about 1.3 million shares in June 2014 to 198 million shares, as of mid-May. That sort of dilution is precisely why the company's shares are down nearly 95% since March 2019.\nThe salt in the wound is that Canada's legal weed sales have been hitting monthly records, all while Aurora's recreational pot revenue was more than halved in its fiscal third quarter.\nImage source: Getty Images.\nSundial Growers\nYet another Canadian pot stock in the no-buy zone for Wall Street is small-cap Sundial Growers (NASDAQ:SNDL). Even though it's the fourth most-held stock on Robinhood, four of the six analysts covering the company rate it a sell.\nDespite sitting on a boatload of cash, cash equivalents, and long-term investments (about $948 million), Sundial Growers has three factors working against it.\nTo begin with, Sundial's approach to raising capital has destroyed shareholder value. Initially, it looked as if management would sell enough common stock to simply pay off the company's outstanding debt. But in a nine-month stretch between Oct. 1, 2020 and June 30, 2021, Sundial's executives have unrelentingly issued stock to raise additional capital.\nThe end result is the issuance of roughly 1.5 billion shares of stock. With 2 billion shares now outstanding, Sundial has virtually no chance of ever generating meaningful earnings per share, and it'll likely struggle to remain listed on the Nasdaq exchange without a substantial reverse split.\nSecond, Sundial's management team hasn't laid out a concrete plan for its capital. While it did undertake a cash-and-stock deal to acquire Inner Spirit Holdings in July, and it's committed roughly $425 million to its joint venture with SAF Group, known as SunStream Bancorp, to invest in cannabis industry opportunities, the company has continued to raise cash with no stated purpose.\nThird, Sundial has shifted its operating model away from wholesale cannabis to take advantage of the higher margins associated with the retail side of the equation. Unfortunately, having to start from scratch has led to significant year-over-year sales declines at a time when legal weed sales are rapidly growing.\nIn March I more or less referred to Sundial as the worst cannabis stock money could buy. That descriptor still holds true today.\nImage source: Getty Images.\nAMC Entertainment\nBut the most popular stock of all that's getting absolutely no love from Wall Street analysts and investment banks is movie theater chain AMC Entertainment (NYSE:AMC). The third most-held stock on Robinhood has nine analysts covering the company. Five of them have it rated a sell, with four others chiming in with a hold rating.\nThis rating distribution isn't a surprise given that Wall Street's consensus price target for AMC is $5.44. Shares of the company would need to fall 86% from where they closed last week to reach this consensus target.\nThe reason AMC's share price has rocketed higher in 2021 primarily has to do with retail investors piling into the stock and betting on a short squeeze -- i.e., a very short-term event whereby pessimists (short-sellers) run for the exit and buy shares to cover their positions. The issue for these optimists is that none of the data surrounding AMC is working in their favor.\nFor one, short squeezes typically require certain conditions be met, which simply aren't there at the moment. While the company's 18.8% short interest at the end of August is higher than most stocks, its large daily trading volume means it would take less than a day for all 95.94 million short shares to be covered. The liquidity of AMC's stock means short-sellers have no fear of being trapped in their position.\nFundamentally, the movie theater industry has been in a nearly two-decade decline. Tickets sold and inflation-adjusted gross at the box office have fallen 22% between 2002 and 2019, the last full year before the pandemic. Streaming offerings and substantially reduced film exclusivity (30 to 45 days now, compared to 75 to 90 days prior to the pandemic) bode poorly for the industry's future.\nAnd then there's AMC's operating performance and liability-riddled balance sheet. Despite a record $2.023 billion in liquidity ($1.81 billion in cash), AMC burned through $576.5 million in cash in the first six months of 2021. Its lease liabilities are soaring, it owes $420 million in deferred rent, and it's lugging around nearly $5.5 billion in debt that it likely can't pay.\nMore than $1 billion in aggregate debt due in 2026 and 2027 is also valued at 70% to 74% of face value. Debt going for this much below par is a very real warning sign that bondholders believe a future default is possible.\nLong story short, Wall Street has every reason to be skeptical of AMC.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":862349899,"gmtCreate":1632839556017,"gmtModify":1632839556069,"author":{"id":"3585642689958579","authorId":"3585642689958579","name":"HeroSmurf","avatar":"https://static.tigerbbs.com/6015b234d96461c6ef8db8d919ac3473","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3585642689958579","authorIdStr":"3585642689958579"},"htmlText":"None of the above? Or should I?","listText":"None of the above? Or should I?","text":"None of the above? Or should I?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862349899","repostId":2170778116,"repostType":4,"repost":{"id":"2170778116","kind":"highlight","pubTimestamp":1632829153,"share":"https://www.laohu8.com/m/news/2170778116?lang=&edition=full","pubTime":"2021-09-28 19:39","market":"us","language":"en","title":"3 Ultra-Popular Stocks With No Buy Ratings on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2170778116","media":"Motley Fool","summary":"These widely held stocks are getting no love from analysts.","content":"<p>Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.</p>\n<p>According to data from CNBC, over 90% of all <b>S&amp;P 500</b> stock ratings from Wall Street analysts were the equivalent of \"buy\" or \"hold\" between 1997 and 2017. With the exception of short periods in 2002-2003 and 2008-2009, sell ratings have consistently accounted for only 1% to 6% of all ratings for S&amp;P 500 companies this century.</p>\n<p>One reason for this \"buy bias\" is due to the U.S. and global economy growing over time. Historically, the stock market moves higher over the long run, too. Wall Street analysts might simply be playing the favorable odds that higher-quality businesses will increase in value over time.</p>\n<p>Additionally, <i>The Wall Street Journal</i> noted some years back that Wall Street analysts are hesitant to issue sell ratings so as not to burn bridges for their clients or themselves with the companies they cover. No matter the reasoning, sell ratings are rare on Wall Street.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fb1fd3c71278c123e5dd0404a4dbb43c\" tg-width=\"700\" tg-height=\"525\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<p>But don't tell that to shareholders of the following three ultra-popular stocks. These are three of the 16 most-held stocks on the <b>Robinhood</b> (NASDAQ:HOOD) platform, and not one of them has a single buy rating from a Wall Street analyst.</p>\n<h2>Aurora Cannabis</h2>\n<p>One of the biggest buzzkills, according to Wall Street, is Canadian marijuana stock <b>Aurora Cannabis</b> (NASDAQ:ACB). Aurora, which at one time was the most-held stock on Robinhood, is being covered by 13 Wall Street institutions, seven of which rate the company the equivalent of a hold and six of which believe it's a sell.</p>\n<p>Though Aurora Cannabis does foot the blame for a lot of this negativity, some of its issues can be traced to Canadian federal and provincial regulators failing the pot industry. For example, Ontario's lottery system to assign retail licenses through 2019 was terrible and resulted in only a few dozen dispensaries opening. Canadian pot stocks are still trying to recover from supply chain bottlenecks in the country's most populous province.</p>\n<p>But as I mentioned, Aurora Cannabis isn't without fault. The company expanded its production capacity far beyond what was needed. At one time, it held 15 production facilities that could have yielded more than 600,000 kilos of annual cannabis output if fully operational. Management has since closed five of these smaller facilities, sold a 1-million-square-foot greenhouse that wasn't retrofitted for cannabis production, and halted construction on two of the company's largest projects.</p>\n<p>Yet, even with this aggressive cost-cutting, Aurora Cannabis is still a long way from generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). With the company continuing to burn cash and the previous management team grossly overpaying for about a dozen acquisitions, it's regularly had to sell its common stock to raise capital to pay its bills and fund buyouts.</p>\n<p>Taking into account a reverse split enacted last year to stave off delisting, Aurora's share count has ballooned from about 1.3 million shares in June 2014 to 198 million shares, as of mid-May. That sort of dilution is precisely why the company's shares are down nearly 95% since March 2019.</p>\n<p>The salt in the wound is that Canada's legal weed sales have been hitting monthly records, all while Aurora's recreational pot revenue was more than halved in its fiscal third quarter.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/bc514068ded899a817770f684369db36\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Sundial Growers</h2>\n<p>Yet another Canadian pot stock in the no-buy zone for Wall Street is small-cap <b>Sundial Growers</b> (NASDAQ:SNDL). Even though it's the fourth most-held stock on Robinhood, four of the six analysts covering the company rate it a sell.</p>\n<p>Despite sitting on a boatload of cash, cash equivalents, and long-term investments (about $948 million), Sundial Growers has three factors working against it.</p>\n<p>To begin with, Sundial's approach to raising capital has destroyed shareholder value. Initially, it looked as if management would sell enough common stock to simply pay off the company's outstanding debt. But in a nine-month stretch between Oct. 1, 2020 and June 30, 2021, Sundial's executives have unrelentingly issued stock to raise additional capital.</p>\n<p>The end result is the issuance of roughly 1.5 billion shares of stock. With 2 billion shares now outstanding, Sundial has virtually no chance of ever generating meaningful earnings per share, and it'll likely struggle to remain listed on the <b>Nasdaq</b>&nbsp;exchange without a substantial reverse split.</p>\n<p>Second, Sundial's management team hasn't laid out a concrete plan for its capital. While it did undertake a cash-and-stock deal to acquire <a href=\"https://laohu8.com/S/INSHF\">Inner Spirit Holdings</a> in July, and it's committed roughly $425 million to its joint venture with SAF Group, known as SunStream Bancorp, to invest in cannabis industry opportunities, the company has continued to raise cash with no stated purpose.</p>\n<p>Third, Sundial has shifted its operating model away from wholesale cannabis to take advantage of the higher margins associated with the retail side of the equation. Unfortunately, having to start from scratch has led to significant year-over-year sales declines at a time when legal weed sales are rapidly growing.</p>\n<p>In March I more or less referred to Sundial as the worst cannabis stock money could buy. That descriptor still holds true today.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1c6cb4d9fcdf85f542f333fc71a2dd58\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>AMC Entertainment</h2>\n<p>But the most popular stock of all that's getting absolutely no love from Wall Street analysts and investment banks is movie theater chain <b>AMC Entertainment</b> (NYSE:AMC). The third most-held stock on Robinhood has nine analysts covering the company. Five of them have it rated a sell, with four others chiming in with a hold rating.</p>\n<p>This rating distribution isn't a surprise given that Wall Street's consensus price target for AMC is $5.44. Shares of the company would need to fall 86% from where they closed last week to reach this consensus target.</p>\n<p>The reason AMC's share price has rocketed higher in 2021 primarily has to do with retail investors piling into the stock and betting on a short squeeze -- i.e., a very short-term event whereby pessimists (short-sellers) run for the exit and buy shares to cover their positions. The issue for these optimists is that none of the data surrounding AMC is working in their favor.</p>\n<p>For one, short squeezes typically require certain conditions be met, which simply aren't there at the moment. While the company's 18.8% short interest at the end of August is higher than most stocks, its large daily trading volume means it would take less than a day for all 95.94 million short shares to be covered. The liquidity of AMC's stock means short-sellers have no fear of being trapped in their position.</p>\n<p>Fundamentally, the movie theater industry has been in a nearly two-decade decline. Tickets sold and inflation-adjusted gross at the box office have fallen 22% between 2002 and 2019, the last full year before the pandemic. Streaming offerings and substantially reduced film exclusivity (30 to 45 days now, compared to 75 to 90 days prior to the pandemic) bode poorly for the industry's future.</p>\n<p>And then there's AMC's operating performance and liability-riddled balance sheet. Despite a record $2.023 billion in liquidity ($1.81 billion in cash), AMC burned through $576.5 million in cash in the first six months of 2021. Its lease liabilities are soaring, it owes $420 million in deferred rent, and it's lugging around nearly $5.5 billion in debt that it likely can't pay.</p>\n<p>More than $1 billion in aggregate debt due in 2026 and 2027 is also valued at 70% to 74% of face value. Debt going for this much below par is a very real warning sign that bondholders believe a future default is possible.</p>\n<p>Long story short, Wall Street has every reason to be skeptical of AMC.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Ultra-Popular Stocks With No Buy Ratings on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Ultra-Popular Stocks With No Buy Ratings on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-28 19:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.\nAccording to data from CNBC, over 90% of all S&P 500 stock ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ACB":"奥罗拉大麻公司","SNDL":"SNDL Inc.","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2170778116","content_text":"Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.\nAccording to data from CNBC, over 90% of all S&P 500 stock ratings from Wall Street analysts were the equivalent of \"buy\" or \"hold\" between 1997 and 2017. With the exception of short periods in 2002-2003 and 2008-2009, sell ratings have consistently accounted for only 1% to 6% of all ratings for S&P 500 companies this century.\nOne reason for this \"buy bias\" is due to the U.S. and global economy growing over time. Historically, the stock market moves higher over the long run, too. Wall Street analysts might simply be playing the favorable odds that higher-quality businesses will increase in value over time.\nAdditionally, The Wall Street Journal noted some years back that Wall Street analysts are hesitant to issue sell ratings so as not to burn bridges for their clients or themselves with the companies they cover. No matter the reasoning, sell ratings are rare on Wall Street.\nImage source: Getty Images.\nBut don't tell that to shareholders of the following three ultra-popular stocks. These are three of the 16 most-held stocks on the Robinhood (NASDAQ:HOOD) platform, and not one of them has a single buy rating from a Wall Street analyst.\nAurora Cannabis\nOne of the biggest buzzkills, according to Wall Street, is Canadian marijuana stock Aurora Cannabis (NASDAQ:ACB). Aurora, which at one time was the most-held stock on Robinhood, is being covered by 13 Wall Street institutions, seven of which rate the company the equivalent of a hold and six of which believe it's a sell.\nThough Aurora Cannabis does foot the blame for a lot of this negativity, some of its issues can be traced to Canadian federal and provincial regulators failing the pot industry. For example, Ontario's lottery system to assign retail licenses through 2019 was terrible and resulted in only a few dozen dispensaries opening. Canadian pot stocks are still trying to recover from supply chain bottlenecks in the country's most populous province.\nBut as I mentioned, Aurora Cannabis isn't without fault. The company expanded its production capacity far beyond what was needed. At one time, it held 15 production facilities that could have yielded more than 600,000 kilos of annual cannabis output if fully operational. Management has since closed five of these smaller facilities, sold a 1-million-square-foot greenhouse that wasn't retrofitted for cannabis production, and halted construction on two of the company's largest projects.\nYet, even with this aggressive cost-cutting, Aurora Cannabis is still a long way from generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). With the company continuing to burn cash and the previous management team grossly overpaying for about a dozen acquisitions, it's regularly had to sell its common stock to raise capital to pay its bills and fund buyouts.\nTaking into account a reverse split enacted last year to stave off delisting, Aurora's share count has ballooned from about 1.3 million shares in June 2014 to 198 million shares, as of mid-May. That sort of dilution is precisely why the company's shares are down nearly 95% since March 2019.\nThe salt in the wound is that Canada's legal weed sales have been hitting monthly records, all while Aurora's recreational pot revenue was more than halved in its fiscal third quarter.\nImage source: Getty Images.\nSundial Growers\nYet another Canadian pot stock in the no-buy zone for Wall Street is small-cap Sundial Growers (NASDAQ:SNDL). Even though it's the fourth most-held stock on Robinhood, four of the six analysts covering the company rate it a sell.\nDespite sitting on a boatload of cash, cash equivalents, and long-term investments (about $948 million), Sundial Growers has three factors working against it.\nTo begin with, Sundial's approach to raising capital has destroyed shareholder value. Initially, it looked as if management would sell enough common stock to simply pay off the company's outstanding debt. But in a nine-month stretch between Oct. 1, 2020 and June 30, 2021, Sundial's executives have unrelentingly issued stock to raise additional capital.\nThe end result is the issuance of roughly 1.5 billion shares of stock. With 2 billion shares now outstanding, Sundial has virtually no chance of ever generating meaningful earnings per share, and it'll likely struggle to remain listed on the Nasdaq exchange without a substantial reverse split.\nSecond, Sundial's management team hasn't laid out a concrete plan for its capital. While it did undertake a cash-and-stock deal to acquire Inner Spirit Holdings in July, and it's committed roughly $425 million to its joint venture with SAF Group, known as SunStream Bancorp, to invest in cannabis industry opportunities, the company has continued to raise cash with no stated purpose.\nThird, Sundial has shifted its operating model away from wholesale cannabis to take advantage of the higher margins associated with the retail side of the equation. Unfortunately, having to start from scratch has led to significant year-over-year sales declines at a time when legal weed sales are rapidly growing.\nIn March I more or less referred to Sundial as the worst cannabis stock money could buy. That descriptor still holds true today.\nImage source: Getty Images.\nAMC Entertainment\nBut the most popular stock of all that's getting absolutely no love from Wall Street analysts and investment banks is movie theater chain AMC Entertainment (NYSE:AMC). The third most-held stock on Robinhood has nine analysts covering the company. Five of them have it rated a sell, with four others chiming in with a hold rating.\nThis rating distribution isn't a surprise given that Wall Street's consensus price target for AMC is $5.44. Shares of the company would need to fall 86% from where they closed last week to reach this consensus target.\nThe reason AMC's share price has rocketed higher in 2021 primarily has to do with retail investors piling into the stock and betting on a short squeeze -- i.e., a very short-term event whereby pessimists (short-sellers) run for the exit and buy shares to cover their positions. The issue for these optimists is that none of the data surrounding AMC is working in their favor.\nFor one, short squeezes typically require certain conditions be met, which simply aren't there at the moment. While the company's 18.8% short interest at the end of August is higher than most stocks, its large daily trading volume means it would take less than a day for all 95.94 million short shares to be covered. The liquidity of AMC's stock means short-sellers have no fear of being trapped in their position.\nFundamentally, the movie theater industry has been in a nearly two-decade decline. Tickets sold and inflation-adjusted gross at the box office have fallen 22% between 2002 and 2019, the last full year before the pandemic. Streaming offerings and substantially reduced film exclusivity (30 to 45 days now, compared to 75 to 90 days prior to the pandemic) bode poorly for the industry's future.\nAnd then there's AMC's operating performance and liability-riddled balance sheet. Despite a record $2.023 billion in liquidity ($1.81 billion in cash), AMC burned through $576.5 million in cash in the first six months of 2021. Its lease liabilities are soaring, it owes $420 million in deferred rent, and it's lugging around nearly $5.5 billion in debt that it likely can't pay.\nMore than $1 billion in aggregate debt due in 2026 and 2027 is also valued at 70% to 74% of face value. Debt going for this much below par is a very real warning sign that bondholders believe a future default is possible.\nLong story short, Wall Street has every reason to be skeptical of AMC.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":862958131,"gmtCreate":1632832849129,"gmtModify":1632832849129,"author":{"id":"4087873768935830","authorId":"4087873768935830","name":"Ong2021","avatar":"https://static.tigerbbs.com/eec6b0f9969a9aab1913945a2c49ea24","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4087873768935830","authorIdStr":"4087873768935830"},"htmlText":"[What]&nbsp;","listText":"[What]&nbsp;","text":"[What]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/862958131","repostId":2170778116,"repostType":4,"repost":{"id":"2170778116","kind":"highlight","pubTimestamp":1632829153,"share":"https://www.laohu8.com/m/news/2170778116?lang=&edition=full","pubTime":"2021-09-28 19:39","market":"us","language":"en","title":"3 Ultra-Popular Stocks With No Buy Ratings on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2170778116","media":"Motley Fool","summary":"These widely held stocks are getting no love from analysts.","content":"<p>Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.</p>\n<p>According to data from CNBC, over 90% of all <b>S&amp;P 500</b> stock ratings from Wall Street analysts were the equivalent of \"buy\" or \"hold\" between 1997 and 2017. With the exception of short periods in 2002-2003 and 2008-2009, sell ratings have consistently accounted for only 1% to 6% of all ratings for S&amp;P 500 companies this century.</p>\n<p>One reason for this \"buy bias\" is due to the U.S. and global economy growing over time. Historically, the stock market moves higher over the long run, too. Wall Street analysts might simply be playing the favorable odds that higher-quality businesses will increase in value over time.</p>\n<p>Additionally, <i>The Wall Street Journal</i> noted some years back that Wall Street analysts are hesitant to issue sell ratings so as not to burn bridges for their clients or themselves with the companies they cover. No matter the reasoning, sell ratings are rare on Wall Street.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fb1fd3c71278c123e5dd0404a4dbb43c\" tg-width=\"700\" tg-height=\"525\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<p>But don't tell that to shareholders of the following three ultra-popular stocks. These are three of the 16 most-held stocks on the <b>Robinhood</b> (NASDAQ:HOOD) platform, and not one of them has a single buy rating from a Wall Street analyst.</p>\n<h2>Aurora Cannabis</h2>\n<p>One of the biggest buzzkills, according to Wall Street, is Canadian marijuana stock <b>Aurora Cannabis</b> (NASDAQ:ACB). Aurora, which at one time was the most-held stock on Robinhood, is being covered by 13 Wall Street institutions, seven of which rate the company the equivalent of a hold and six of which believe it's a sell.</p>\n<p>Though Aurora Cannabis does foot the blame for a lot of this negativity, some of its issues can be traced to Canadian federal and provincial regulators failing the pot industry. For example, Ontario's lottery system to assign retail licenses through 2019 was terrible and resulted in only a few dozen dispensaries opening. Canadian pot stocks are still trying to recover from supply chain bottlenecks in the country's most populous province.</p>\n<p>But as I mentioned, Aurora Cannabis isn't without fault. The company expanded its production capacity far beyond what was needed. At one time, it held 15 production facilities that could have yielded more than 600,000 kilos of annual cannabis output if fully operational. Management has since closed five of these smaller facilities, sold a 1-million-square-foot greenhouse that wasn't retrofitted for cannabis production, and halted construction on two of the company's largest projects.</p>\n<p>Yet, even with this aggressive cost-cutting, Aurora Cannabis is still a long way from generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). With the company continuing to burn cash and the previous management team grossly overpaying for about a dozen acquisitions, it's regularly had to sell its common stock to raise capital to pay its bills and fund buyouts.</p>\n<p>Taking into account a reverse split enacted last year to stave off delisting, Aurora's share count has ballooned from about 1.3 million shares in June 2014 to 198 million shares, as of mid-May. That sort of dilution is precisely why the company's shares are down nearly 95% since March 2019.</p>\n<p>The salt in the wound is that Canada's legal weed sales have been hitting monthly records, all while Aurora's recreational pot revenue was more than halved in its fiscal third quarter.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/bc514068ded899a817770f684369db36\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Sundial Growers</h2>\n<p>Yet another Canadian pot stock in the no-buy zone for Wall Street is small-cap <b>Sundial Growers</b> (NASDAQ:SNDL). Even though it's the fourth most-held stock on Robinhood, four of the six analysts covering the company rate it a sell.</p>\n<p>Despite sitting on a boatload of cash, cash equivalents, and long-term investments (about $948 million), Sundial Growers has three factors working against it.</p>\n<p>To begin with, Sundial's approach to raising capital has destroyed shareholder value. Initially, it looked as if management would sell enough common stock to simply pay off the company's outstanding debt. But in a nine-month stretch between Oct. 1, 2020 and June 30, 2021, Sundial's executives have unrelentingly issued stock to raise additional capital.</p>\n<p>The end result is the issuance of roughly 1.5 billion shares of stock. With 2 billion shares now outstanding, Sundial has virtually no chance of ever generating meaningful earnings per share, and it'll likely struggle to remain listed on the <b>Nasdaq</b>&nbsp;exchange without a substantial reverse split.</p>\n<p>Second, Sundial's management team hasn't laid out a concrete plan for its capital. While it did undertake a cash-and-stock deal to acquire <a href=\"https://laohu8.com/S/INSHF\">Inner Spirit Holdings</a> in July, and it's committed roughly $425 million to its joint venture with SAF Group, known as SunStream Bancorp, to invest in cannabis industry opportunities, the company has continued to raise cash with no stated purpose.</p>\n<p>Third, Sundial has shifted its operating model away from wholesale cannabis to take advantage of the higher margins associated with the retail side of the equation. Unfortunately, having to start from scratch has led to significant year-over-year sales declines at a time when legal weed sales are rapidly growing.</p>\n<p>In March I more or less referred to Sundial as the worst cannabis stock money could buy. That descriptor still holds true today.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1c6cb4d9fcdf85f542f333fc71a2dd58\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>AMC Entertainment</h2>\n<p>But the most popular stock of all that's getting absolutely no love from Wall Street analysts and investment banks is movie theater chain <b>AMC Entertainment</b> (NYSE:AMC). The third most-held stock on Robinhood has nine analysts covering the company. Five of them have it rated a sell, with four others chiming in with a hold rating.</p>\n<p>This rating distribution isn't a surprise given that Wall Street's consensus price target for AMC is $5.44. Shares of the company would need to fall 86% from where they closed last week to reach this consensus target.</p>\n<p>The reason AMC's share price has rocketed higher in 2021 primarily has to do with retail investors piling into the stock and betting on a short squeeze -- i.e., a very short-term event whereby pessimists (short-sellers) run for the exit and buy shares to cover their positions. The issue for these optimists is that none of the data surrounding AMC is working in their favor.</p>\n<p>For one, short squeezes typically require certain conditions be met, which simply aren't there at the moment. While the company's 18.8% short interest at the end of August is higher than most stocks, its large daily trading volume means it would take less than a day for all 95.94 million short shares to be covered. The liquidity of AMC's stock means short-sellers have no fear of being trapped in their position.</p>\n<p>Fundamentally, the movie theater industry has been in a nearly two-decade decline. Tickets sold and inflation-adjusted gross at the box office have fallen 22% between 2002 and 2019, the last full year before the pandemic. Streaming offerings and substantially reduced film exclusivity (30 to 45 days now, compared to 75 to 90 days prior to the pandemic) bode poorly for the industry's future.</p>\n<p>And then there's AMC's operating performance and liability-riddled balance sheet. Despite a record $2.023 billion in liquidity ($1.81 billion in cash), AMC burned through $576.5 million in cash in the first six months of 2021. Its lease liabilities are soaring, it owes $420 million in deferred rent, and it's lugging around nearly $5.5 billion in debt that it likely can't pay.</p>\n<p>More than $1 billion in aggregate debt due in 2026 and 2027 is also valued at 70% to 74% of face value. Debt going for this much below par is a very real warning sign that bondholders believe a future default is possible.</p>\n<p>Long story short, Wall Street has every reason to be skeptical of AMC.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Ultra-Popular Stocks With No Buy Ratings on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Ultra-Popular Stocks With No Buy Ratings on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-28 19:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.\nAccording to data from CNBC, over 90% of all S&P 500 stock ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ACB":"奥罗拉大麻公司","SNDL":"SNDL Inc.","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/09/28/3-ultra-popular-stocks-no-buy-ratings-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2170778116","content_text":"Looking to buy a stock? Chances are Wall Street has a favorable view of the publicly traded company you're looking to add to your portfolio.\nAccording to data from CNBC, over 90% of all S&P 500 stock ratings from Wall Street analysts were the equivalent of \"buy\" or \"hold\" between 1997 and 2017. With the exception of short periods in 2002-2003 and 2008-2009, sell ratings have consistently accounted for only 1% to 6% of all ratings for S&P 500 companies this century.\nOne reason for this \"buy bias\" is due to the U.S. and global economy growing over time. Historically, the stock market moves higher over the long run, too. Wall Street analysts might simply be playing the favorable odds that higher-quality businesses will increase in value over time.\nAdditionally, The Wall Street Journal noted some years back that Wall Street analysts are hesitant to issue sell ratings so as not to burn bridges for their clients or themselves with the companies they cover. No matter the reasoning, sell ratings are rare on Wall Street.\nImage source: Getty Images.\nBut don't tell that to shareholders of the following three ultra-popular stocks. These are three of the 16 most-held stocks on the Robinhood (NASDAQ:HOOD) platform, and not one of them has a single buy rating from a Wall Street analyst.\nAurora Cannabis\nOne of the biggest buzzkills, according to Wall Street, is Canadian marijuana stock Aurora Cannabis (NASDAQ:ACB). Aurora, which at one time was the most-held stock on Robinhood, is being covered by 13 Wall Street institutions, seven of which rate the company the equivalent of a hold and six of which believe it's a sell.\nThough Aurora Cannabis does foot the blame for a lot of this negativity, some of its issues can be traced to Canadian federal and provincial regulators failing the pot industry. For example, Ontario's lottery system to assign retail licenses through 2019 was terrible and resulted in only a few dozen dispensaries opening. Canadian pot stocks are still trying to recover from supply chain bottlenecks in the country's most populous province.\nBut as I mentioned, Aurora Cannabis isn't without fault. The company expanded its production capacity far beyond what was needed. At one time, it held 15 production facilities that could have yielded more than 600,000 kilos of annual cannabis output if fully operational. Management has since closed five of these smaller facilities, sold a 1-million-square-foot greenhouse that wasn't retrofitted for cannabis production, and halted construction on two of the company's largest projects.\nYet, even with this aggressive cost-cutting, Aurora Cannabis is still a long way from generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). With the company continuing to burn cash and the previous management team grossly overpaying for about a dozen acquisitions, it's regularly had to sell its common stock to raise capital to pay its bills and fund buyouts.\nTaking into account a reverse split enacted last year to stave off delisting, Aurora's share count has ballooned from about 1.3 million shares in June 2014 to 198 million shares, as of mid-May. That sort of dilution is precisely why the company's shares are down nearly 95% since March 2019.\nThe salt in the wound is that Canada's legal weed sales have been hitting monthly records, all while Aurora's recreational pot revenue was more than halved in its fiscal third quarter.\nImage source: Getty Images.\nSundial Growers\nYet another Canadian pot stock in the no-buy zone for Wall Street is small-cap Sundial Growers (NASDAQ:SNDL). Even though it's the fourth most-held stock on Robinhood, four of the six analysts covering the company rate it a sell.\nDespite sitting on a boatload of cash, cash equivalents, and long-term investments (about $948 million), Sundial Growers has three factors working against it.\nTo begin with, Sundial's approach to raising capital has destroyed shareholder value. Initially, it looked as if management would sell enough common stock to simply pay off the company's outstanding debt. But in a nine-month stretch between Oct. 1, 2020 and June 30, 2021, Sundial's executives have unrelentingly issued stock to raise additional capital.\nThe end result is the issuance of roughly 1.5 billion shares of stock. With 2 billion shares now outstanding, Sundial has virtually no chance of ever generating meaningful earnings per share, and it'll likely struggle to remain listed on the Nasdaq exchange without a substantial reverse split.\nSecond, Sundial's management team hasn't laid out a concrete plan for its capital. While it did undertake a cash-and-stock deal to acquire Inner Spirit Holdings in July, and it's committed roughly $425 million to its joint venture with SAF Group, known as SunStream Bancorp, to invest in cannabis industry opportunities, the company has continued to raise cash with no stated purpose.\nThird, Sundial has shifted its operating model away from wholesale cannabis to take advantage of the higher margins associated with the retail side of the equation. Unfortunately, having to start from scratch has led to significant year-over-year sales declines at a time when legal weed sales are rapidly growing.\nIn March I more or less referred to Sundial as the worst cannabis stock money could buy. That descriptor still holds true today.\nImage source: Getty Images.\nAMC Entertainment\nBut the most popular stock of all that's getting absolutely no love from Wall Street analysts and investment banks is movie theater chain AMC Entertainment (NYSE:AMC). The third most-held stock on Robinhood has nine analysts covering the company. Five of them have it rated a sell, with four others chiming in with a hold rating.\nThis rating distribution isn't a surprise given that Wall Street's consensus price target for AMC is $5.44. Shares of the company would need to fall 86% from where they closed last week to reach this consensus target.\nThe reason AMC's share price has rocketed higher in 2021 primarily has to do with retail investors piling into the stock and betting on a short squeeze -- i.e., a very short-term event whereby pessimists (short-sellers) run for the exit and buy shares to cover their positions. The issue for these optimists is that none of the data surrounding AMC is working in their favor.\nFor one, short squeezes typically require certain conditions be met, which simply aren't there at the moment. While the company's 18.8% short interest at the end of August is higher than most stocks, its large daily trading volume means it would take less than a day for all 95.94 million short shares to be covered. The liquidity of AMC's stock means short-sellers have no fear of being trapped in their position.\nFundamentally, the movie theater industry has been in a nearly two-decade decline. Tickets sold and inflation-adjusted gross at the box office have fallen 22% between 2002 and 2019, the last full year before the pandemic. Streaming offerings and substantially reduced film exclusivity (30 to 45 days now, compared to 75 to 90 days prior to the pandemic) bode poorly for the industry's future.\nAnd then there's AMC's operating performance and liability-riddled balance sheet. Despite a record $2.023 billion in liquidity ($1.81 billion in cash), AMC burned through $576.5 million in cash in the first six months of 2021. Its lease liabilities are soaring, it owes $420 million in deferred rent, and it's lugging around nearly $5.5 billion in debt that it likely can't pay.\nMore than $1 billion in aggregate debt due in 2026 and 2027 is also valued at 70% to 74% of face value. Debt going for this much below par is a very real warning sign that bondholders believe a future default is possible.\nLong story short, Wall Street has every reason to be skeptical of AMC.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6025984,"gmtCreate":1632832856980,"gmtModify":1634783424285,"authorId":4087873768935830,"author":{"id":4087873768935830,"idStr":"4087873768935830","authorId":4087873768935830,"name":"Ong2021","avatar":"https://static.tigerbbs.com/eec6b0f9969a9aab1913945a2c49ea24","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":862958131,"type":1,"supId":0,"prevId":0,"content":"[Miser]","text":"[Miser]","html":"[Miser]"}],"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":202,"commentSize":18,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false}}